U.S. patent application number 14/389066 was filed with the patent office on 2015-02-26 for igf1 biomarker for igf1r inhibitor therapy.
The applicant listed for this patent is MERCK SHARP & DOHME CORP.. Invention is credited to Mark Ayers, Sriram Sathyanarayanan.
Application Number | 20150056191 14/389066 |
Document ID | / |
Family ID | 49261146 |
Filed Date | 2015-02-26 |
United States Patent
Application |
20150056191 |
Kind Code |
A1 |
Sathyanarayanan; Sriram ; et
al. |
February 26, 2015 |
IGF1 BIOMARKER FOR IGF1R INHIBITOR THERAPY
Abstract
The present invention provides, inter alia, methods for treating
tumors that are sensitive to an IGF1R inhibitor. The tumor are
determined to be sensitive if the level of IGF1 mRNA expression in
the tumor cells, relative to one or more reference genes, reaches a
certain threshold level. Methods for evaluating patients as
candidates for receipt of the IGF1R inhibitor therapy are also
provided as well along with in vitro assay methods and kits for
performing any of the methods.
Inventors: |
Sathyanarayanan; Sriram;
(Lexington, MA) ; Ayers; Mark; (Pennington,
NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
MERCK SHARP & DOHME CORP. |
RAHWAY |
NJ |
US |
|
|
Family ID: |
49261146 |
Appl. No.: |
14/389066 |
Filed: |
March 25, 2013 |
PCT Filed: |
March 25, 2013 |
PCT NO: |
PCT/US13/33694 |
371 Date: |
September 29, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61617954 |
Mar 30, 2012 |
|
|
|
Current U.S.
Class: |
424/133.1 ;
435/6.11; 506/16; 506/9 |
Current CPC
Class: |
C12Q 2600/106 20130101;
A61K 31/7068 20130101; A61K 39/39558 20130101; A61K 31/439
20130101; C12Q 2600/158 20130101; A61K 31/517 20130101; C07K
16/2866 20130101; C12Q 1/6886 20130101 |
Class at
Publication: |
424/133.1 ;
435/6.11; 506/9; 506/16 |
International
Class: |
C12Q 1/68 20060101
C12Q001/68; A61K 31/439 20060101 A61K031/439; A61K 31/7068 20060101
A61K031/7068; A61K 31/517 20060101 A61K031/517; C07K 16/28 20060101
C07K016/28; A61K 39/395 20060101 A61K039/395 |
Claims
1. A method for treating a tumor in a subject in need of such
treatment, that expresses IGF1 mRNA, comprising determining if the
fractional cycle number of a real time polymerase chain reaction
amplification of IGF1 cDNA, that was reverse transcribed from IGF1
mRNA from a cell of said tumor, normalized relative to that of one
or more reference genes, wherein acceleration of amplification is
at a maximum, is at or below about 2.03 or at or below about 2.87;
and, if the fractional cycle number is at or below about 2.03 or at
or below about 2.87, then administering a therapeutically effective
amount of an IGF1R inhibitor, optionally in association with
gemcitabine and/or ridaforolimus, to said subject.
2. The method of claim 1 wherein the point at which acceleration of
amplification is at a maximum is determined by determining the
second derivative maxima of an amplification curve of the
reaction.
3. The method of claim 1 wherein the level of IGF1 mRNA expression
in cells of said tumor is determined by a method comprising: (a)
obtaining cells of the subject's tumor; (b) isolating RNA from said
cells (c) generating cDNA by reverse transcribing the RNA (d)
separately amplifying the cDNA encoding IGF1 and encoding one or
more reference genes selected from the group consisting of: CYC1,
HMBS, TOP1, SDHA, GUSB, PUM1, HPRT1, ACTB, UBC, B2M, GAPDH, and
TUBB2A while monitoring production of the cDNA during the
amplification; and (e) determining the quantity amplified cDNA
generated and; optionally, normalizing the determined quantity of
IGF1 with that of the reference gene(s).
4. The method of claim 1 wherein the IGF1R inhibitor is a member
selected from the group consisting of dalotuzumab, robatumumab,
figitumumab, cixutumumab, ganitumab, AVE1642, OSI-906, NVP-AEW541
and NVP-ADW742.
5. The method of claim 1 wherein, if the subject is administered
the IGF1R inhibitor, then the subject is also administered a
further chemotherapeutic agent.
6. The method of claim 5 wherein the further chemotherapeutic agent
is a member selected from the group consisting of: 5-fluorouridine;
131-I-TM-601; 13-cis-retinoic acid;
3-[5-(methylsulfonylpiperadinemethyl)-indolyl]-quinolone;
40-O-(2-hydroxyethyl)-rapamycin; 4-hydroxytamoxifen;
5-deooxyuridine; 6-mercaptopurine; 7-hydroxy staurosporine; a
combination of irinotecan, 5-fluorouracil and leucovorin; a
combination of oxaliplatin fluorouracil and folinic acid; A-443654;
abiraterone acetate; abraxane; ABT-578; acolbifene; ADS-100380;
AG-013736; alprazolam; ALT-110; altretamine; amifostine;
aminoglutethimide; AMN-107; amrubicin; amsacrine; an antiandrogen;
anagrelide; anastrazole; angiostatin; an EGF Receptor antagonuist;
an selective estrogen receptor modulator (SERM); an AKT inhibitor;
an anti-angiogenesis agents; an anti-EGFR antibody; an anti-emetic;
an anti-HER2 antibody; an anti-VEGF antibody; an aromatase
inhibitor; an CDK inhibitor; an CYP17 lyase inhibitor; an estrogen;
an GnRH agonists; a HER2 antagonist; a lutenizing hormone-releasing
hormone agonist; an MEK inhibitor; an mTOR inhibitor; an NK-1
receptor antagonists; a PI3 kinase inhibitor; a progestational
agent; a Raf inhibitor; a VEGFR inhibitor; AP-23573; aprepitant;
ARQ-197; arzoxifene; AS-252424; AS-605240; asparaginase; AT-9263;
atrasentan; AV-299; AZD 1152; AZD 6244; azd2171; AZD-6244; Bacillus
Calmette-Guerin vaccine; batabulin; BC-210; bevacizumab;
bicalutamide; Bio 111; BIO 140; bleomycin; BMS-214662; BMS-247550;
BMS-275291; BMS-310705; bortezimib; buserelin; busulfan;
calcitriol; camptothecin; canertinib; capecitabine; carboplatin;
carmustine; casopitant; CC 8490; CG-1521; CG-781; chlamydocin;
chlorambucil; cilengitide; cimitidine; cisplatin; Cladribine;
clodronate; COL-3; conjugated estrogens; CP-724714;
cyclophosphamide; cyproterone; cyproterone acetate; cytarabine;
cytosine arabinoside; cytproterone acetate; dacarbazine;
dactinomycin; darbepoetin alfa; dasatanib; daunorubicin; decatanib;
deguelin; denileukin; deoxycoformycin; depsipeptide;
DES(diethylstilbestrol); dexamethasone; diarylpropionitrile;
diethylstilbestrol; diftitox; diphenhydramine; DN-101; docetaxel;
dolasetron; dovitinib; doxorubicin; doxorubicin HCl liposome
injection; droloxifene; dronabinol; droperidol; edotecarin;
edotreotide (yttrium-90 labeled or unlabeled); EKB-569; EMD121974;
endostatin; enzastaurin; epirubicin; epithilone B; epoetin alfa;
ERA-923; erbitux; erlotinib; erythropoietin; estradiol;
estramustine; etoposide; everolimus; exemestane; finasteride;
flavopiridol; floxuridine; fludarabine; fludrocortisones;
fluoxymesterone; flutamide; fulvestrant; galeterone; GDC-0941;
gefitinib; gemcitabine; a combination of gemcitabine in association
with erlotinib; gimatecan; goserelin; goserelin acetate; gossypol;
granisetron; GSK461364; GSK690693; GW-572016; haloperidol; HKI-272;
HMR-3339; hydroxyprogesterone caproate; hydroxyurea; hydroxyzine;
IC87114; idarubicin; Idoxifene; ifosfamide; IL13-PE38QQR; IM862;
imatinib; IMC-1C11; INO 1001; interferon; interleukin-12; IPdR;
ipilimumab; irinotecan; JNJ-16241199; ketoconazole; KRN951;
KRX-0402; L-779,450; lapatanib; lasofoxifene; Lep-etu; letrozole;
leucovorin; leuprolide; leuprolide acetate; levamisole; lomustine;
lonafarnib; lorazepam; Lucanthone; LY 317615; LY292223; LY292696;
LY293646; LY293684; LY294002; marimastat; MDV-3100;
mechlorethamine; medroxyprogesterone acetate; megestrol acetate;
melphalan; mercaptopurine; mesna; methotrexate; methylprednisolone;
metoclopramide; mithramycin; mitomycin; mitotane; mitoxantrone;
MK-0457; MLN8054; neovastat; netupitant; neuradiab; nilotinib;
nilutimide; nolatrexed; NVP-BEZ235; NVP-LAQ824; oblimersen;
octreotide; ofatumumab; ON 0910.Na; ondansetron; oregovomab;
orteronel; oxaliplatin; paclitaxel; palonosetron; pamidronate;
panitumumab; pazopanib; PD0325901; PEG-filgrastim; PEG-interferon;
PEG-labeled irinotecan; pemetrexed; pentostatin; perifosine;
PHA-739358; phenylalanine mustard; PI-103; PIK-75; pipendoxifene;
PKI-166; plicamycin; porfimer; prednisone; procarbazine;
prochlorperazine; progestins; PTK787/ZK 222584; PX-866; R-763;
RAD001; raloxifene; raltitrexed; razoxin; ridaforolimus; rituximab;
romidepsin; RTA 744; rubitecan; scriptaid; Sdx 102; seliciclib;
semaxanib; SF1126; sirolimus; SN36093; sorafenib; spironolactone;
squalamine; SR13668; streptozocin; SU6668; suberoyl analide
hydroxamic acid; sunitinib; sunitinib malate; talampanel;
tamoxifen; temozolomide; temsirolimus; teniposide; tesmilifene;
testosterone; tetrandrine; TGX-221; thalidomide; thioguanine;
thiotepa; ticilimumab; tipifarnib; TKI-258; TLK 286; topotecan;
toremifene citrate; trabectedin; trastuzumab; tretinoin;
trichostatin A; triciribine phosphate monohydrate; triptorelin
pamoate; tropisetron; TSE-424; uracil mustard; valproic acid;
valrubicin; vandetanib; vatalanib; VEGF trap; vinblastine;
vincristine; vindesine; vinorelbine; vitaxin; vitespan; vorinostat;
VX-745; wortmannin; Xr 311; zanolimumab; ZK186619; ZK-304709,
ZM336372; ZSTK474;
cis-3-[4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]prop-
anoic acid; ##STR00011## ##STR00012##
7. A method for selecting a subject with a tumor for treatment with
an IGF1R inhibitor, optionally in association with gemcitabine
and/or ridaforolimus, comprising determining if the fractional
cycle number of a real time polymerase chain reaction amplification
of IGF1 cDNA, that was reverse transcribed from IGF1 mRNA from a
cell of said tumor, normalized relative to that of one or more
reference genes, in which acceleration of amplification is at a
maximum, is at or below about 2.03 or at or below about 2.87 and,
if the fractional cycle number is at or below about 2.03 or at or
below about 2.87, then selecting the subject for treatment of the
tumor with the IGF1R inhibitor, optionally in association with
gemcitabine and/or ridaforolimus; and, optionally, further
comprising administering a therapeutically effective amount of
IGF1R inhibitor, optionally in association with gemcitabine and/or
ridaforolimus, to the subject.
8. The method of claim 7 wherein the point at which acceleration of
amplification is at a maximum is determined by determining the
second derivative maxima of an amplification curve of the
reaction.
9. The method of claim 7 further comprising administering a
therapeutically effective amount of IGF1R inhibitor to the
subject.
10. The method of claim 7 wherein the IGF1R inhibitor is a member
selected from the group consisting of dalotuzumab, robatumumab,
figitumumab, cixutumumab, ganitumab, AVE1642, OSI-906, NVP-AEW541
and NVP-ADW742.
11. The method of claim 7 wherein, if the subject is administered
the IGF1R inhibitor, then the subject is also administered a
further chemotherapeutic agent.
12. The method of claim 11 wherein the further chemotherapeutic
agent is a member selected from the group consisting of:
5-fluorouridine; 131-I-TM-601; 13-cis-retinoic acid;
3-[5-(methylsulfonylpiperadinemethyl)-indolyl]-quinolone;
40-O-(2-hydroxyethyl)-rapamycin; 4-hydroxytamoxifen;
5-deooxyuridine; 6-mercaptopurine; 7-hydroxy staurosporine; a
combination of irinotecan, 5-fluorouracil and leucovorin; a
combination of oxaliplatin fluorouracil and folinic acid; A-443654;
abiraterone acetate; abraxane; ABT-578; acolbifene; ADS-100380;
AG-013736; alprazolam; ALT-110; altretamine; amifostine;
aminoglutethimide; AMN-107; amrubicin; amsacrine; an antiandrogen;
anagrelide; anastrazole; angiostatin; an EGF Receptor antagonuist;
an selective estrogen receptor modulator (SERM); an AKT inhibitor;
an anti-angiogenesis agents; an anti-EGFR antibody; an anti-emetic;
an anti-HER2 antibody; an anti-VEGF antibody; an aromatase
inhibitor; an CDK inhibitor; an CYP17 lyase inhibitor; an estrogen;
an GnRH agonists; a HER2 antagonist; a lutenizing hormone-releasing
hormone agonist; an MEK inhibitor; an mTOR inhibitor; an NK-1
receptor antagonists; a PI3 kinase inhibitor; a progestational
agent; a Raf inhibitor; a VEGFR inhibitor; AP-23573; aprepitant;
ARQ-197; arzoxifene; AS-252424; AS-605240; asparaginase; AT-9263;
atrasentan; AV-299; AZD 1152; AZD 6244; azd2171; AZD-6244; Bacillus
Calmette-Guerin vaccine; batabulin; BC-210; bevacizumab;
bicalutamide; Bio 111; BIO 140; bleomycin; BMS-214662; BMS-247550;
BMS-275291; BMS-310705; bortezimib; buserelin; busulfan;
calcitriol; camptothecin; canertinib; capecitabine; carboplatin;
carmustine; casopitant; CC 8490; CG-1521; CG-781; chlamydocin;
chlorambucil; cilengitide; cimitidine; cisplatin; Cladribine;
clodronate; COL-3; conjugated estrogens; CP-724714;
cyclophosphamide; cyproterone; cyproterone acetate; cytarabine;
cytosine arabinoside; cytproterone acetate; dacarbazine;
dactinomycin; darbepoetin alfa; dasatanib; daunorubicin; decatanib;
deguelin; denileukin; deoxycoformycin; depsipeptide;
DES(diethylstilbestrol); dexamethasone; diarylpropionitrile;
diethylstilbestrol; diftitox; diphenhydramine; DN-101; docetaxel;
dolasetron; dovitinib; doxorubicin; doxorubicin HCl liposome
injection; droloxifene; dronabinol; droperidol; edotecarin;
edotreotide (yttrium-90 labeled or unlabeled); EKB-569; EMD121974;
endostatin; enzastaurin; epirubicin; epithilone B; epoetin alfa;
ERA-923; erbitux; erlotinib; erythropoietin; estradiol;
estramustine; etoposide; everolimus; exemestane; finasteride;
flavopiridol; floxuridine; fludarabine; fludrocortisones;
fluoxymesterone; flutamide; fulvestrant; galeterone; GDC-0941;
gefitinib; gemcitabine; a combination of gemcitabine in association
with erlotinib; gimatecan; goserelin; goserelin acetate; gossypol;
granisetron; GSK461364; GSK690693; GW-572016; haloperidol; HKI-272;
HMR-3339; hydroxyprogesterone caproate; hydroxyurea; hydroxyzine;
IC87114; idarubicin; Idoxifene; ifosfamide; IL13-PE38QQR; IM862;
imatinib; IMC-1C11; INO 1001; interferon; interleukin-12; IPdR;
ipilimumab; irinotecan; JNJ-16241199; ketoconazole; KRN951;
KRX-0402; L-779,450; lapatanib; lasofoxifene; Lep-etu; letrozole;
leucovorin; leuprolide; leuprolide acetate; levamisole; lomustine;
lonafarnib; lorazepam; Lucanthone; LY 317615; LY292223; LY292696;
LY293646; LY293684; LY294002; marimastat; MDV-3100;
mechlorethamine; medroxyprogesterone acetate; megestrol acetate;
melphalan; mercaptopurine; mesna; methotrexate; methylprednisolone;
metoclopramide; mithramycin; mitomycin; mitotane; mitoxantrone;
MK-0457; MLN8054; neovastat; netupitant; neuradiab; nilotinib;
nilutimide; nolatrexed; NVP-BEZ235; NVP-LAQ824; oblimersen;
octreotide; ofatumumab; ON 0910.Na; ondansetron; oregovomab;
orteronel; oxaliplatin; paclitaxel; palonosetron; pamidronate;
panitumumab; pazopanib; PD0325901; PEG-filgrastim; PEG-interferon;
PEG-labeled irinotecan; pemetrexed; pentostatin; perifosine;
PHA-739358; phenylalanine mustard; PI-103; PIK-75; pipendoxifene;
PKI-166; plicamycin; porfimer; prednisone; procarbazine;
prochlorperazine; progestins; PTK787/ZK 222584; PX-866; R-763;
RAD001; raloxifene; raltitrexed; razoxin; ridaforolimus; rituximab;
romidepsin; RTA 744; rubitecan; scriptaid; Sdx 102; seliciclib;
semaxanib; SF1126; sirolimus; SN36093; sorafenib; spironolactone;
squalamine; SR13668; streptozocin; SU6668; suberoyl analide
hydroxamic acid; sunitinib; sunitinib malate; talampanel;
tamoxifen; temozolomide; temsirolimus; teniposide; tesmilifene;
testosterone; tetrandrine; TGX-221; thalidomide; thioguanine;
thiotepa; ticilimumab; tipifarnib; TKI-258; TLK 286; topotecan;
toremifene citrate; trabectedin; trastuzumab; tretinoin;
trichostatin A; triciribine phosphate monohydrate; triptorelin
pamoate; tropisetron; TSE-424; uracil mustard; valproic acid;
valrubicin; vandetanib; vatalanib; VEGF trap; vinblastine;
vincristine; vindesine; vinorelbine; vitaxin; vitespan; vorinostat;
VX-745; wortmannin; Xr 311; zanolimumab; ZK186619; ZK-304709,
ZM336372; ZSTK474;
cis-3-[4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]prop-
anoic acid; ##STR00013## ##STR00014##
13. A method for selecting a therapy for a subject with a tumor
comprising determining if the fractional cycle number of a real
time polymerase chain reaction amplification of IGF1 cDNA, that was
reverse transcribed from IGF1 mRNA from a cell of said tumor,
normalized relative to that of one or more reference genes, in
which acceleration of amplification is at a maximum, is at or below
about 2.03 or at or below about 2.87; and if the fractional cycle
number is at or below about 2.03 or at or below about 2.87; then
selecting an IGF1R inhibitor, optionally in association with
gemcitabine and/or ridaforolimus, for treatment of the tumor in the
subject; and, optionally, further comprising administering a
therapeutically effective amount of IGF1R inhibitor, optionally in
association with gemcitabine and/or ridaforolimus, to the
subject.
14. The method of claim 13 wherein the point at which acceleration
of amplification is at a maximum is determined by determining the
second derivative maxima of an amplification curve of the
reaction.
15. The method claim 13 further comprising administering a
therapeutically effective amount of IGF1R inhibitor to the
subject.
16. The method of claim 13 wherein the IGF1R inhibitor is a member
selected from the group consisting of dalotuzumab, robatumumab,
figitumumab, cixutumumab, ganitumab, AVE1642, OSI-906, NVP-AEW541
and NVP-ADW742.
17. The method of claim 13 wherein, if the subject is administered
a therapeutically effective amount of IGF1R inhibitor then the
subject is also administered a further chemotherapeutic agent.
18. The method of claim 17 wherein the further chemotherapeutic
agent is a member selected from the group consisting of:
5-fluorouridine; 131-I-TM-601; 13-cis-retinoic acid;
3-[5-(methylsulfonylpiperadinemethyl)-indolyl]-quinolone;
40-O-(2-hydroxyethyl)-rapamycin; 4-hydroxytamoxifen;
5-deooxyuridine; 6-mercaptopurine; 7-hydroxy staurosporine; a
combination of irinotecan, 5-fluorouracil and leucovorin; a
combination of oxaliplatin fluorouracil and folinic acid; A-443654;
abiraterone acetate; abraxane; ABT-578; acolbifene; ADS-100380;
AG-013736; alprazolam; ALT-110; altretamine; amifostine;
aminoglutethimide; AMN-107; amrubicin; amsacrine; an antiandrogen;
anagrelide; anastrazole; angiostatin; an EGF Receptor antagonuist;
an selective estrogen receptor modulator (SERM); an AKT inhibitor;
an anti-angiogenesis agents; an anti-EGFR antibody; an anti-emetic;
an anti-HER2 antibody; an anti-VEGF antibody; an aromatase
inhibitor; an CDK inhibitor; an CYP17 lyase inhibitor; an estrogen;
an GnRH agonists; a HER2 antagonist; a lutenizing hormone-releasing
hormone agonist; an MEK inhibitor; an mTOR inhibitor; an NK-1
receptor antagonists; a PI3 kinase inhibitor; a progestational
agent; a Raf inhibitor; a VEGFR inhibitor; AP-23573; aprepitant;
ARQ-197; arzoxifene; AS-252424; AS-605240; asparaginase; AT-9263;
atrasentan; AV-299; AZD 1152; AZD 6244; azd2171; AZD-6244; Bacillus
Calmette-Guerin vaccine; batabulin; BC-210; bevacizumab;
bicalutamide; Bio 111; BIO 140; bleomycin; BMS-214662; BMS-247550;
BMS-275291; BMS-310705; bortezimib; buserelin; busulfan;
calcitriol; camptothecin; canertinib; capecitabine; carboplatin;
carmustine; casopitant; CC 8490; CG-1521; CG-781; chlamydocin;
chlorambucil; cilengitide; cimitidine; cisplatin; Cladribine;
clodronate; COL-3; conjugated estrogens; CP-724714;
cyclophosphamide; cyproterone; cyproterone acetate; cytarabine;
cytosine arabinoside; cytproterone acetate; dacarbazine;
dactinomycin; darbepoetin alfa; dasatanib; daunorubicin; decatanib;
deguelin; denileukin; deoxycoformycin; depsipeptide;
DES(diethylstilbestrol); dexamethasone; diarylpropionitrile;
diethylstilbestrol; diftitox; diphenhydramine; DN-101; docetaxel;
dolasetron; dovitinib; doxorubicin; doxorubicin HCl liposome
injection; droloxifene; dronabinol; droperidol; edotecarin;
edotreotide (yttrium-90 labeled or unlabeled); EKB-569; EMD121974;
endostatin; enzastaurin; epirubicin; epithilone B; epoetin alfa;
ERA-923; erbitux; erlotinib; erythropoietin; estradiol;
estramustine; etoposide; everolimus; exemestane; finasteride;
flavopiridol; floxuridine; fludarabine; fludrocortisones;
fluoxymesterone; flutamide; fulvestrant; galeterone; GDC-0941;
gefitinib; gemcitabine; a combination of gemcitabine in association
with erlotinib; gimatecan; goserelin; goserelin acetate; gossypol;
granisetron; GSK461364; GSK690693; GW-572016; haloperidol; HKI-272;
HMR-3339; hydroxyprogesterone caproate; hydroxyurea; hydroxyzine;
IC87114; idarubicin; Idoxifene; ifosfamide; IL13-PE38QQR; IM862;
imatinib; IMC-1C11; INO 1001; interferon; interleukin-12; IPdR;
ipilimumab; irinotecan; JNJ-16241199; ketoconazole; KRN951;
KRX-0402; L-779,450; lapatanib; lasofoxifene; Lep-etu; letrozole;
leucovorin; leuprolide; leuprolide acetate; levamisole; lomustine;
lonafarnib; lorazepam; Lucanthone; LY 317615; LY292223; LY292696;
LY293646; LY293684; LY294002; marimastat; MDV-3100;
mechlorethamine; medroxyprogesterone acetate; megestrol acetate;
melphalan; mercaptopurine; mesna; methotrexate; methylprednisolone;
metoclopramide; mithramycin; mitomycin; mitotane; mitoxantrone;
MK-0457; MLN8054; neovastat; netupitant; neuradiab; nilotinib;
nilutimide; nolatrexed; NVP-BEZ235; NVP-LAQ824; oblimersen;
octreotide; ofatumumab; ON 0910.Na; ondansetron; oregovomab;
orteronel; oxaliplatin; paclitaxel; palonosetron; pamidronate;
panitumumab; pazopanib; PD0325901; PEG-filgrastim; PEG-interferon;
PEG-labeled irinotecan; pemetrexed; pentostatin; perifosine;
PHA-739358; phenylalanine mustard; PI-103; PIK-75; pipendoxifene;
PKI-166; plicamycin; porfimer; prednisone; procarbazine;
prochlorperazine; progestins; PTK787/ZK 222584; PX-866; R-763;
RAD001; raloxifene; raltitrexed; razoxin; ridaforolimus; rituximab;
romidepsin; RTA 744; rubitecan; scriptaid; Sdx 102; seliciclib;
semaxanib; SF1126; sirolimus; SN36093; sorafenib; spironolactone;
squalamine; SR13668; streptozocin; SU6668; suberoyl analide
hydroxamic acid; sunitinib; sunitinib malate; talampanel;
tamoxifen; temozolomide; temsirolimus; teniposide; tesmilifene;
testosterone; tetrandrine; TGX-221; thalidomide; thioguanine;
thiotepa; ticilimumab; tipifarnib; TKI-258; TLK 286; topotecan;
toremifene citrate; trabectedin; trastuzumab; tretinoin;
trichostatin A; triciribine phosphate monohydrate; triptorelin
pamoate; tropisetron; TSE-424; uracil mustard; valproic acid;
valrubicin; vandetanib; vatalanib; VEGF trap; vinblastine;
vincristine; vindesine; vinorelbine; vitaxin; vitespan; vorinostat;
VX-745; wortmannin; Xr 311; zanolimumab; ZK186619; ZK-304709,
ZM336372; ZSTK474;
cis-3-[4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]prop-
anoic acid; ##STR00015## ##STR00016##
19. A method for evaluating the sensitivity of in vitro tumor
cells, obtained from a subject, to IGF1R inhibitor therapy,
optionally in association with gemcitabine and/or ridaforolimus,
comprising determining if the fractional cycle number of a real
time polymerase chain reaction amplification of IGF1 cDNA, that was
reverse transcribed from IGF1 mRNA from a cell of said tumor,
normalized relative to that of one or more reference genes, in
which acceleration of amplification is at a maximum, is at or below
about 2.03 or at or below about 2.87; and, if the fractional cycle
number is at or below about 2.03 or at or below about 2.87, then
determining that the tumor cells are sensitive; and, optionally,
further comprising administering a therapeutically effective amount
of the IGF1R inhibitor, optionally in association with gemcitabine
and/or ridaforolimus, to the subject.
20. The method of claim 19 wherein the point at which acceleration
of amplification is at a maximum is determined by determining the
second derivative maxima of an amplification curve of the
reaction.
21. The method of claim 1 wherein the level of KRAS expression
and/or whether KRAS is wild-type or mutated, in the tumor cells, is
determined.
22. A kit for determining whether tumor cells are sensitive to an
IGF1R inhibitor comprising an IGF1R inhibitor an instructions for
performing the method of any claim 19.
23. The method of claim 1 wherein IGF1 comprises the nucleotide
sequence set forth in SEQ ID NO: 13 or a cDNA sequence thereof or a
nucleotide sequence comprising at least 80% identity thereto and/or
wherein the reference gene comprises a nucleotide sequence selected
from the group consisting of SEQ ID NOs: 14-25 or a cDNA sequence
thereof or a nucleotide sequence comprising at least 80% identity
thereto.
Description
[0001] This application claims the benefit of U.S. provisional
patent application No. 61/617,954, filed Mar. 30, 3012; which is
herein incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0002] The field of the present invention provides methods for
treating a tumor that expresses IGF1 at a certain threshold level
with an IGF1R inhibitor.
BACKGROUND OF THE INVENTION
[0003] The IGF1R signaling pathway has been therapeutically
targeted for cancer therapy. Various antibodies and small molecules
targeting IGF1R are currently undergoing various stages of clinical
development. One of the key challenges in the development of
targeted therapies is to identify the patient population most
likely to benefit from the targeted therapies. IGF1 is a key ligand
for the activation of the IGF1R pathway. Increased IGF1 levels in a
tumor are a useful indicator that the tumor is sensitivity to IGF1R
inhibitor therapy. The degree to which IGF1 expression levels in a
tumor cell must be increased to reliably indicate that the cell is
IGF1R inhibitor sensitive is not known in the art.
SUMMARY OF THE INVENTION
[0004] The present invention provides a method for treating a tumor
in a subject (e.g., a mammal such as a human; e.g., a subject
having a tumor that is sensitive to IGFIR inhibitor therapy and/or
likely to experience a positive clinical outcome upon treatment
with an IGF1R inhibitor) in need of such treatment, that expresses
IGF1 mRNA, comprising administering a therapeutically effective
amount of an IGF1R inhibitor (e.g., dalotuzumab, robatumumab,
figitumumab, cixutumumab, ganitumab, AVE1642, OSI-906, NVP-AEW541
or NVP-ADW742), optionally in association with a further
chemotherapeutic agent, to said subject; if the fractional cycle
number of a real time polymerase chain reaction amplification of
IGF1 cDNA, that was reverse transcribed from IGF1 mRNA from a cell
of said tumor, normalized relative to that of one or more reference
genes, wherein acceleration of amplification is at a maximum (e.g.,
wherein the point at which acceleration of amplification is at a
maximum is determined by determining the second derivative maxima
of an amplification curve of the reaction), is at or below about
2.87 or at or below about 1.83 to about 2.03.
[0005] The present invention further provides a method for
selecting a subject (e.g., a mammal such as a human) with a tumor
(e.g., a subject having a tumor that is sensitive to IGF1R
inhibitor therapy and/or likely to experience a positive clinical
outcome upon treatment with an IGF1R inhibitor) for treatment with
an IGF1R inhibitor (e.g., dalotuzumab, robatumumab, figitumumab,
cixutumumab, ganitumab, AVE1642, OSI-906, NVP-AEW541 or
NVP-ADW742), optionally in association with a further
chemotherapeutic agent, comprising selecting the subject for
treatment of the tumor with the IGF1R inhibitor if the fractional
cycle number of a real time polymerase chain reaction amplification
of IGF1 cDNA, that was reverse transcribed from IGF1 mRNA from a
cell of said tumor, normalized relative to that of one or more
reference genes, in which acceleration of amplification is at a
maximum (e.g., wherein the point at which acceleration of
amplification is at a maximum is determined by determining the
second derivative maxima of an amplification curve of the
reaction), is at or below about 2.87 or at or below about 1.83 to
about 2.03. Optionally, the method further comprises administering
a therapeutically effective amount of IGF1R inhibitor to the
selected subject.
[0006] The present invention also provides a method for selecting a
therapy for a subject (e.g., a mammal such as a human) with a tumor
(e.g., a subject having a tumor that is sensitive to IGF1R
inhibitor therapy and/or likely to experience a positive clinical
outcome upon treatment with an IGF1R inhibitor) comprising
selecting an IGF1R inhibitor (e.g., dalotuzumab, robatumumab,
figitumumab, cixutumumab, ganitumab, AVE1642, OSI-906, NVP-AEW541
or NVP-ADW742), optionally in association with a further
chemotherapeutic agent, for treatment of the tumor in the subject
if the fractional cycle number of a real time polymerase chain
reaction amplification of IGF1 cDNA, that was reverse transcribed
from IGF1 mRNA from a cell of said tumor, normalized relative to
that of one or more reference genes, in which acceleration of
amplification is at a maximum (e.g., wherein the point at which
acceleration of amplification is at a maximum is determined by
determining the second derivative maxima of an amplification curve
of the reaction), is at or below about 2.87 or at or below about
1.83 to about 2.03. Optionally, the method further comprises
administering a therapeutically effective amount of IGF1R
inhibitor, as the selected therapy, to the subject.
[0007] The present invention also provides a method for evaluating
the sensitivity of tumor cells (e.g., in vitro tumor cells) to
IGF1R inhibitor therapy comprising determining that the tumor cells
are sensitive to the IGF1R inhibitor (e.g., dalotuzumab,
robatumumab, figitumumab, cixutumumab, ganitumab, AVE1642, OSI-906,
NVP-AEW541 or NVP-ADW742), optionally in association with a further
chemotherapeutic agent, if the fractional cycle number of a real
time polymerase chain reaction amplification of IGF1 cDNA, that was
reverse transcribed from IGF1 mRNA from a cell of said tumor,
normalized relative to that of one or more reference genes, in
which acceleration of amplification is at a maximum (e.g., wherein
the point at which acceleration of amplification is at a maximum is
determined by determining the second derivative maxima of an
amplification curve of the reaction), is at or below about 2.87 or
at or below about 1.83 to about 2.03. Optionally, the method
further comprises administering a therapeutically effective amount
of IGF1R inhibitor to a subject (e.g., a mammal such as a human)
from whom the tumor cells were obtained.
[0008] The methods of the present invention can include any one or
more of the following steps, (a) obtaining cells of the subject's
tumor; (b) isolating RNA from said cells; (c) generating cDNA by
reverse transcribing the RNA; (d) separately amplifying the cDNA
encoding IGF1 and encoding one or more reference genes selected
from the group consisting of: CYC1, HMBS, TOP1, SDHA, GUSB, PUM1,
HPRT1, ACTB, UBC, B2M, GAPDH, and TUBB2A while monitoring
production of the cDNA during the amplification; and (e)
determining the quantity amplified cDNA generated and; optionally,
normalizing the determined quantity of IGF1 with that of the
reference gene(s).
[0009] A further chemotherapeutic agent to be provided with an
IGF1R inhibitor in a method of the present invention can be any one
or more of the following: 5-fluorouridine; 131-I-TM-601;
13-cis-retinoic acid;
3-[5-(methylsulfonylpiperadinemethyl)-indolyl]-quinolone;
40-O-(2-hydroxyethyl)-rapamycin; 4-hydroxytamoxifen;
5-deooxyuridine; 6-mercaptopurine; 7-hydroxy staurosporine; a
combination of irinotecan, 5-fluorouracil and leucovorin; a
combination of oxaliplatin fluorouracil and folinic acid; A-443654;
abiraterone acetate; abraxane; ABT-578; acolbifene; ADS-100380;
AG-013736; alprazolam; ALT-110; altretamine; amifostine;
aminoglutethimide; AMN-107; amrubicin; amsacrine; an antiandrogen;
anagrelide; anastrazole; angiostatin; an EGF Receptor antagonuist;
an selective estrogen receptor modulator (SERM); an AKT inhibitor;
an anti-angiogenesis agents; an anti-EGFR antibody; an anti-emetic;
an anti-HER2 antibody; an anti-VEGF antibody; an aromatase
inhibitor; an CDK inhibitor; an CYP17 lyase inhibitor; an estrogen;
an GnRH agonists; a HER2 antagonist; a lutenizing hormone-releasing
hormone agonist; an MEK inhibitor; an mTOR inhibitor; an NK-1
receptor antagonists; a PI3 kinase inhibitor; a progestational
agent; a Raf inhibitor; a VEGFR inhibitor; AP-23573; aprepitant;
ARQ-197; arzoxifene; AS-252424; AS-605240; asparaginase; AT-9263;
atrasentan; AV-299; AZD 1152; AZD 6244; azd2171; AZD-6244; Bacillus
Calmette-Guerin vaccine; batabulin; BC-210; bevacizumab;
bicalutamide; Bio 111; BIO 140; bleomycin; BMS-214662; BMS-247550;
BMS-275291; BMS-310705; bortezimib; buserelin; busulfan;
calcitriol; camptothecin; canertinib; capecitabine; carboplatin;
carmustine; casopitant; CC 8490; CG-1521; CG-781; chlamydocin;
chlorambucil; cilengitide; cimitidine; cisplatin; Cladribine;
clodronate; COL-3; conjugated estrogens; CP-724714;
cyclophosphamide; cyproterone; cyproterone acetate; cytarabine;
cytosine arabinoside; cytproterone acetate; dacarbazine;
dactinomycin; darbepoetin alfa; dasatanib; daunorubicin; decatanib;
deguelin; denileukin; deoxycoformycin; depsipeptide;
DES(diethylstilbestrol); dexamethasone; diarylpropionitrile;
diethylstilbestrol; diftitox; diphenhydramine; DN-101; docetaxel;
dolasetron; dovitinib; doxorubicin; doxorubicin HCl liposome
injection; droloxifene; dronabinol; droperidol; edotecarin;
edotreotide (yttrium-90 labeled or unlabeled); EKB-569; EMD121974;
endostatin; enzastaurin; epirubicin; epithilone B; epoetin alfa;
ERA-923; erbitux; erlotinib; erythropoietin; estradiol;
estramustine; etoposide; everolimus; exemestane; finasteride;
flavopiridol; floxuridine; fludarabine; fludrocortisones;
fluoxymesterone; flutamide; fulvestrant; galeterone; GDC-0941;
gefitinib; gemcitabine; a combination of gemcitabine in association
with erlotinib; gimatecan; goserelin; goserelin acetate; gossypol;
granisetron; GSK461364; GSK690693; GW-572016; haloperidol; HKI-272;
HMR-3339; hydroxyprogesterone caproate; hydroxyurea; hydroxyzine;
IC87114; idarubicin; Idoxifene; ifosfamide; IL13-PE38QQR; IM862;
imatinib; IMC-1C11; INO 1001; interferon; interleukin-12; IPdR;
ipilimumab; irinotecan; JNJ-16241199; ketoconazole; KRN951;
KRX-0402; L-779,450; lapatanib; lasofoxifene; Lep-etu; letrozole;
leucovorin; leuprolide; leuprolide acetate; levamisole; lomustine;
lonafarnib; lorazepam; Lucanthone; LY 317615; LY292223; LY292696;
LY293646; LY293684; LY294002; marimastat; MDV-3100;
mechlorethamine; medroxyprogesterone acetate; megestrol acetate;
melphalan; mercaptopurine; mesna; methotrexate; methylprednisolone;
metoclopramide; mithramycin; mitomycin; mitotane; mitoxantrone;
MK-0457; MLN8054; neovastat; netupitant; neuradiab; nilotinib;
nilutimide; nolatrexed; NVP-BEZ235; NVP-LAQ824; oblimersen;
octreotide; ofatumumab; ON 0910.Na; ondansetron; oregovomab;
orteronel; oxaliplatin; paclitaxel; palonosetron; pamidronate;
panitumumab; pazopanib; PD0325901; PEG-filgrastim; PEG-interferon;
PEG-labeled irinotecan; pemetrexed; pentostatin; perifosine;
PHA-739358; phenylalanine mustard; PI-103; PIK-75; pipendoxifene;
PKI-166; plicamycin; porfimer; prednisone; procarbazine;
prochlorperazine; progestins; PTK787/ZK 222584; PX-866; R-763;
RAD001; raloxifene; raltitrexed; razoxin; ridaforolimus; rituximab;
romidepsin; RTA 744; rubitecan; scriptaid; Sdx 102; seliciclib;
semaxanib; SF1126; sirolimus; SN36093; sorafenib; spironolactone;
squalamine; SR13668; streptozocin; SU6668; suberoyl analide
hydroxamic acid; sunitinib; sunitinib malate; talampanel;
tamoxifen; temozolomide; temsirolimus; teniposide; tesmilifene;
testosterone; tetrandrine; TGX-221; thalidomide; thioguanine;
thiotepa; ticilimumab; tipifarnib; TKI-258; TLK 286; topotecan;
toremifene citrate; trabectedin; trastuzumab; tretinoin;
trichostatin A; triciribine phosphate monohydrate; triptorelin
pamoate; tropisetron; TSE-424; uracil mustard; valproic acid;
valrubicin; vandetanib; vatalanib; VEGF trap; vinblastine;
vincristine; vindesine; vinorelbine; vitaxin; vitespan; vorinostat;
VX-745; wortmannin; Xr 311; zanolimumab; ZK186619; ZK-304709,
ZM336372; ZSTK474;
##STR00001## ##STR00002##
[0010] The various methods of using the IGF1 biomarker that are
disussed herein (e.g., methods of treatment or methods of
evaluating a subject for treatment with an IGF1R inhibitor),
optionally further comprising evaluating the expression level of
KRAS and/or evaluating whether the KRAS is wild-type or mutated, in
connection with any of the specific IGF1R inhibitors that are
discussed herein (e.g., under the IGF1R Inhibitors section herein,
e.g., dalotuzumab), optionally in association with any 1, 2 or 3 of
the specific further chemotherapeutic agents discussed herein
(e.g., under the Further Chemotherapeutics section herein; e.g.,
ridaforolimus), wherein the method of using the biomarker is in
connection with a subject suffering from any of osteosarcoma,
rhabdomyosarcoma, neuroblastoma, kidney cancer, leukemia, renal
transitional cell cancer, bladder cancer, Wilm's cancer, ovarian
cancer, pancreatic cancer (e.g., where in the subject is
administered the IGF1R inhibitor (e.g., MK0646) in association with
gemcitabine, and optionally, ridaforolimus), breast cancer,
prostate cancer, bone cancer, lung cancer, gastric cancer,
colorectal cancer, cervical cancer, synovial sarcoma, head and neck
cancer, squamous cell carcinoma, multiple myeloma, renal cell
cancer, retinoblastoma, hepatoblastoma, hepatocellular carcinoma,
melanoma, rhabdoid tumor of the kidney, Ewing's sarcoma,
chondrosarcoma, brain cancer, glioblastoma, meningioma, pituitary
adenoma, vestibular schwannoma, a primitive neuroectodermal tumor,
medulloblastoma, astrocytoma, anaplastic astrocytoma,
oligodendroglioma, ependymoma, choroid plexus papilloma,
polycythemia vera, thrombocythemia, idiopathic myelfibrosis, soft
tissue sarcoma, thyroid cancer, endometrial cancer, carcinoid
cancer or liver cancer; are encompassed by the present
invention.
BRIEF DESCRIPTION OF THE FIGURES
[0011] FIG. 1: H2122 NSCLC cells were grown in the presence and
absence of IGF1 and MK-0646 and relative cell growth was compared.
A statistically significant growth inhibition by MK-0646 treatment
was observed in H2122 cell grown in the presence of the ligand
IGF1.
[0012] FIG. 2. High IGF1 identifies MK0646 responsive tumors in
colorectal cancer primary tumor xenograft models.
[0013] FIG. 3. In silica BLAST analysis with the IGF1 forward &
reverse primer sequences
[0014] FIG. 4. Electropherogram showing specific product for
IGF1.
[0015] FIG. 5(A-B). Reverse transcription polymerase chain reaction
(RT-PCR) amplification curve and standard curve.
[0016] FIG. 6. IGF1 expression levels in tumor tissue of colorectal
cancer patients.
[0017] FIG. 7. Kaplan-Meier Curve: progression free survival (PFS)
of patients with high and low IGF1 expression levels in tumor
tissue.
[0018] FIG. 8. Kaplan-Meier Curve: overall survival (OS) of
patients with high and low IGF1 expression levels in tumor
tissue.
DETAILED DESCRIPTION OF THE INVENTION
[0019] The present invention comprises methods for treating a
subset of patients suffering from a tumor that expresses IGF1 using
an IGF1R inhibitor (e.g., dalotuzumab). An evaluation of the IGF1
mRNA expression levels in a population of tumors has identified a
clear distinction between tumors that are highly sensitive to IGF1R
inhibitors and those that are less responsive. The cut point
between the highly sensitive and less sensitive subpopulations of
tumors can be expressed in terms of IGF1 mRNA expression levels
relative to any of a number of reference genes as determined by
real time PCR amplification of IGF1 cDNA that was generated by
reverse transcription of IGF1 mRNA from cells of the tumors.
[0020] In a certain embodiment of the invention, measurement of
IGF1 RNA and/or protein in the serum of a patient with a tumor, in
the practice of a methods described herein, is specifically
excluded from the invention.
[0021] A "subject" or "patient" or the like is a mammal such as a
human, monkey, primate, canine, feline, rat, rabbit or mouse.
[0022] When the cells of a tumor are analyzed to determine IGF1
expression, in an embodiment of the invention, tumor cells or both
stromal cells and tumor cells are analyzed.
[0023] "IGF1" is insulin-like growth factor 1, for example, human
insulin-like growth factor 1. In an embodiment of the invention,
human IGF1 comprises the nucleotide sequence or nucleotides 220-696
thereof (see Genbank accession no. NM.sub.--001111283):
TABLE-US-00001 IGF1 >nucfasta||NM_001111283 NM_001111283 1 (SEQ
ID NO: 13) ttttgtagataaatgtgaggattttctctaaatccctcttctgtt
tgctaaatctcactgtcactgctaaattcagagcagatagagcct
gcgcaatggaataaagtcctcaaaattgaaatgtgacattgctct
caacatctcccatctctctggatttctttttgcttcattattcct
gctaaccaattcattttcagactttgtacttcagaagcaatggga
aaaatcagcagtcttccaacccaattatttaagtgctgcttttgt
gatttcttgaaggtgaagatgcacaccatgtcctcctcgcatctc
ttctacctggcgctgtgcctgctcaccttcaccagctctgccacg
gctggaccggagacgctctgcggggctgagctggtggatgctctt
cagttcgtgtgtggagacaggggcttttatttcaacaagcccaca
gggtatggctccagcagtcggagggcgcctcagacaggcatcgtg
gatgagtgctgcttccggagctgtgatctaaggaggctggagatg
tattgcgcacccctcaagcctgccaagtcagctcgctctgtccgt
gcccagcgccacaccgacatgcccaagacccagaagtatcagccc
ccatctaccaacaagaacacgaagtctcagagaaggaaaggaagt
acatttgaagaacgcaagtagagggagtgcaggaaacaagaacta
caggatgtaggaagaccctcctgaggagtgaagagtgacatgcca
ccgcaggatcctttgctctgcacgagttacctgttaaactttgga
acacctaccaaaaaataagtttgataacatttaaaagatgggcgt
ttcccccaatgaaatacacaagtaaacattccaacattgtcttta
ggagtgatttgcaccttgcaaaaatggtcctggagttggtagatt
gctgttgatcttttatcaataatgttctatagaaaagaaaaaaaa
aatatatatatatatatatcttagtccctgcctctcaagagccac
aaatgcatgggtgttgtatagatccagttgcactaaattcctctc
tgaatcttggctgctggagccattcattcagcaaccttgtctaag
tggtttatgaattgtttccttatttgcacttctttctacacaact
cgggctgtttgttttacagtgtctgataatcttgttagtctatac
ccaccacctcccttcataacctttatatttgccgaatttggcctc
ctcaaaagcagcagcaagtcgtcaagaagcacaccaattctaacc
cacaagattccatctgtggcatttgtaccaaatataagttggatg
cattttattttagacacaaagctttatttttccacatcatgctta
caaaaaagaataatgcaaatagttgcaactttgaggccaatcatt
tttaggcatatgttttaaacatagaaagtttcttcaactcaaaag
agttccttcaaatgatgagttaatgtgcaacctaattagtaactt
tcctctttttattttttccatatagagcactatgtaaatttagca
tatcaattatacaggatatatcaaacagtatgtaaaactctgttt
tttagtataatggtgctattttgtagtttgttatatgaaagagtc
tggccaaaacggtaatacgtgaaagcaaaacaataggggaagcct
ggagccaaagatgacacaaggggaagggtactgaaaacaccatcc
atttgggaaagaaggcaaagtccccccagttatgccttccaagag
gaacttcagacacaaaagtccactgatgcaaattggactggcgag
tccagagaggaaactgtggaatggaaaaagcagaaggctaggaat
tttagcagtcctggtttctttttctcatggaagaaatgaacatct
gccagctgtgtcatggactcaccactgtgtgaccttgggcaagtc
acttcacctctctgtgcctcagtttcctcatctgcaaaatggggg
caatatgtcatctacctacctcaaaggggtggtataaggtttaaa
aagataaagattcagattttttttaccctgggttgctgtaagggt
gcaacatcagggcgcttgagttgctgagatgcaaggaattctata
aataacccattcatagcatagctagagattggtgaattgaatgct
cctgacatctcagttcttgtcagtgaagctatccaaataactggc
caactagttgttaaaagctaacagctcaatctcttaaaacacttt
tcaaaatatgtgggaagcatttgattttcaatttgattttgaatt
ctgcatttggttttatgaatacaaagataagtgaaaagagagaaa
ggaaaagaaaaaggagaaaaacaaagagatttctaccagtgaaag
gggaattaattactctttgttagcactcactgactcttctatgca
gttactacatatctagtaaaacctcgtttaatactataaataata
ttctattcattttgaaaaacacaatgattccttcttttctaggca
atataaggaaagtgatccaaaatttgaaatattaaaataatatct
aataaaaagtcacaaagttatcttctttaacaaactttactctta
ttcttagctgtatatacatttttttaaaagtttgttaaaatatgc
ttgactagagtttccagttgaaaggcaaaaacttccatcacaaca
agaaatttcccatgcctgctcagaagggtagcccctagctctctg
tgaatgtgttttatccattcaactgaaaattggtatcaagaaagt
ccactggttagtgtactagtccatcatagcctagaaaatgatccc
tatctgcagatcaagattttctcattagaacaatgaattatccag
cattcagatctttctagtcaccttagaactttttggttaaaagta
cccaggcttgattatttcatgcaaattctatattttacattcttg
gaaagtctatatgaaaaacaaaaataacatcttcagtttttctcc
cactgggtcacctcaaggatcagaggccaggaaaaaaaaaaaaaa
gactccctggatctctgaatatatgcaaaaagaaggccccattta
gtggagccagcaatcctgttcagtcaacaagtattttaactctca
gtccaacattatttgaattgagcacctcaagcatgcttagcaatg
ttctaatcactatggacagatgtaaaagaaactatacatcatttt
tgccctctgcctgttttccagacatacaggttctgtggaataaga
tactggactcctcttcccaagatggcacttctttttatttcttgt
ccccagtgtgtaccttttaaaattattccctctcaacaaaacttt
ataggcagtcttctgcagacttaacgtgttttctgtcatagttag
atgtgataattctaagagtgtctatgacttatttccttcacttaa
ttctatccacagtcaaaaatcccccaaggaggaaagctgaaagat
gcactgccatattatctttcttaactttttccaacacataatcct
ctccaactggattataaataaattgaaaataactcattataccaa
ttcactattttattttttaatgaattaaaactagaaaacaaattg
atgcaaaccctggaagtcagttgattactatatactacagcagaa
tgactcagatttcatagaaaggagcaaccaaaatgtcacaaccca
aaactttacaagctttgcttcagaattagattgctttataattct
tgaatgaggcaatttcaagatatttgtaaaagaacagtaaacatt
ggtaagaatgagctttcaactcataggcttatttccaatttaatt
gaccatactggatacttaggtcaaatttctgttctctcttcccca
aataatattaaagtattatttgaactttttaagatgaggcagttc
ccctgaaaaagttaatgcagctctccatcagaatccactcttcta
gggatatgaaaatctcttaacacccaccctacatacacagacaca
cacacacacacacacacacacacacacacacacattcaccctaag
gatccaatggaatactgaaaagaaatcacttccttgaaaatttta
ttaaaaaacaaacaaacaaacaaaaagcctgtccacccttgagaa
tccttcctctccttggaacgtcaatgtttgtgtagatgaaaccat
ctcatgctctgtggctccagggtttctgttactattttatgcact
tgggagaaggcttagaataaaagatgtagcacattttgctttccc
atttattgtttggccagctatgccaatgtggtgctattgtttctt
taagaaagtacttgactaaaaaaaaaagaaaaaaagaaaaaaaag
aaagcatagacatatttttttaaagtataaaaacaacaattctat
agatagatggcttaataaaatagcattaggtctatctagccacca
ccacctttcaactttttatcactcacaagtagtgtactgttcacc
aaattgtgaatttgggggtgcaggggcaggagttggaaatttttt
aaagttagaaggctccattgttttgttggctctcaaacttagcaa
aattagcaatatattatccaatcttctgaacttgatcaagagcat
ggagaataaacgcgggaaaaaagatcttataggcaaatagaagaa
tttaaaagataagtaagttccttattgatttttgtgcactctgct
ctaaaacagatattcagcaagtggagaaaataagaacaaagagaa
aaaatacatagatttacctgcaaaaaatagcttctgccaaatccc
ccttgggtattctttggcatttactggtttatagaagacattctc
ccttcacccagacatctcaaagagcagtagctctcatgaaaagca
atcactgatctcatttgggaaatgttggaaagtatttccttatga
gatgggggttatctactgataaagaaagaatttatgagaaattgt
tgaaagagatggctaacaatctgtgaagattttttgtttcttgtt
tttgttttttttttttttttactttatacagtctttatgaatttc
ttaatgttcaaaatgacttggttcttttcttctttttttatatca
gaatgaggaataataagttaaacccacatagactctttaaaacta
taggctagatagaaatgtatgtttgacttgttgaagctataatca
gactatttaaaatgttttgctatttttaatcttaaaagattgtgc
taatttattagagcagaacctgtttggctctcctcagaagaaaga
atctttccattcaaatcacatggctttccaccaatattttcaaaa
gataaatctgatttatgcaatggcatcatttattttaaaacagaa
gaattgtgaaagtttatgcccctcccttgcaaagaccataaagtc
cagatctggtaggggggcaacaacaaaaggaaaatgttgttgatt
cttggttttggattttgttttgttttcaatgctagtgtttaatcc
tgtagtacatatttgcttattgctattttaatattttataagacc
ttcctgttaggtattagaaagtgatacatagatatcttttttgtg
taatttctatttaaaaaagagagaagactgtcagaagctttaagt
gcatatggtacaggataaagatatcaatttaaataaccaattcct
atctggaacaatgcttttgttttttaaagaaacctctcacagata
agacagaggcccaggggatttttgaagctgtctttattctgcccc
catcccaacccagcccttattattttagtatctgcctcagaattt
tatagagggctgaccaagctgaaactctagaattaaaggaacctc
actgaaaacatatatttcacgtgttccctctttttttttttcctt
tttgtgagatggggtctcgcactgtcccccaggctggagtgcagt
ggcatgatctcggctcactgcaacctccacctcctgggtttaagc
gattctcctgcctcagcctcctgagtagctgggattacaggcacc
caccactatgcccggctaattttttggatttttaatagagacggg
gttttaccatgttggccaggttggtctcaaactcctgaccttgtg
atttgcccgcctcagcctcccaaattgctgggattacaggcatga
gccaccacaccctgcccatgtgttccctcttaatgtatgattaca
tggatcttaaacatgatccttctctcctcattcttcaactatctt
tgatggggtctttcaaggggaaaaaaatccaagcttttttaaagt
aaaaaaaaaaaaagagaggacacaaaaccaaatgttactgctcaa
ctgaaatatgagttaagatggagacagagtttctcctaataaccg
gagctgaattacctttcactttcaaaaacatgaccttccacaatc
cttagaatctgcctttttttatattactgaggcctaaaagtaaac
attactcattttattttgcccaaaatgcactgatgtaaagtagga
aaaataaaaacagagctctaaaatccctttcaagccacccattga
ccccactcaccaactcatagcaaagtcacttctgttaatccctta
atctgattttgtttggatatttatcttgtacccgctgctaaacac
actgcaggagggactctgaaacctcaagctgtctacttacatctt
ttatctgtgtctgtgtatcatgaaaatgtctattcaaaatatcaa
aacctttcaaatatcacgcagcttatattcagtttacataaaggc
cccaaataccatgtcagatctttttggtaaaagagttaatgaact
atgagaattgggattacatcatgtattttgcctcatgtattttta
tcacacttataggccaagtgtgataaataaacttacagacactga
attaatttcccctgctactttgaaaccagaaaataatgactggcc
attcgttacatctgtcttagttgaaaagcatattttttattaaat
taattctgattgtatttgaaattattattcaattcacttatggca
gaggaatatcaatcctaatgacttctaaaaatgtaactaattgaa
tcattatcttacatttactgtttaataagcatattttgaaaatgt
atggctagagtgtcataataaaatggtatatctttctttagtaat
tacattaaaattagtcatgtttgattaattagttc
[0024] A "reference gene" is a gene whose expression is known not
to increase or decrease significantly in a tumor cell of a given
type (e.g., breast, lung, colorectal or any of the tumor types
discussed herein) as compared to the corresponding normal,
non-tumor cell. Examples of such reference genes include CYC1,
HMBS, TOP1, SDHA, GUSH, PUM1, HPRT1, ACTS, UBC, B2M, GAPDH, and
TUBB2A.
[0025] In an embodiment of the invention TUBB2A comprises the
nucleotide sequence or nucleotides 87-1424 thereof (see Genbank
accession no. NM.sub.--001069):
TABLE-US-00002 TUBB2A >nucfasta||NM_001069 NM_001069 2 (SEQ ID
NO: 14) gcggcaggtctctgcgcagcccagcccgccggtccacgccgcgcaccg
ctccgagggccagcgccacccgctccgcagccggcaccatgcgcgaga
tcgtgcacatccaggcgggccagtgcggcaaccagatcggcgccaagt
tttgggaggtcatcagcgatgagcatgggatcgaccccacaggcagtt
accatggagacagtgacttgcagctggagagaatcaacgtgtactaca
atgaggctgctggtaacaaatatgtacctcgggccatcctggtggatc
tggagcctggcaccatggactctgtcaggtctggacccttcggccaga
tcttcagaccagacaacttcgtgttcggccagagtggagccgggaata
actgggccaagggccactacacagagggagccgagctggtcgactcgg
tcctggatgtggtgaggaaggagtcagagagctgtgactgtctccagg
gcttccagctgacccactctctggggggcggcacggggtccgggatgg
gcaccctgctcatcagcaagatccgggaagagtacccagaccgcatca
tgaacaccttcagcgtcatgccctcacccaaggtgtcagacacggtgg
tggagccctacaacgccaccctctctgtccaccagctggtggaaaaca
cagatgaaacctactccattgataacgaggccctgtatgacatctgct
tccgcaccctgaagctgaccacccccacctacggggacctcaaccacc
tggtgtcggccaccatgagcggggtcaccacctgcctgcgcttcccgg
gccagctgaacgcagacctgcgcaagctggcggtgaacatggtgccct
tccctcgcctgcacttcttcatgcccggcttcgcgcccctgaccagcc
ggggcagccagcagtaccgggcgctcacggtgcccgagctcacccagc
agatgttcgactccaagaacatgatggccgcctgcgacccgcgccacg
gccgctacctgacggtggctgccatcttccggggccgcatgtccatga
aggaggtggacgagcagatgctcaacgtgcagaacaagaacagcagct
acttcgtggagtggatccccaacaacgtgaagacggccgtgtgcgaca
tcccgccccgcggcctgaagatgtcggccaccttcatcggcaacagca
cggccatccaggagctgttcaagcgcatctccgagcagttcacggcca
tgttccggcgcaaggccttcctgcactggtacacgggcgagggcatgg
acgagatggagttcaccgaggccgagagcaacatgaacgacctggtgt
ccgagtaccagcagtaccaggacgccacggccgacgaacaaggggagt
tcgaggaggaggagggcgaggacgaggcttaaaaacttctcagatcaa
tcgtgcatccttagtgaacttctgttgtcctcaagcatggtctttcta
cttgtaaactatggtgctcagttttgcctctgttagaaattcacactg
ttgatgtaatgatgtggaactcctctaaaaattacagtattgtctgtg
aaggtatctatactaataaaaaagcatgtgtagaaaa
[0026] In an embodiment of the invention PUM1 comprises the
nucleotide sequence or nucleotides 114-3674 thereof (see Genbank
accession no. NM.sub.--014676):
TABLE-US-00003 PUM1 >nucfasta||NM_014676 NM_014676 2 (SEQ ID NO:
15) agtgggccgccatgttgtcggagtgaaaggtaagggggagcgagagcg
ccagagagagaagatcggggggctgaaatccatcttcatcctaccgct
ccgcccgtgttggtggaatgagcgttgcatgtgtcttgaagagaaaag
cagtgctttggcaggactctttcagcccccacctgaaacatcaccctc
aagaaccagctaatcccaacatgcctgttgttttgacatctggaacag
ggtcgcaagcgcagccacaaccagctgcaaatcaggctcttgcagctg
ggactcactccagccctgtcccaggatctataggagttgcaggccgtt
cccaggacgacgctatggtggactacttctttcagaggcagcatggtg
agcagcttgggggaggaggaagtggaggaggcggctataataatagca
aacatcgatggcctactggggataacattcatgcagaacatcaggtgc
gttccatggatgaactgaatcatgattttcaagcacttgctctggagg
gaagagcgatgggagagcagctcttgccaggtaaaaagttttgggaaa
cagatgaatccagcaaagatggaccaaaaggaatattcctgggtgatc
aatggcgagacagtgcctggggaacatcagatcattcagtttcccagc
caatcatggtgcagagaagacctggtcagagtttccatgtgaacagtg
aggtcaattctgtactgtccccacgatcggagagtgggggactaggcg
ttagcatggtggagtatgtgttgagctcatccccgggcgattcctgtc
taagaaaaggaggatttggcccaagggatgcagacagtgatgaaaacg
acaaaggtgaaaagaagaacaagggtacgtttgatggagataagctag
gagatttgaaggaggagggtgatgtgatggacaagaccaatggtttac
cagtgcagaatgggattgatgcagacgtcaaagattttagccgtaccc
ctggtaattgccagaactctgctaatgaagtggatcttctgggtccaa
accagaatggttctgagggcttagcccagotgaccagcaccaatggtg
ccaagcctgtggaggatttctccaacatggagtcccagagtgtcccct
tggaccccatggaacatgtgggcatggagcctcttcagtttgattatt
caggcacgcaggtacctgtggactcagcagcagcaactgtgggacttt
ttgactacaattctcaacaacagctgttccaaagacctaatgcgcttg
ctgtccagcagttgacagctgctcagcagcagcagtatgcactggcag
ctgctcatcagccgcacatcggtttagctcccgctgcgtttgtcccca
atccatacatcatcagcgctgctcccccagggacggacccctacacag
ctggattggctgcagcagcgacactaggcccagctgtggtccctcacc
agtattatggagttactccctggggagtctaccctgccagtcttttcc
agcagcaagctgccgctgccgctgcagcaactaattcagctaatcaac
agaccaccccacaggctcagcaaggacagcagcaggttctccgtggag
gagccagccaacgtcctttgaccccaaaccagaaccagcagggacagc
aaacggatccccttgtggcagctgcagcagtgaattctgcccttgcat
ttggacaaggtctggcagcaggcatgccaggttatccggtgttggctc
ctgctgcttactatgaccaaactggtgcccttgtagtgaatgcaggcg
cgagaaatggtcttggagctcctgttcgacttgtagctcctgccccag
tcatcattagttcctcagctgcacaagcagctgttgcagcagccgcag
cttcagcaaatggagcagctggtggtcttgctggaacaacaaatggac
catttcgccctttaggaacacagcagcctcagccccagccccagcagc
agcccaataacaacctggcatccagttctttctacggcaacaactctc
tgaacagcaattcacagagcagctccctcttctcccagggctctgccc
agcctgccaacacatccttgggattcggaagtagcagttctctcggcg
ccaccctgggatccgcccttggagggtttggaacagcagttgcaaact
ccaacactggcagtggctcccgccgtgactccctgactggcagcagtg
acctttataagaggacatcgagcagcttgacccccattggacacagtt
tttataacggccttagcttttcctcctctcctggacccgtgggcatgc
ctctccctagtcagggaccaggacattcacagacaccacctccttccc
tctcttcacatggatcctcttcaagcttaaacctgggaggactcacga
atggcagtggaagatacatctctgctgctccaggcgctgaagccaagt
accgcagtgcaagcagcgcctccagcctcttcagcccgagcagcactc
ttttctcttcctctcgtttgcgatatggaatgtctgatgtcatgcctt
ctggcaggagcaggcttttggaagattttcgaaacaaccggtacccca
atttacaactgcgggagattgctggacatataatggaattttcccaag
accagcatgggtccagattcattcagctgaaactggagcgtgccacac
cagctgagcgccagcttgtcttcaatgaaatcctccaggctgcctacc
aactcatggtggatgtgtttggtaattacgtcattcagaagttctttg
aatttggcagtcttgaacagaagctggctttggcagaacggattcgag
gccacgtcctgtcattggcactacagatgtatggctgccgtgttatcc
agaaagctcttgagtttattccttcagaccagcagaatgagatggttc
gggaactagatggccatgtcttgaagtgtgtgaaagatcagaatggca
atcacgtggttcagaaatgcattgaatgtgtacagccccagtctttgc
aatttatcatcgatgcgtttaagggacaggtatttgccttatccacac
atccttatggctgccgagtgattcagagaatcctggagcactgtctcc
ctgaccagacactccctattttagaggagcttcaccagcacacagagc
agcttgtacaggatcaatatggaaattatgtaatccaacatgtactgg
agcacggtcgtcctgaggataaaagcaaaattgtagcagaaatccgag
gcaatgtacttgtattgagtcagcacaaatttgcaagcaatgttgtgg
agaagtgtgttactcacgcctcacgtacggagcgcgctgtgctcatcg
atgaggtgtgcaccatgaacgacggtccccacagtgccttatacacca
tgatgaaggaccagtatgccaactacgtggtccagaagatgattgacg
tggcggagccaggccagcggaagatcgtcatgcataagatccggcccc
acatcgcaactcttcgtaagtacacctatggcaagcacattctggcca
agctggagaagtactacatgaagaacggtgttgacttagggcccatct
gtggcccccctaatggtatcatctgaggcagtgtcacccgctgttccc
tcattcccgctgacctcactggcccactggcaaatccaaccagcaacc
agaaatgttctagtgtagagtctgagacgggcaagtggttgctccagg
attactccctcctccaaaaaaggaatcaaatccacgagtggaaaagcc
tttgtaaatttaattttattacacataacatgtactattttttttaat
tgactaattgccctgctgttttactggtgtataggatacttgtacata
ggtaaccaatgtacatgggaggccacatattttgttcactgttgtatc
tatatttcacatgtggaaactttcagggtggttggtttaacaaaaaaa
aaaagctttaaaaaaaaaagaaaaaaaggaaaaggtttttagctcatt
tgcctggccggcaagttttgcaaatagctcttccccacctcctcattt
tagtaaaaaacaaacaaaaacaaaaaaacctgagaagtttgaattgta
gttaaatgaccccaaactggcatttaacactgtttataaaaaatatat
atatatatatatatatatataatgaaaaaggtttcagagttgctaaag
cttcagtttgtgacattaagtttatgaaattctaaaaaatgccttttt
tggagactatattatgctgaagaaggctgttcgtgaggaggagatgcg
agcacccagaacgtcttttgaggctgggcgggtgtgattgtttactgc
ctactggatttttttctattaacattgaaaggtaaaatctgattattt
agcatgagaaaaaaaaatccaactctgcttttggtcttgcttctataa
atatatagtgtatacttggtgtagactttgcatatatacaaatttgta
gtattttcttgttttgatgtctaatctgtatctataatgtaccctagt
agtcgaacatacttttgattgtacaattgtacatttgtatacctgtaa
tgtaaatgtggagaagtttgaatcaacataaacacgttttttggtaag
aaaagagaattagccagccctgtgcattcagtgtatattctcaccttt
tatggtcgtagcatatagtgttgtatattgtaaattgtaatttcaacc
agaagtaaatttttttcttttgaaggaataaatgttctttatacagcc
tagttaatgtttaaaaagaaaaaaatagcttggttttatttgtcatct
agtctcaagtatagcgagattctttctaaatgttattcaagattgagt
tctcactagtgtttttttaatcctaaaaaagtaatgttttgattttgt
gacagtcaaaaggacgtgcaaaagtctagccttgcccgagctttcctt
acaatcagagcccctctcaccttgtaaagtgtgaatcgcccttccctt
ttgtacagaagatgaactgtattttgcattttgtctacttgtaagtga
atgtaacatactgtcaattttccttgtttgaatatagaattgtaacac
tacacggtgtacatttccagagccttgtgtatatttccaatgaacttt
tttgcaagcacacttgtaaccatatgtgtataattaacaaacctgtgt
atgcttatgcctgggcaactattttttgtaactcttgtgtagattgtc
tctaaacaatgtgtgatctttattttgaaaaatacagaactttggaat
ctgaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
[0027] In an embodiment of the invention UBC comprises the
nucleotide sequence or nucleotides 459-2516 thereof (see Genbank
accession no. NM.sub.--021009):
TABLE-US-00004 UBC >nucfasta||NM_021009 NM_021009 5 (SEQ ID NO:
16) aggggccgcggagccgcggctaaggaacgcgggccgcccacccgctcc
cggtgcascggcctccgcgccgggttttggcgcctcccgcgggcgccc
ccctcctcacggcgagcgctgccacgtcagacgaagggcgcagcgagc
gtcctgatccttccgcccggacgctcaggacagcggcccgctgctcat
aagactcggccttagaaccccagtatcagcagaaggacattttaggac
gggacttgggtgactctagggcactggttttctttccagagagcggaa
caggcgaggaaaagtagtcccttctcggcgattctgcggagggatctc
cgtggggcggtgaacgccgatgattatataaggacgcgccgggtgtgg
cacagctagttccgtcgcagccgggatttgggtcgcagttcttgtttg
tggatcgctgtgatcgtcacttgacaatgcagatcttcgtgaagactc
tgactggtaagaccatcaccctcgaggttgagcccagtgacaccatcg
agaatgtcaaggcaaagatccaagataaggaaggcatccctcctgacc
agcagaggctgatctttgctggaaaacagctggaagatgggcgcaccc
tgtctgactacaacatccagaaagagtccaccctgcacctggtgctcc
gtctcagaggtgggatgcaaatcttcgtgaagacactcactggcaaga
ccatcacccttgaggtcgagcccagtgacaccatcgagaacgtcaaag
caaagatccaggacaaggaaggcattcctcctgaccagcagaggttga
tctttgccggaaagcagctggaagatgggcgcaccctgtctgactaca
acatccagaaagagtctaccctgcacctggtgctccgtctcagaggtg
ggatgcagatcttcgtgaagaccctgactggtaagaccatcaccctcg
aggtggagcccagtgacaccatcgagaatgtcaaggcaaagatccaag
ataaggaaggcattccttctgatcagcagaggttgatctttgccggaa
aacagctggaagatggtcgtaccctgtctgactacaacatccagaaag
agtccaccttgcacctggtactccgtctcagaggtgggatgcaaatct
tcgtgaagacactcactggcaagaccatcacccttgaggtcgagccca
gtgacactatcgagaacgtcaaagcaaagatccaagacaaggaaggca
ttcctcctgaccagcagaggttgatctttgccggaaagcagctggaag
atgggcgcaccctgtctgactacaacatccagaaagagtctaccctgc
acctggtgctccgtctcagaggtgggatgcagatcttcgtgaagaccc
tgactggtaagaccatcactctcgaagtggagccgagtgacaccattg
agaatgtcaaggcaaagatccaagacaaggaaggcatccctcctgacc
agcagaggttgatctttgccggaaaacagctggaagatggtcgtaccc
tgtctgactacaacatccagaaagagtccaccttgcacctggtgctcc
gtctcagaggtgggatgcagatcttcgtgaagaccctgactggtaaga
ccatcactctcgaggtggagccgagtgacaccattgagaatgtcaagg
caaagatccaagacaaggaaggcatccctcctgaccagcagaggttga
tctttgctgggaaacagctggaagatggacgcaccctgtctgactaca
acatccagaaagagtccaccctgcacctggtgctccgtcttagaggtg
ggatgcagatcttcgtgaagaccctgactggtaagaccatcactctcg
aagtggagccgagtgacaccattgagaatgtcaaggcaaagatccaag
acaaggaaggcatccctcctgaccagcagaggttgatctttgctggga
aacagctggaagatggacgcaccctgtctgactacaacatccagaaag
agtccaccctgcacctggtgctccgtcttagaggtgggatgcagatct
tcgtgaagaccctgactggtaagaccatcactctcgaagtggagccga
gtgacaccattgagaatgtcaaggcaaagatccaagacaaggaaggca
tccctcctgaccagcagaggttgatctttgctgggaaacagctggaag
atggacgcaccctgtctgactacaacatccagaaagagtccaccctgc
acctggtgctccgtctcagaggtgggatgcaaatcttcgtgaagaccc
tgactggtaagaccatcaccctcgaggtggagcccagtgacaccatcg
agaatgtcaaggcaaagatccaagataaggaaggcatccctcctgatc
agcagaggttgatctttgctgggaaacagctggaagatggacgcaccc
tgtctgactacaacatccagaaagagtccactctgcacttggtcctgc
gcttgagggggggtgtctaagtttccccttttaaggtttcaacaaatt
tcattgcactttcctttcaataaagttgttgcattcccaaaaaaaaaa aa
[0028] In an embodiment of the invention HPRT1 comprises the
nucleotide sequence or nucleotides 168-824 thereof (see Genbank
accession no. NM.sub.--000194):
TABLE-US-00005 HPRT1 >nucfasta||NM_000194 NM_000194 2 (SEQ ID
NO: 17) ggcggggcctgcttctcctcagcttcaggcggctgcgacgagccctca
ggcgaacctctcggctttcccgcgcggcgccgcctcttgctgcgcctc
cgcctcctcctctgctccgccaccggcttcctcctcctgagcagtcag
cccgcgcgccggccggctccgttatggcgacccgcagccctggcgtcg
tgattagtgatgatgaaccaggttatgaccttgatttattttgcatac
ctaatcattatgctgaggatttggaaagggtgtttattcctcatggac
taattatggacaggactgaacgtcttgctcgagatgtgatgaaggaga
tgggaggccatcacattgtagccctctgtgtgctcaaggggggctata
aattctttgctgacctgctggattacatcaaagcactgaatagaaata
gtgatagatccattcctatgactgtagattttatcagactgaagagct
attgtaatgaccagtcaacaggggacataaaagtaattggtggagatg
atctctcaactttaactggaaagaatgtcttgattgtggaagatataa
ttgacactggcaaaacaatgcagactttgctttccttggtcaggcagt
ataatccaaagatggtcaaggtcgcaagcttgctggtgaaaaggaccc
cacgaagtgttggatataagccagactttgttggatttgaaattccag
acaagtttgttgtaggatatgcccttgactataatgaatacttcaggg
atttgaatcatgtttgtgtcattagtgaaactggaaaagcaaaataca
aagcctaagatgagagttcaagttgagtttggaaacatctggagtcct
attgacatcgccagtaaaattatcaatgttctagttctgtggccatct
gcttagtagagctttttgcatgtatcttctaagaattttatctgtttt
gtactttagaaatgtcagttgctgcattcctaaactgtttatttgcac
tatgagcctatagactatcagttccctttgggcggattgttgtttaac
ttgtaaatgaaaaaattctcttaaaccacagcactattgagtgaaaca
ttgaactcatatctgtaagaaataaagagaagatatattagtttttta
attggtattttaatttttatatatgcaggaaagaatagaagtgattga
atattgttaattataccaccgtgtgttagaaaagtaagaagcagtcaa
ttttcacatcaaagacagcatctaagaagttttgttctgtcctggaat
tattttagtagtgtttcagtaatgttgactgtattttccaacttgttc
aaattattaccagtgaatctttgtcagcagttcccttttaaatgcaaa
tcaataaattcccaaaaatttaaaaaaaaaaaaaaaaaaaaaa
[0029] In an embodiment of the invention CYC1 comprises the
nucleotide sequence or nucleotides 44-1021 thereof (see Genbank
accession no. NM.sub.--001916):
TABLE-US-00006 CYC1 >nucfasta||NM_001916 NM_001916 3 (SEQ ID NO:
18) cccaggggccgacgggagtggcggccgcgcggaggaggccaagatggc
ggcagctgcggcttcgcttcgcggggtagtgttgggcccgcggggcgc
ggggctcccgggcgcgcgtgcccggggtctgctgtgcagcgcgcgtcc
cgggcagctcccgctacggacacctcaggcagtggccttgtcgtcgaa
gtctggcctttcccgaggccggaaagtgatgctgtcagcgctgggcat
gctggcggcagggggtgcggggctggccgtggctctgcattcggctgt
gagtgccagtgacctggagctgcacccccccagctatccgtggtctca
ccgtggcctcctctcttccttggaccacaccagcatccggaggggttt
ccaggtatataagcaggtgtgcgcctcctgccacagcatggacttcgt
ggcctaccgccacctggtgggcgtgtgctacacggaggatgaagctaa
ggagctggctgcggaggtggaggttcaagacggccccaatgaagatgg
ggagatgttcatgcggccagggaagctgttcgactatttcccaaaacc
ataccccaacagtgaggctgctcgagctgccaacaacggagcattgcc
ccctgacctcagctacatcgtgcgagctaggcatggtggtgaggacta
cgtcttctccctgctcacgggctactgcgagccacccaccggggtgtc
actgcgggaaggtctctacttcaacccctactttcctggccaggccat
tgccatggcccctcccatctacacagatgtcttagagtttgacgatgg
caccccagctaccatgtcccagatagccaaggatgtgtgcaccttcct
gcgctgggcatctgagccagagcacgaccatcgaaaacgcatggggct
caagatgttgatgatgatggctctgctggtgcccctggtctacaccat
aaagcggcacaagtggtcagtcctgaagagtcggaagctggcatatcg
gccgcccaagtgaccctgtccagtgtctgcttgccatcctgccagaac
aggccctcaagcccaagagccatcccaggcctgttcaggcctcagcta
agcctctcttcatctggaagaagaggcaagggggcaggagaccaggct
ctagctctgggccctccttcagcccccatcatgggaataaattaattt
tctcaatgtaaaaaaaaaaaaaaaaaaaaaaaaaa
[0030] In an embodiment of the invention HMBS comprises the
nucleotide sequence or nucleotides 158-1243 thereof (see Genbank
accession no. NM.sub.--000190):
TABLE-US-00007 HMBS >nucfasta||NM_000190 NM_000190 3 (SEQ ID NO:
19) ccggaagtgacgcgaggctctgcggagaccaggagtcagactgtagga
cgacctcgggtcccacgtgtccccggtactcgccggccggagcccccg
gcttcccggggccgggggaccttagcggcacccacacacagcctactt
tccaagcggagccatgtctggtaacggcaatgcggctgcaacggcgga
agaaaacagcccaaagatgagagtgattcgcgtgggtacccgcaagag
ccagcttgctcgcatacagacggacagtgtggtggcaacattgaaagc
ctcgtaccctggcctgcagtttgaaatcattgctatgtccaccacagg
ggacaagattcttgatactgcactctctaagattggagagaaaagcct
gtttaccaaggagcttgaacatgccctggagaagaacgaagtggacct
ggttgttcactccttgaaggacctgcccactgtgcttcctcctggctt
caccatcggagccatctgcaagcgggaaaaccctcatgatgctgttgt
ctttcacccaaaatttgttgggaagaccctagaaaccctgccagagaa
gagtgtggtgggaaccagctccctgcgaagagcagcccagctgcagag
aaagttcccgcatctggagttcaggagtattcggggaaacctcaacac
ccggcttcggaagctggacgagcagcaggagttcagtgccatcatcct
ggcaacagctggcctgcagcgcatgggctggcacaaccgggtggggca
gatcctgcaccctgaggaatgcatgtatgctgtgggccagggggcctt
gggcgtggaagtgcgagccaaggaccaggacatcttggatctggtggg
cgtgctgcacgatcccgagactctgcttcgctgcatcgctgaaagggc
cttcctgaggcacctggaaggaggctgcagtgtgccagtagccgtgca
tacagctatgaaggatgggcaactgtacctgactggaggagtctggag
tctagacggctcagatagcatacaagagaccatgcaggctaccatcca
tgtccctgcccagcatgaagatggccctgaggatgacccacagttggt
aggcatcactgctcgtaacattccacgagggccccagttggctgccca
gaacttgggcatcagcctggccaacttgttgctgagcaaaggagccaa
aaacatcctggatgttgcacggcagcttaacgatgcccattaactggt
ttgtggggcacagatgcctgggttgctgctgtccagtgcctacatccc
gggcctcagtgccccattctcactgctatctggggagtgattaccccg
ggagactgaactgcagggttcaagccttccagggatttgcctcacctt
ggggccttgatgactgccttgcctcctcagtatgtgggggcttcatct
ctttagagaagtccaagcaacagcctttgaatgtaaccaatcctacta
ataaaccagttctgaaggtgtaaaaaaaaaaaaaaaaa
[0031] In an embodiment of the invention SDHA comprises the
nucleotide sequence or nucleotides 116-2110 thereof (see Genbank
accession no. NM.sub.--004168):
TABLE-US-00008 SDHA>nucfasta||NM_004168 NM_004168 2 (SEQ ID NO:
20) tccggcgtggtgcgcaggcgcggtatcccccctcccccgccagctcga
ccccggtgtggtgcgcaggcgcagtctgcgcagggactggcgggactg
cgcggcggcaacagcagacatgtcgggggtccggggcctgtcgcggct
gctgagcgctcggcgcctggcgctggccaaggcgtggccaacagtgtt
gcaaacaggaacccgaggttttcacttcactgttgatgggaacaagag
ggcatctgctaaagtttcagattccatttctgctcagtatccagtagt
ggatcatgaatttgatgcagtggtggtaggcgctggaggggcaggctt
gcgagctgcatttggcctttctgaggcagggtttaatacagcatgtgt
taccaagctgtttcctaccaggtcacacactgctgcagcacagggagg
aatcaatgctgctctggggaacatggaggaggacaactggaggtggca
tttctacgacaccgtgaagggctccgactggctgggggaccaggatgc
catccactacatgacggagcaggcccccgccgccgtggtcgagctaga
aaattatggcatgccgtttagcagaactgaagatgggaagatttatca
gcgtgcatttggtggacagagcctcaagtttggaaagggcgggcaggc
ccatcggtgctgctgtgtggctgatcggactggccactcgctattgca
caccttatatggaaggtctctgcgatatgataccagctattttgtgga
gtattttgccttggatctcctgatggagaatggggagtgccgtggtgt
catcgcactgtgcatagaggacgggtccatccatcgcataagagcaaa
gaacactgttgttgccacaggaggctacgggcgcacctacttcagctg
cacgtctgcccacaccagcactggcgacggcacggccatgatcaccag
ggcaggccttccttgccaggacctagagtttgttcagttccaccctac
aggcatatatggtgctggttgtctcattacggaaggatgtcgtggaga
gggaggcattctcattaacagtcaaggcgaaaggtttatggagcgata
cgcccctgtcgcgaaggacctggcgtctagagatgtggtgtctcggtc
catgactctggagatccgagaaggaagaggctgtggccctgagaaaga
tcacgtctacctgcagctgcaccacctacctccagagcagctggccac
gcgcctgcctggcatttcagagacagccatgatcttcgctggcgtgga
cgtcacgaaggagccgatccctgtcctccccaccgtgcattataacat
gggcggcattcccaccaactacaaggggcaggtcctgaggcacgtgaa
tggccaggatcagattgtgcccggcctgtacgcctgtggggaggccgc
ctgtgcctcggtacatggtgccaaccgcctcggggcaaactcgctctt
ggacctggttgtctttggtcgggcatgtgccctgagcatcgaagagtc
atgcaggcctggagataaagtccctccaattaaaccaaacgctgggga
agaatctgtcatgaatcttgacaaattgagatttgctgatggaagcat
aagaacatcggaactgcgactcagcatgcagaagtcaatgcaaaatca
tgctgccgtgttccgtgtgggaagcgtgttgcaagaaggttgtgggaa
aatcagcaagctctatggagacctaaagcacctgaagacgttcgaccg
gggaatggtctggaacacggacctggtggagaccctggagctgcagaa
cctgatgctgtgtgcgctgcagaccatctacggagcagaggcacggaa
ggagtcacggggcgcgcatgccagggaagactacaaggtgcggattga
tgagtacgattactccaagcccatccaggggcaacagaagaagccctt
tgaggagcactggaggaagcacaccctgtcctatgtggacgttggcac
tgggaaggtcactctggaatatagacccgtgatcgacaaaactttgaa
cgaggctgactgtgccaccgtcccgccagccattcgctcctactgatg
agacaagatgtggtgatgacagaatcagcttttgtaattatgtataat
agctcatgcatgtgtccatgtcataactgtcttcatacgcttctgcac
tctggggaagaaggagtacattgaagggagattggcacctagtggctg
ggagcttgccaggaacccagtggccagggagcgtggcacttacctttg
tcccttgcttcattcttgtgagatgataaaactgggcacagctcttaa
ataaaatataaatgaacaaactttcttttatttccaaaaaaaaaaaaa aaaaa
[0032] In an embodiment of the invention ACTB comprises the
nucleotide sequence or nucleotides 85-1212 thereof (see Genbank
accession no. NM.sub.--001101):
TABLE-US-00009 ACTB >nucfasta||NM_001101 NM_001101 3 (SEQ ID NO:
21) accgccgagaccgcgtccgccccgcgagcacagagcctcgcctttgcc
gatccgccgcccgtccacacccgccgccagctcaccatggatgatgat
atcgccgcgctcgtcgtcgacaacggctccggcatgtgcaaggccggc
ttcgcgggcgacgatgccccccgggccgtcttcccctccatcgtgggg
cgccccaggcaccagggcgtgacggtgggcatgggtcagaaggattcc
tatgtgggcgacgaggcccagagcaagagaggcatcctcaccctgaag
taccccatcgagcacggcatcgtcaccaactgggacgacatggagaaa
atctggcaccacaccttctacaatgagctgcgtgtggctcccgaggag
caccccgtgctgctgaccgaggcccccctgaaccccaaggccaaccgc
gagaagatgacccagatcatgtttgagaccttcaacaccccagccatg
tacgttgctatccaggctgtgctatccctgtacgcctctggccgtacc
actggcatcgtgatggactccggtgacggggtcacccacactgtgccc
atctacgaggggtatgccctcccccatgccatcctgcgtctggacctg
gctggccgggacctgactgactacctcatgaagatcctcaccgagcgc
ggctacagcttcaccaccacggccgagcgggaaatcgtgcgtgacatt
aaggagaagctgtgctacgtcgccctggacttcgagcaagagatggcc
acggctgcttccagctcctccctggagaagagctacgagctgcctgac
ggccaggtcatcaccattggcaatgagcggttccgctgccctgaggca
ctcttccagccttccttcctgggcatggagtcctgtggcatccacgaa
actaccttcaactccatcatgaagtgtgacgtggacatccgcaaagac
ctgtacgccaacacagtgctgtctggcggcaccaccatgtaccctggc
attgccgacaggatgcagaaggagatcactgccctggcacccagcaca
atgaagatcaagatcattgctcctcctgagcgcaagtactccgtgtgg
atcggcggctccatcctggcctcgctgtccaccttccagcagatgtgg
atcagcaagcaggagtatgacgagtccggcccctccatcgtccaccgc
aaatgcttctaggcggactatgacttagttgcgttacaccctttcttg
acaaaacctaacttgcgcagaaaacaagatgagattggcatggcttta
tttgttttttttgttttgttttggttttttttttttttttggcttgac
tcaggatttaaaaactggaacggtgaaggtgacagcagtcggttggag
cgagcatcccccaaagttcacaatgtggccgaggactttgattgcaca
ttgttgtttttttaatagtcattccaaatatgagatgcgttgttacag
gaagtcccttgccatcctaaaagccaccccacttctctctaaggagaa
tggcccagtcctctcccaagtccacacaggggaggtgatagcattgct
ttcgtgtaaattatgtaatgcaaaatttttttaatcttcgccttaata
cttttttattttgttttattttgaatgatgagccttcgtgccccccct
tcccccttttttgtcccccaacttgagatgtatgaaggcttttggtct
ccctgggagtgggtggaggcagccagggcttacctgtacactgacttg
agaccagttgaataaaagtgcacaccttaaaaatgaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaa
[0033] In an embodiment of the invention GUSB comprises the
nucleotide sequence or nucleotides 132-2087 thereof (see Genbank
accession no. NM.sub.--000181):
TABLE-US-00010 GUSB >nucfasta||NM_000181 NM_000181 3 (SEQ ID NO:
22) gtcctcaaccaagatggcgcggatggcttcaggcgcatcacgacaccg
gcgcgtcacgcgacccgccctacgggcacctcccgcgcttttcttagc
gccgcagacggtggccgagcgggggaccgggaagcatggcccgggggt
cggcggttgcctgggcggcgctcgggccgttgttgtggggctgcgcgc
tggggctgcagggcgggatgctgtacccccaggagagcccgtcgcggg
agtgcaaggagctggacggcctctggagcttccgcgccgacttctctg
acaaccgacgccggggcttcgaggagcagtggtaccggcggccgctgt
gggagtcaggccccaccgtggacatgccagttccctccagcttcaatg
acatcagccaggactggcgtctgcggcattttgtcggctgggtgtggt
acgaacgggaggtgatcctgccggagcgatggacccaggacctgcgca
caagagtggtgctgaggattggcagtgcccattcctatgccatcgtgt
gggtgaatggggtcgacacgctagagcatgaggggggctacctcccct
tcgaggccgacatcagcaacctggtccaggtggggcccctgccctccc
ggctccgaatcactatcgccatcaacaacacactcacccccaccaccc
tgccaccagggaccatccaatacctgactgacacctccaagtatccca
agggttactttgtccagaacacatattttgactttttcaactacgctg
gactgcagcggtctgtacttctgtacacgacacccaccacctacatcg
atgacatcaccgtcaccaccagcgtggagcaagacagtgggctggtga
attaccagatctctgtcaagggcagtaacccgttcaagttggaagtgc
gtcttttggatgcagaaaacaaagtcgtggcgaatgggactgggaccc
agggccaacttaaggtgccaggtgtcagcctctggtggccgtacctga
tgcacgaacgccctgcctatctgtattcattggaggtgcagctgactg
cacagacgtcactggggcctgtgtctgacttctacacactccctgtgg
ggatccgcactgtggctgtcaccaagagccagttcctcatcaatggga
aacctttctatttccacggtgtcaacaagcatgaggatgcggacatcc
gagggaagggcttcgactggccgctgctggtgaaggacttcaacctgc
ttcgctggcttggtgccaacgctttccgtaccagccactacccctatg
cagaggaagtgatgcagatgtgtgaccgctatgggattgtggtcatcg
atgagtgtcccggcgtgggcctggcgctgccgcagttcttcaacaacg
tttctctgcatcaccacatgcaggtgatggaagaagtggtgcgtaggg
acaagaaccaccccgcggtcgtgatgtggtctgtggccaacgagcctg
cgtcccacctagaatctgctggctactacttgaagatggtgatcgctc
acaccaaatccttggacccctcccggcctgtgacctttgtgagcaact
ctaactatgcagcagacaagggggctccgtatgtggatgtgatctgtt
tgaacagctactactcttggtatcacgactacgggcacctggagttga
ttcagctgcagctggccacccagtttgagaactggtataagaagtatc
agaagcccattattcagagcgagtatggagcagaaacgattgcagggt
ttcaccaggatccacctctgatgttcactgaagagtaccagaaaagtc
tgctagagcagtaccatctgggtctggatcaaaaacgcagaaaatacg
tggttggagagctcatttggaattttgccgatttcatgactgaacagt
caccgacgagagtgctggggaataaaaaggggatcttcactcggcaga
gacaaccaaaaagtgcagcgttccttttgcgagagagatactggaaga
ttgccaatgaaaccaggtatccccactcagtagccaagtcacaatgtt
tggaaaacagcctgtttacttgagcaagactgataccacctgcgtgtc
ccttcctccccgagtcagggcgacttccacagcagcagaacaagtgcc
tcctggactgttcacggcagaccagaacgtttctggcctgggttttgt
ggtcatctattctagcagggaacactaaaggtggaaataaaagatttt
ctattatggaaataaagagttggcatgaaagtggctactgaaaaaaaa
aaaaaaaaaaaaaaaaa
[0034] In an embodiment of the invention TOP1 comprises the
nucleotide sequence or nucleotides 247-2544 thereof (see Genbank
accession no. NM.sub.--003286):
TABLE-US-00011 TOP1 >nucfasta|| NM_003286 NM_003286 2 (SEQ ID
NO: 23) caaatgcgaacttaggctgttacacaactgctggggtctgttctcgcc
gcccgcccggcagtcaggcagcgtcgccgccgtggtagcagcctcagc
cgtttctggagtctcgggcccacagtcaccgccgcttacctgcgcctc
ctcgagcctccggagtccccgtccgcccgcacaggccggttcgccgtc
tgcgtctcccccacgccgcctcgcctgccgccgcgctcgtccctccgg
gccgacatgagtggggaccacctccacaacgattcccagatcgaagcg
gatttccgattgaatgattctcataaacacaaagataaacacaaagat
cgagaacaccggcacaaagaacacaagaaggagaaggaccgggaaaag
tccaagcatagcaacagtgaacataaagattctgaaaagaaacacaaa
gagaaggagaagaccaaacacaaagatggaagctcagaaaagcataaa
gacaaacataaagacagagacaaggaaaaacgaaaagaggaaaaggtt
cgagcctctggggatgcaaaaataaagaaggagaaggaaaatggcttc
tctagtccaccacaaattaaagatgaacctgaagatgatggctatttt
gttcctcctaaagaggatataaagccattaaagagacctcgagatgag
gatgatgctgattataaacctaagaaaattaaaacagaagataccaag
aaggagaagaaaagaaaactagaagaagaagaggatggtaaattgaaa
aaacccaagaataaagataaagataaaaaagttcctgagccagataac
aagaaaaagaagccgaagaaagaagaggaacagaagtggaaatggtgg
gaagaagagcgctatcctgaaggcatcaagtggaaattcctagaacat
aaaggtccagtatttgccccaccatatgagcctcttccagagaatgtc
aagttttattatgatggtaaagtcatgaagctgagccccaaagcagag
gaagtagctacgttctttgcaaaaatgctcgaccatgaatatactacc
aaggaaatatttaggaaaaatttctttaaagactggagaaaggaaatg
actaatgaagagaagaatattatcaccaacctaagcaaatgtgatttt
acccagatgagccagtatttcaaagcccagacggaagctcggaaacag
atgagcaaggaagagaaactgaaaatcaaagaggagaatgaaaaatta
ctgaaagaatatggattctgtattatggataaccacaaagagaggatt
gctaacttcaagatagagcctcctggacttttccgtggccgcggcaac
caccccaagatgggcatgctgaagagacgaatcatgcccgaggatata
atcatcaactgtagcaaagatgccaaggttccttctcctcctccagga
cataagtggaaagaagtccggcatgataacaaggttacttggctggtt
tcctggacagagaacatccaaggttccattaaatacatcatgcttaac
cctagttcacgaatcaagggtgagaaggactggcagaaatacgagact
gctcggcggctgaaaaaatgtgtggacaagatccggaaccagtatcga
gaagactggaagtccaaagagatgaaagtccggcagagagctgtagcc
ctgtacttcatcgacaagcttgctctgagagcaggcaatgaaaaggag
gaaggagaaacagcggacactgtgggctgctgctcacttcgtgtggag
cacatcaatctacacccagagttggatggtcaggaatatgtggtagag
tttgacttcctcgggaaggactccatcagatactataacaaggtccct
gttgagaaacgagtttttaagaacctacaactatttatggagaacaag
cagcccgaggatgatctttttgatagactcaatactggtattctgaat
aagcatcttcaggatctcatggagggcttgacagccaaggtattccgt
acatacaatgcctccatcacgctacagcagcagctaaaagaactgaca
gccccggatgagaacatcccagcgaagatcctttcttataaccgtgcc
aatcgagctgttgcaattctttgtaaccatcagagggcaccaccaaaa
acttttgagaagtctatgatgaacttgcaaactaagattgatgccaag
aaggaacagctagcagatgcccggagagacctgaaaagtgctaaggct
gatgccaaggtcatgaaggatgcaaagacgaagaaggtagtagagtca
aagaagaaggctgttcagagactggaggaacagttgatgaagctggaa
gttcaagccacagaccgagaggaaaataaacagattgccctgggaacc
tccaaactcaattatctggaccctaggatcacagtggcttggtgcaag
aagtggggtgtcccaattgagaagatttacaacaaaacccagcgggag
aagtttgcctgggccattgacatggctgatgaagactatgagttttag
ccagtctcaagaggcagagttctgtgaagaggaacagtgtggtttggg
aaagatggataaactgagcctcacttgccctcgtgcctgggggagaga
ggcagcaagtcttaacaaaccaacatctttgcgaaaagataaacctgg
agatattataagggagagctgagccagttgtcctatggacaacttatt
taaaaatatttcagatatcaaaattctagctgtatgatttgttttgaa
ttttgtttttattttcaagagggcaagtggatgggaatttgtcagcgt
tctaccaggcaaattcactgtttcactgaaatgtttggattctcttag
ctactgtatgcaaagtccgattatattggtgcgtttttacagttaggg
ttttgcaataacttctatattttaatagaaataaattcctaaactccc
ttccctctctcccatttcaggaatttaaaattaagtagaacaaaaaac
ccagcgcacctgttagagtcgtcactctctattgtcatggggatcaat
tttcattaaacttgaagcagtcgtggctttggcagtgttttggttcag
acacctgttcacagaaaaagcatgatgggaaaatatttcctgacttga
gtgttcctttttaaatgtgaatttttatttctttttaattattttaaa
atatttaaacctttttcttgatcttaaagatcgtgtagattggggttg
gggagggatgaagggcgagtgaatctaaggataatgaaataatcagtg
actgaaaccattttcccatcatcctttgttctgagcattcgctgtacc
ctttaagatatccatctttttctttttaaccctaatctttcacttgaa
agattttattgtataaaaagtttcacaggtcaataaacttagaggaaa
atgagtatttggtccaaaaaaaggaaaaataatcaagattttagggct
tttattttttcttttgtaattgtgtaaaaaatggaaaaaaacataaaa
agcagaattttaatgtgaagacattttttgctataatcattagtttta
gaggcattgttagtttagtgtgtgtgcagagtccatttcccacatctt
tcctcaagtatcttctatttttatcatgaattcccttttaatcaactg
taggttatttaaaataaattcctacaacttaatggaaa
[0035] In an embodiment of the invention B2M comprises the
nucleotide sequence or nucleotides 61-420 thereof (see Genbank
accession no. NM.sub.--004048):
TABLE-US-00012 B2M >nucfasta|| NM_004048 NM_004048 2 (SEQ ID NO:
24) aatataagtggaggcgtcgcgctggcgggcattcctgaagctgacagc
attcgggccgagatgtctcgctccgtggccttagctgtgctcgcgcta
ctctctctttctggcctggaggctatccagcgtactccaaagattcag
gtttactcacgtcatccagcagagaatggaaagtcaaatttcctgaat
tgctatgtgtctgggtttcatccatccgacattgaagttgacttactg
aagaatggagagagaattgaaaaagtggagcattcagacttgtctttc
agcaaggactggtctttctatctcttgtactacactgaattcaccccc
actgaaaaagatgagtatgcctgccgtgtgaaccatgtgactttgtca
cagcccaagatagttaagtgggatcgagacatgtaagcagcatcatgg
aggtttgaagatgccgcatttggattggatgaattccaaattctgctt
gcttgctttttaatattgatatgcttatacacttacactttatgcaca
aaatgtagggttataataatgttaacatggacatgatcttctttataa
ttctactttgagtgctgtctccatgtttgatgtatctgagcaggttgc
tccacaggtagctctaggagggctggcaacttagaggtggggagcaga
gaattctcttatccaacatcaacatcttggtcagatttgaactcttca
atctcttgcactcaaagcttgttaagatagttaagcgtgcataagtta
acttccaatttacatactctgcttagaatttgggggaaaatttagaaa
tataattgacaggattattggaaatttgttataatgaatgaaacattt
tgtcatataagattcatatttacttcttatacatttgataaagtaagg
catggttgtggttaatctggtttatttttgttccacaagttaaataaa
tcataaaacttgatgtgttatctctta
[0036] In an embodiment of the invention GAPDH comprises the
nucleotide sequence or nucleotides 103-1110 thereof (see Genbank
accession no. NM.sub.--002046):
TABLE-US-00013 GAPDH >nucfasta||NM_002046 NM_002046 3 (SEQ ID
NO: 25) aaattgagccogcagcctcccgcttcgctctctgctcctcctgttcga
cagtcagccgcatcttcttttgcgtcgccagccgagccacatcgctca
gacaccatggggaaggtgaaggtcggagtcaacggatttggtcgtatt
gggcgcctggtcaccagggctgcttttaactctggtaaagtggatatt
gttgccatcaatgaccccttcattgacctcaactacatggtttacatg
ttccaatatgattccacccatggcaaattccatggcaccgtcaaggct
gagaacgggaagcttgtcatcaatggaaatcccatcaccatcttccag
gagcgagatccctccaaaatcaagtggggcgatgctggcgctgagtac
gtcgtggagtccactggcgtcttcaccaccatggagaaggctggggct
catttgcagggsggagccaaaagggtcatcatctctgccccctctgct
gatgcccccatgttcgtcatgggtgtgaaccatgagaagtatgacaac
agcctcaagatcatcagcaatgcctcctgcaccaccaactgcttagca
cccctggccaaggtcatccatgacaactttggtatcgtggaaggactc
atgaccacagtccatgccatcactgccacccagaagactgtggatggc
ccctccgggaaactgtggcgtgatggccgcggggctctccagaacatc
atccctgcctctactggcgctgccaaggctgtgggcaaggtcatccct
gagctgaacgggaagctcactggcatggccttccgtgtccccactgcc
aacgtgtcagtggtggacctgacctgccgtctagaaaaacctgccaaa
tatgatgacatcaagaaggtggtgaagcaggcgtcggagggccccctc
aagggcatcctgggctacactgagcaccaggtggtctcctctgacttc
aacagcgacacccactcctccacctttgacgctggggctggcattgcc
ctcaacgaccactttgtcaagctcatttcctggtatgacaacgaattt
ggctacagcaacagggtggtggacctcatggcccacatggcctocaag
gagtaagacccctggaccaccagccccagcaagagcacaagaggaaga
gagagaccctcactgctggggagtccctgccacactcagtcccccacc
acactgaatctcccctcctcacagttgccatgtagaccccttgaagag
gggaggggcctagggagccgcaccttgtcatgtaccatcaataaagta ccctgtgctcaacc
[0037] In an embodiment of the invention, the reference gene used
in methods of the present invention comprises a nucleotide sequence
selected from SEQ ID NOs: 14-25 or a polypeptide coding sequence
thereof or a variant of the gene that comprise at least 80% (e.g.,
90%, 92%, 95%, 98% or 99%) identity to a reference sequence
selected from SEQ ID NOs: 14-25 when the comparison is performed by
a BLAST algorithm (e.g., BLASTN) wherein the parameters of the
algorithm are selected to give the largest match between the
respective sequences over the entire length of the respective
reference sequences.
[0038] "Cq" is the fractional cycle number, of a real time
polymerase chain reaction amplification of a given target gene,
wherein acceleration of amplification in the reaction is at a
maximum; or, wherein logarithmic increases in amplification over
time can no longer be sustained; which may be expressed relative to
that of one or more reference genes.
[0039] A fractional cycle number of at or below about 1.83 to at or
below about 2.03, in an embodiment of the invention, includes
fractional cycle numbers at or below values up to 5% (e.g., 1%, 2%,
3%, 4% or 5%) less than 1.83 and/or at or below values up to 5%
(e.g., 1%, 2%, 3%, 4% or 5%) higher than of 2.03. At or below
"about 1.83 to about 2.03" as used herein includes values at or
below 1.83 (or - up to 5% thereof) or at or below 2.03 (or + up to
5% thereof) as well as any value at or below values that are
between these limits, e.g., at or below 1.84, at or below 1.85, at
or below 1.86, at or below 1.87, at or below 1.88, at or below
1.89, at or below 1.90, at or below 1.91, at or below 1.92, at or
below 1.93, at or below 1.94, at or below 1.95, at or below 1.96,
at or below 1.97, at or below 1.98, at or below 1.99, at or below
2.00, at or below 2.01; or at or below 2.02 (e.g., at or below
about 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6 or
0.5). Accordingly, methods described herein in terms of fractional
cycle numbers at or below values in this range should also be
understood to include embodiments wherein these methods are
described in terms of fractional cycle numbers having values at or
below any of these single values.
[0040] The methods of the present invention may further comprise
evaluation of KRAS expression in tumors (in association with
evaluation of IGF1 expression as discussed herein) (e.g., ovarian
tumors) to determine whether a tumor cell is sensitive to IGF1R
inhibitor therapy. Specifically, KRAS expression levels can be
measured wherein, when KRAS levels are observed to be low, then, in
an embodiment of the invention, the tumor cell analyzed is
determined to be sensitive to IGF1R inhibitor therapy.
Identification of high expression of KRAS or the presence of an
activating KRAS mutation (e.g., Gly12Asp, Gly12Ala, Gly12Val,
Gly12Ser, Gly12Arg or Gly13Asp) in a tumor cell indicates, in an
embodiment of the invention, that the tumor cell is relatively
insensitive to IGF1R inhibitor therapy. See Scartozzi et al., Int J
Cancer. 127(8):1941-1947 (2010).
[0041] A positive clinical outcome, in an embodiment of the
invention, refers to shrinkage of a tumor or an increase in
progression free survival or overall survival or an improvement in
the signs and/or symptoms of the tumor in a subject, e.g., relative
to that of the subject pre-treatment or another subject with a
similar disease not having treatment.
Molecular Biology
[0042] In accordance with the present invention there may be
employed conventional molecular biology, microbiology, and
recombinant DNA techniques within the skill of the art. Such
techniques are explained fully in the literature. See, e.g.,
Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory
Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, N.Y. (herein "Sambrook, et al., 1989"); DNA
Cloning: A Practical Approach, Volumes I and II (D. N. Glover ed.
1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic
Acid Hybridization (B. D. Hames & S. J. Higgins eds. (1985));
Transcription And Translation (B. D. Hames & S. J. Higgins,
eds. (1984)); Animal Cell Culture (R. I. Freshney, ed. (1986));
Immobilized Cells And Enzymes (IRL Press, (1986)); B. Perbal, A
Practical Guide To Molecular Cloning (1984); F. M. Ausubel, et al.
(eds.), Current Protocols in Molecular Biology, John Wiley &
Sons, Inc. (1994).
[0043] Reverse transcription polymerase chain reaction (RT-PCR) is
a variant of polymerase chain reaction (PCR) wherein RNA is reverse
transcribed into its DNA complement (complementary DNA, or cDNA)
using the enzyme reverse transcriptase, and the resulting cDNA is
amplified using PCR. These two steps may occur in a single tube or
in separate tubes.
[0044] A polypeptide or protein comprises two or more amino
acids.
[0045] The term "isolated protein", "isolated polypeptide" or
"isolated antibody" is a protein, polypeptide or antibody was
purified to any degree.
[0046] A "polynucleotide", "nucleic acid" or "nucleic acid
molecule" includes double-stranded and single-stranded DNA and
RNA.
[0047] A "polynucleotide sequence", "nucleic acid sequence" or
"nucleotide sequence" is a series of nucleotide bases (also called
"nucleotides") in a nucleic acid, such as DNA or RNA, and means any
chain of two or more nucleotides.
[0048] An amino acid sequence comprises two or more amino
acids.
[0049] A "coding sequence" or a sequence "encoding" an expression
product, such as an RNA or polypeptide, is a nucleotide sequence
that, when expressed, results in production of the product.
[0050] The nucleic acids herein may be flanked by natural
regulatory (expression control) sequences, or may be associated
with heterologous sequences, including promoters, internal ribosome
entry sites (IRES) and other ribosome binding site sequences,
enhancers, response elements, suppressors, signal sequences,
polyadenylation sequences, introns, 5'- and 3'-non-coding regions,
and the like.
[0051] A coding sequence, such as a reporter gene, is "under the
control of", "functionally associated with" or "operably linked to"
a transcriptional and translational control sequence, such as a
promoter, e.g., in an isolated host cell, when the sequences direct
RNA polymerase mediated transcription of the coding sequence into
RNA, e.g., mRNA, which then may be trans-RNA spliced (if it
contains introns) and, optionally, translated into a protein
encoded by the coding sequence.
[0052] The terms "express" and "expression" mean allowing or
causing the information in a gene, RNA or DNA sequence to become
manifest; for example, producing a protein by activating the
cellular functions involved in transcription and translation of a
corresponding gene. A DNA sequence is expressed in or by a cell to
form an "expression product" such as an RNA (e.g., mRNA) or a
protein. The expression product itself may also be said to be
"expressed" by the cell.
[0053] The terms "vector", "cloning vector" and "expression vector"
mean the vehicle (e.g., a plasmid) by which a DNA or RNA sequence
can be introduced into a host cell, so as to transform the host
and, optionally, promote expression and/or replication of the
introduced sequence.
[0054] A cell, such as a tumor cell, is sensitive to an IGF1R
inhibitor is its growth, survival and/or metastasis is inhibited by
the inhibitor.
[0055] The following references regarding the BLAST algorithm are
herein incorporated by reference: BLAST ALGORITHMS: Altschul, S.
F., et al., (1990) J. Mol. Biol. 215:403-410; Gish, W., et al.,
(1993) Nature Genet. 3:266-272; Madden, T. L., et al., (1996) Meth.
Enzymol. 266:131-141; Altschul, S. F., et al., (1997) Nucleic Acids
Res. 25:3389-3402; Zhang, J., et al., (1997) Genome Res. 7:649-656;
Wootton, J. C., et al., (1993) Comput. Chem. 17:149-163; Hancock,
J. M., et al., (1994) Comput. Appl. Biosci. 10:67-70; ALIGNMENT
SCORING SYSTEMS: Dayhoff, M. O., et al., "A model of evolutionary
change in proteins." in Atlas of Protein Sequence and Structure,
(1978) vol. 5, suppl. 3. M. O. Dayhoff (ed.), pp. 345-352, Natl.
Biomed. Res. Found., Washington, D.C.; Schwartz, R. M., et al.,
"Matrices for detecting distant relationships." in Atlas of Protein
Sequence and Structure, (1978) vol. 5, suppl. 3." M. O. Dayhoff
(ed.), pp. 353-358, Natl. Biomed. Res. Found., Washington, D.C.;
Altschul, S. F., (1991) J. Mol. Biol. 219:555-565; States, D. J.,
et al., (1991) Methods 3:66-70; Henikoff, S., et al., (1992) Proc.
Natl. Acad. Sci. USA 89:10915-10919; Altschul, S. F., et al.,
(1993) J. Mol. Evol. 36:290-300; ALIGNMENT STATISTICS: Karlin, S.,
et al., (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268; Karlin, S.,
et al., (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877; Dembo, A.,
et al., (1994) Ann. Prob. 22:2022-2039; and Altschul, S. F.
"Evaluating the statistical significance of multiple distinct local
alignments." in Theoretical and Computational Methods in Genome
Research (S. Suhai, ed.), (1997) pp. 1-14, Plenum, New York.
Therapeutic Methods
[0056] The present invention provides a method for treating an
IGF1-expressing tumor (e.g., wherein the tumor also expresses
IGF1R) in a subject; or for selecting a subject (e.g., human) for
IGF1R inhibitor therapy (e.g., dalotuzumab) for a tumor (e.g., a
subject having a tumor that is sensitive to IGF1R inhibitor therapy
and/or likely to experience a positive clinical outcome upon
treatment with an IGF1R inhibitor); or for selecting a therapy in a
subject (e.g., a subject having a tumor that is sensitive to IGF1R
inhibitor therapy and/or likely to experience a positive clinical
outcome upon treatment with an IGF1R inhibitor) with a tumor; based
on the expression level of IGF1 mRNA in cells of the subject's
tumor. The method comprises treating tumors having cells that have
been observed to express IGF1 mRNA at least at a certain threshold
level (e.g., prior to IGF1R inhibitor-based therapy). In an
embodiment of the invention, the threshold level is expressed in
terms of IGF1 mRNA expression levels in said tumor cells, measured
using RT-PCR and real time PCR, relative to or normalized against
mRNA expression levels, measured by RT-PCR and real time PCR, of
any of 12 reference genes: CYC1, HMBS, TOP1, SDHA, GUSB, PUM1,
HPRT1, ACTB, UBC, B2M, GAPDH, and TUBB2A (e.g., any of SEQ ID NOs:
14-25 or a cDNA thereof) in said tumor cells or tissue. In an
embodiment of the invention, any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
or 12 reference gene mRNA levels are used in the comparison to IGF1
mRNA expression levels. The expression levels of IGF1 mRNA
normalized to that of the reference genes is, in an embodiment of
the invention, expressed in terms of comparative quantification
(Cq).
[0057] In an embodiment of the invention, tumor cells treated using
methods of the present invention express IGF1 as well as IGF1R,
wherein, for example, growth and/or survival and/or metastasis of
the tumor cells is mediated, at least in part, by the activity
and/or expression level of IGF1 and/or IGF1R. In such an
embodiment, tumor growth, survival and/or metastasis is inhibited
by an IGF1R inhibitor.
[0058] Tumor IGF1 RNA expression levels are measured prior to a
given course or dose of IGF1R inhibitor therapy in the subject. In
an embodiment of the invention, IGF1RNA expression is measured
before any IGF1R inhibitor therapy has commenced in the subject. In
an embodiment of the invention, IGF1 RNA expression levels can be
measured after one or more courses of IGF1R inhibitor therapy have
started but before one or more further course of IGF1R inhibitor
therapy begin.
[0059] In an embodiment of the invention, reverse transcription
polymerase chain reaction and real time polymerase chain reaction
are used to determine the IGF1 mRNA expression level. Various
methods for performing RT-PCR are known in the art including
one-step and two-step RT-PCR--each of which may be used to
quantitate IGF1 mRNA. Suitable primers may be designed for doing
so; for example, primers comprising the following nucleotide
sequences may be used: forward primer having the nucleotide
sequence of SEQ ID NO: 3, 4, 5, 6 or 7) and reverse primer having
the nucleotide sequence of SEQ ID NO: 8, 9, 10, 11 or 12. The
present invention includes embodiments wherein such primer pairs
are used to quantitate IGF1. The real time PCR data characterizing
IGF1 mRNA expression levels may be normalized against the
expression levels of one or more reference genes (e.g., whose
expression level was also determined by real time PCR) whose
expression is known not to increase or decrease significantly in
tumor cells relative to normal cells. For example, in an embodiment
of the invention, suitable reference genes include any one or more
of CYC1, HMBS, TOP1, SDHA, GUSB, PUM1, HPRT1, ACTB, UBC, B2M,
GAPDH, and TUBB2A (e.g., any of SEQ ID NOs: 14-25 or a cDNA
thereof). The IGF1 mRNA expression levels, normalized against that
of the reference gene(s), can be used to generate a Cq value
wherein the real time PCR expression level data is analyzed using
the absolute quantification second derivative maximum method.
Practitioners of ordinary skill in the art understand how to arrive
at the Cq values for IGF1 mRNA expression levels from tumor
cells.
[0060] A convenient and effective way to accurately determine IGF1
mRNA levels, in connection with the methods of the present
invention, as discussed herein, is through use of quantitative
real-time PCR; such methods form part of the present invention.
Quantitative real time PCR can be performed in the presence of a
double stranded DNA-binding dye that fluoresces upon binding to the
DNA (e.g., SYBR.RTM. Green I; SYBR.RTM. Gold; or YO (Oxazole
Yellow). The SYBR.RTM. Gold excitation maxima for dye-nucleic acid
complexes are at about 495 nm in the visible and about 300 nm, in
the ultraviolet; and the emission maximum is about 537 nm. The
oxazole yellow excitation maxima for dye-nucleic acid complexes are
at about 489 nm and the emission maximum is about 509 nm. Thus, for
example, in real-time PCR using SYBR green I, the DNA-dye complex
absorbs blue light at a wavelength of 497 nm (maximum) and emits
green light at a wavelength of 520 nm (maximum). The present
invention comprises embodiments wherein real time PCR is performed
with such dyes. Fluorescence increases as the dye binds to the
increasing amount of amplified DNA in the reaction tube. Thus, it
is possible to determine the quantity of PCR amplicons present
after each round of amplification. Since the cycle at which PCR
enters log linear amplification is directly proportional to the
amount of starting template, in an embodiment of the invention, one
determines the concentration of an unknown sample by comparing it
to a standard curve generated by dilutions of known amounts of
product. So, for example, samples (e.g., a known control and an
unknown) that differ by a factor of 2 in the original concentration
of cDNA (derived from mRNA) would be 1 cycle apart; and samples
that differ by a factor of 10 would be .about.3.3 cycles apart
(each assuming 100% amplification efficiency) in terms of their
level of DNA amplification and dye fluorescence. The cycle
threshold at which an increase in fluorescence becomes exponential
is called the fractional cycle number and may be designated the
"Ct". The fluorescent signal appears earlier (at lower cycle
number) the higher the concentration of template. Because PCR is
exponential, the correlation is logarithmic. Specifically, the
logarithm of the starting template concentration is inversely
proportional to the fractional cycle number which is the initial
point of exponential amplification on real-time amplification
curve.
[0061] An amplification curve of a real-time PCR reaction is a plot
or data table that documents reaction amplification progress over
time. Reaction progress can be a function of double stranded DNA
binding dye (e.g., SYBR Green) fluorescence.
[0062] In an embodiment of the invention, real time PCR is
performed in an apparatus that can accurately determine and monitor
the level of dye fluorescence while generating amplification curves
that enable the user to view run progress. Computers may be used to
run the various algorithms, e.g., discussed herein, for generating
values to express the concentration of IGF1 mRNA and/or the
reference genes.
[0063] In an embodiment of the invention, IGF1 mRNA expression
levels are determined by relative quantification real-time PCR of
cDNA amplified in an RT-PCR reaction with the mRNA template.
Relative quantification determines the changes in steadystate mRNA
levels of a gene, e.g., across multiple samples, and expresses this
amount relative to the levels of another RNA (e.g., a reference
gene). In an embodiment of the invention, a negative control
reaction lacking template DNA can be performed to measure
background fluorescence or amplification of primer dimers and, in
an embodiment of the invention, this level of fluorescence is
subtracted from that of the IGF1 and/or reference gene real time
PCR reactions. In general, the relative quantification is expressed
as:
Ct value for IGF1 analysis/Ct value for reference gene analysis
(Bustin et al., (2005) J. Mol. Endocrinol. 34: 597-601; Orlando et
al. (1998) Clin. Chem. Lab. Med. 36(5): 255-269; Vandesompele et
al., Genome Biol 3(7): 0034.1-0034.11; Hellemans et al. (2007)
Genome Biol. 8(2):R19; Morse et al., (2005) Anal. Biochem. 342(1):
69-77; Livak & Schmittgen (2001) Methods 25(4): 402-408).
Relative quantification can be performed by the standard curve
method, for example the Pfaffl method (Pfaffl at al. (2001) Nucleic
Acids Res 29:e45); or the .DELTA..DELTA.Ct method (Larionov et al.
(2005) BMC Bioinformatics 6: 62; Livak & Schmittgen (2001)
Methods 25: 402-408).
[0064] Another method for determining the relative level of IGF1
produced relative to that of a reference gene, which, in an
embodiment of the invention, may be used in the methods discussed
herein, is the second derivative maximum method (Rasmussen et al.
(2001) Rapid Cycle Real-time PCR, Methods and Applications,
Springer Press, Heidelberg; LightCycler Software.RTM., Version 3.5;
Roche Molecular Biochemicals (2001); Higuchi at al. (1993)
Biotechnology 11:1026-1030). Using this method, the relative
quantity of IGF1 (as compared to that of one or more reference
genes) is expressed in terms of the fractional cycle number in
which the maximal acceleration of amplification (e.g., as
determined by monitoring fluorescence of a double stranded DNA
binding fluorescent dye in the reaction, e.g., as discussed herein)
within the log-linear phase of amplification, takes place (i.e.,
wherein exponential amplification can no longer be sustained). This
point is determined by determining the second derivative maxima of
the amplification curves. The IGF1 fractional cycle number wherein
amplification acceleration is at a maximum in a given reaction over
time, expressed relative to that of one or more reference genes,
may be referred to as "Cq". A similar method can be employed
wherein sigmoidal and polynomial curve models are fit to the data
and the second derivative maxima are then obtained (Tichopad et al.
(2003) Nucl. Acids Res. 31(20): e122; Tichopad et al. (2004)
Molecular and Cellular Probes 18: 45-50; Tichopad et al. (2003)
Biotechn. Lett. 24: 2053-2056; Liu et al. (2002) Biochem. Biophys.
Res. Commun. 294(2): 347-353; Liu et al. (2002) Anal. Biochem.
302(1): 52-59).
[0065] In an embodiment of the invention, the relative
quantification of expression by real-time PCR is adjusted by the
amplification efficiency of a gene (e.g., IGF1 or a reference
gene). This adjustment is useful since real-time PCR quantification
is based on the assumption that PCR products double each cycle.
When the percentile PCR amplification efficiency is not 100%, the
quantification may be adjusted to take the amplification efficiency
into account. The assessment of the exact amplification
efficiencies of IGF1 and reference genes can be carried out before
any calculation of the normalized gene expression. Software
applications that are commercially available and well known in the
art, e.g., LightCycler Relative Expression Software, Q-Gene, REST
and REST-XL software applications, allow the evaluation of
amplification efficiency plots. For example, in a reaction with
100% efficiency, there will be a doubling of the amount of DNA at
each cycle, with 90% the amount of DNA will increase from 1 to 1.9
at each cycle, and, with 80% and 70% efficiency, there will be an
increase of 1.8 and 1.7 per cycle, respectively.
[0066] In a one-step RT-PCR, both steps, cDNA reverse transcriptase
synthesis and amplification of the cDNA, are performed in a
combined reaction with the same target specific primers and within
the same reaction tube. Two-step RT-PCR, involves carrying out the
reverse transcription step in one tube and the cDNA amplification
step in another tube. Use of both methods is within the scope of
the present invention.
[0067] Any of the methods set forth herein may include one or more
of the following steps:
(a) obtaining cells of the subject's tumor, e.g., by biopsy or from
an in vitro source; (b) isolating RNA (e.g., mRNA) from said cells
(e.g., by lysing the cells. RNA can be isolated by any method known
in the art including precipitation; or fixing in formalin and
embedding in paraffin. Embedded cells can be deparaffinization and
homogenized during proteinase K incubation, then bound to a silica
membrane allowing for RNA isolation, followed by washing and
elution and treatment of the RNA with DNase I); (c) generating cDNA
by reverse transcribing the RNA, e.g., using oligo-dT (e.g.,
anchored) primers and random hexamer primers; (d) amplifying the
cDNA encoding IGF1 and, cDNA encoding one or more reference genes,
e.g., selected from: CYC1, HMBS, TOP1, SDHA, GUSB, PUM1, HPRT1,
ACTB, UBC, B2M, GAPDH, and TUBB2A (e.g., any of SEQ ID NOs: 14-25
or a cDNA thereof); (e) determining the quantity of RNA encoding
IGF1 and the reference gene(s) based on the level of production of
the amplified cDNA; for example, in an embodiment of the invention,
the progress of cDNA amplification is followed by quantitative
real-time PCR; and/or (f) normalizing the determined quantity of
IGF1 with that of the reference gene(s).
[0068] In an embodiment of the invention, the cDNA is pre-amplified
using PCR prior to amplifying in step (d); e.g., for about 10
cycles.
[0069] In an embodiment of the invention, the tumor, in whose cells
IGF1 mRNA is determined, is osteosarcoma, rhabdomyosarcoma,
neuroblastoma, kidney cancer, leukemia, renal transitional cell
cancer, bladder cancer, WiInn's cancer, ovarian cancer, pancreatic
cancer (e.g., where in the subject is administered the IGF1R
inhibitor (e.g., MK0646) in association with gemcitabine, and
optionally, ridaforolimus), breast cancer, prostate cancer, bone
cancer, lung cancer, gastric cancer, colorectal cancer, cervical
cancer, synovial sarcoma, head and neck cancer, squamous cell
carcinoma, multiple myeloma, renal cell cancer, retinoblastoma,
hepatoblastoma, hepatocellular carcinoma, melanoma, rhabdoid tumor
of the kidney, Ewing's sarcoma, chondrosarcoma, brain cancer,
glioblastoma, meningioma, pituitary adenoma, vestibular schwannoma,
a primitive neuroectodermal tumor, medulloblastoma, astrocytoma,
anaplastic astrocytoma, oligodendroglioma, ependymoma, choroid
plexus papilloma, polycythemia vera, thrombocythemia, idiopathic
myelfibrosis, soft tissue sarcoma, thyroid cancer, endometrial
cancer, carcinoid cancer or liver cancer.
[0070] The present invention provides a method for treating a tumor
(e.g., as set forth above), in a subject (e.g., a human) in need of
such treatment (e.g., whose tumor is sensitive to an IGF1R
inhibitor or who is likely to achieve a positive clinical outcome
upon IGF1R inhibitor therapy), that expresses IGF1 mRNA comprising
administering a therapeutically effective amount of an IGF1R
inhibitor (e.g., dalotuzumab) to said subject; if the fractional
cycle number of a real time polymerase chain reaction amplification
of IGF1 cDNA, that was reverse transcribed from IGF1 mRNA from a
cell of said tumor, normalized relative to that of one or more
reference genes (e.g., CYC1, HMBS, TOP1, SDHA, GUSB, PUM1, HPRT1,
ACTB, UBC, B2M, GAPDH, or TUBB2A (e.g., any of SEQ ID NOs: 14-25 or
a cDNA thereof)), in which acceleration of amplification is at a
maximum, is at or below about 2.87 or at or below about 1.83 to
about 2.03.
[0071] The present invention also provides a method for selecting a
subject with a tumor for treatment with an IGF1R inhibitor (e.g.,
dalotuzumab) (e.g., whose tumor is sensitive to an IGF1R inhibitor
or who is likely to achieve a positive clinical outcome upon IGF1R
inhibitor therapy) comprising selecting the subject for treatment
of the tumor with the IGF1R inhibitor if the fractional cycle
number of a real time polymerase chain reaction amplification of
IFG1 cDNA, that was reverse transcribed from IGF1 mRNA from a cell
of said tumor, normalized relative to that of one or more reference
genes (e.g., CYC1, HMBS, TOP1, SDHA, GUSB, PUM1, HPRT1, ACTB, UBC,
B2M, GAPDH, or TUBB2A (e.g., any of SEQ ID NOs: 14-25 or a cDNA
thereof)), in which acceleration of amplification is at a maximum,
is at or below about 2.87 or at or below about 1.83 to about 2.03
(in an embodiment of the invention, if not, the subject is not
selected for the IGF1R inhibitor therapy). Optionally, the method
further comprises administering a therapeutically effective amount
of IGF1R inhibitor to the selected subject.
[0072] The present invention provides a method for selecting a
therapy for a subject with a tumor (e.g., whose tumor is sensitive
to an IGF1R inhibitor or who is likely to achieve a positive
clinical outcome upon IGF1R inhibitor therapy) comprising selecting
an IGF1R inhibitor (e.g., dalotuzumab) for treatment of the tumor
in the subject if the fractional cycle number of a real time
polymerase chain reaction amplification of IGF1 cDNA, that was
reverse transcribed from IGF1 mRNA from a cell of said tumor,
normalized relative to that of one or more reference genes (e.g.,
CYC1, HMBS, TOP1, SDHA, GUSB, PUM1, HPRT1, ACTB, UBC, B2M, GAPDH,
or TUBB2A (e.g., any of SEQ ID NOs: 14-25 or a cDNA thereof)), in
which acceleration of amplification is at a maximum, is at or below
about 2.87 or at or below about 1.83 to about 2.03 (in an
embodiment of the invention, if not, the IGF1R inhibitor therapy is
not selected). Optionally, the method further comprises
administering a therapeutically effective amount of the selected
IGF1R inhibitor to the subject.
[0073] The present invention further provides a method for
evaluating the sensitivity of tumor cells to IGF1R inhibitor (e.g.,
dalotuzumab) therapy. The method provides, in an embodiment of the
invention, determining that the tumor cells are sensitive to the
IGF1R inhibitor if the fractional cycle number of a real time
polymerase chain reaction amplification of IGF1 cDNA, that was
reverse transcribed from IGF1 mRNA from a cell of said tumor,
normalized relative to that of one or more reference genes (e.g.,
CYC1, HMBS, TOP1, SDHA, GUSB, PUM1, HPRT1, ACTB, UBC, B2M, GAPDH,
or TUBB2A (e.g., any of SEQ ID NOs: 14-25 or a cDNA thereof)), in
which acceleration of amplification is at a maximum, is at or below
about 2.87 or at or below about 1.83 to about 2.03; and, if not,
determining that the cells are not sensitive. As discussed above,
this method may include any one or more of the following steps: (a)
obtaining cells of the subject's tumor; (b) isolating RNA (e.g.,
mRNA) from said cells; (c) generating cDNA by reverse transcribing
the RNA, e.g., using oligo-dT (e.g., anchored) primers and random
hexamer primers; (d) amplifying the reverse transcribed cDNA
encoding IGF1 and encoding one or more reference genes, e.g.,
selected from: CYC1, HMBS, TOP1, SDHA, GUSB, PUM1, HPRT1, ACTS,
UBC, B2M, GAPDH, and TUBB2A (e.g., any of SEQ ID NOs: 14-25 or a
cDNA thereof) in a real time polymerase chain reaction.
[0074] The present invention provides a method for predicting
whether a subject with a tumor will experience a positive clinical
outcome by treatment with an IGF1R inhibitor comprising determining
that the subject will experience the positive clinical outcome if
the fractional cycle number of a real time polymerase chain
reaction amplification of IGF1 cDNA, that was reverse transcribed
from IGF1 mRNA from a cell of said tumor, normalized relative to
that of one or more reference genes (e.g., CYC1, HMBS, TOP1, SDHA,
GUSB, PUM1, HPRT1, ACTB, UBC, B2M, GAPDH, or TUBB2A (e.g., any of
SEQ ID NOs: 14-25 or a cDNA thereof)), in which acceleration of
amplification is at a maximum, is at or below about 2.87 or at or
below about 1.83 to about 2.03.
In Vitro Methods
[0075] The present invention also provides in vitro assays for
determining whether a given in vitro tumor cell or tissue (e.g.,
which has been obtained at some point from an in vivo source, such
as the body of a subject) expresses IGF1 RNA at a sufficient level
indicating that growth, survival or metastasis of the tumor cells
would be sensitive to an IGF1R inhibitor. In an embodiment of the
invention, the method comprises quantitating the expression level
of IGF1 RNA in isolated tumor cells or tissue and determining, on
this basis, whether the growth, survival or metastasis of the tumor
would be sufficiently sensitive to an IGF1R inhibitor.
[0076] As is discussed herein, IGF1 mRNA expression in the in vitro
tumor cells can be determined using real time PCR amplification of
cDNA encoding the IGF1 and one or more reference genes. In an
embodiment of the invention, if the fractional cycle number of a
real time polymerase chain reaction amplification of IGF1 cDNA,
that was reverse transcribed from IGF1 mRNA from a cell of said
tumor, normalized relative to that of one or more reference genes
(e.g., CYC1, HMBS, TOP1, SDHA, GUSB, PUM1, HPRT1, ACTB, UBC, B2M,
GAPDH, or TUBB2A (e.g., any of SEQ ID NOs: 14-25 or a cDNA
thereof)), in which acceleration of amplification (e.g., as
determined by monitoring fluorescence of a double stranded DNA
binding fluorescent dye in the reaction, e.g., as discussed herein)
is at a maximum, is at or below about 2.87 or at or below about
1.83 to about 2.03, then the in vitro tumor cell being analyzed is
determined to be sensitive to IGF1R inhibitor and, if not, the cell
is determined not to be sufficiently sensitive.
[0077] For example, in an embodiment of the invention, an in vitro
method of the present invention comprises:
(a) obtaining tumor cells (e.g., from a subjects tumor), e.g., by
biopsy, and optionally purifying, treating or culturing the cells
in vitro; (b) isolating RNA (e.g., mRNA) from said cells (e.g., by
lysing the cells. RNA can be isolated by any method known in the
art including precipitation; or fixing in formalin and embedding in
paraffin. Embedded cells can be deparaffinization and homogenized
during proteinase K incubation, then bound to a silica membrane
allowing for RNA isolation, followed by washing and elution and
treatment of the RNA with DNase I); (c) generating cDNA by reverse
transcribing the RNA, e.g., using oligo-dT (e.g., anchored) primers
and random hexamer primers; (d) amplifying the cDNA encoding IGF1
and, cDNA encoding one or more reference genes, e.g., selected
from: CYC1, HMBS, TOP1, SDHA, GUSB, PUM1, HPRT1, ACTB, UBC, B2M,
GAPDH, and TUBB2A (e.g., any of SEQ ID NOs: 14-25 or a cDNA
thereof); and (e) determining the quantity of RNA encoding IGF1
relative to that of the reference gene(s) based on the level of
production of the amplified cDNA; e.g., using real time PCR, for
example, as discussed herein.
[0078] In an embodiment of the invention, the cDNA is pre-amplified
using PCR prior to amplifying in step (d); e.g., for about 10
cycles.
[0079] In an embodiment of the invention, the RT-PCR amplification
efficiency of IGF1 and/or reference gene RNA is estimated, e.g.,
using a reference RNA sample, and the efficiency calculation is
used to correct the quantity of IGF1 and reference gene
amplification in a real time PCR assay.
[0080] The present invention also comprises a kit for performing
any of the in vitro methods set forth herein. For example, in an
embodiment of the invention, the kit comprises an IGF1R inhibitor
and instructions for performing the method.
IGF1R Inhibitors
[0081] The present invention includes methods wherein an IGF1R
inhibitor is used. In an embodiment of the invention, the IGF1R
inhibitor is an antibody or antigen-binding fragment that binds
specifically to IGF1R.
[0082] In an embodiment of the invention, the IGF1R inhibitor is
dalotuzumab (MK0646; CAS no. 1005389-60-5), robatumumab,
figitumumab, cixutumumab, ganitumab, AVE1642, OSI-906, NVP-AEW541
or NVP-ADW742.
[0083] In an embodiment of the invention, the IGF1R inhibitor
comprises the light chain CDRs and/or the heavy chain CDRs; and/or
the light chain variable region and/or the heavy chain variable
region of the immunoglobulin chains in any of the antibodies
selected from dalotuzumab (MK0646; CAS no. 1005389-60-5),
robatumumab, figitumumab, cixutumumab and ganitumab; or from the
light and/or heavy chain immunoglobulins set forth below:
TABLE-US-00014 LIGHT CHAIN (SEQ ID NO: 1) 1 DIVMTQSPLS LPVTPGEPAS
ISCRSSQSIV HSNGNTYLQW YLQKPGQSPQ 51 LLIYKVSNRL YGVPDRFSGS
GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP 101 WTFGQGTKVE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK 151 VQWKVDNALQ SGNSQESVTE
QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 201 VTHQGLSSPV TKSFNRGEC
[0084] In an embodiment of the inveniton, the CDRs are
underscored.
TABLE-US-00015 HEAVY CHAIN (SEQ ID NO: 2) 1 QVQLQESGPG LVKPSETLSL
TCTVSGYSIT GGYLWNWIRQ PPGKGLEWIG 51 YISYDGTNNY KPSLKDRVTI
SRDTSKNQFS LKLSSVTAAD TAVYYCARYG 101 RVFFDYWGQG TLVTVSSAST
KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 151 PEPVTVSWNS GALTSGVHTF
PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 201 NVNHKPSNTK VDKRVEPKSC
DKTHTCPPCP APELLGGPSV FLFPPRPKDT 251 LMISRTPEVT CVVVDVSHED
PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 301 RVVSVLTVLH QDWLNGKEYK
CKVSNKALPA PIEKTISKAK GQPREPQVYT 351 LPPSREEMTK NQVSLTCLVK
GFYPSDIAVE WESNGQPENN YKTTPPVLDS 401 DGSFFLYSKL TVDKSRWQQG
NVFSCSVMHE ALHNHYTQKS LSLSPGK
[0085] In an embodiment of the inveniton, the CDRs are
underscored.
[0086] In an embodiment of the invention, wherein the IGF1R
inhibitor is an antibody or antigen-binding fragment, the light
chain immunoglobulin variable domain is linked to a light chain
immunoglobulin constant domain selected from the group consisting
of a kappa chain and lambda chain and/or wherein the heavy chain
immunoglobulin variable domain is linked to a heavy chain
immunoglobulin constant domain selected from the group consisting
of a gamma-1 chain, a gamma-2 chain, a gamma-3 chain and a gamma-4
chain.
[0087] In an embodiment of the invention, the antibody or
antigen-binding fragment is a monoclonal antibody, a recombinant
antibody, a labeled antibody, a bivalent antibody, a polyclonal
antibody, a bispecific antibody, a chimeric antibody, an
anti-idiotypic antibody, a humanized antibody, a bispecific
antibody, a camelized single domain antibody, a diabody, an scfv,
an scfv dimer, a dsfv, a (dsfv).sub.2, a dsFv-dsfv', a bispecific
ds diabody, an Fv, a nanobody, an Fab, an Fab', an F(ab').sub.2, or
a domain antibody; or any of the foregoing that comprises any of
the CDRs and/or heavy chain variable regions and/or light chain
variable regions of the antibodies discussed herein.
Pharmaceutical Formulation
[0088] The present invention includes methods wherein an IGF1R
inhibitor is administered to a subject or selected or identified.
An IGF1R inhibitor or any other chemotherapeutic agent for use in
any of the methods set forth herein may be formulated with a
pharmaceutically acceptable carrier or excipient or the like to
make a pharmaceutical composition. Pharmaceutical compositions may
be prepared by any methods well known in the art of pharmacy; see,
e.g., Gilman, et al., (eds.) (1990), The Pharmacological Bases of
Therapeutics, 8th Ed., Pergamon Press; A. Gennaro (ed.),
Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack
Publishing Co., Easton, Pa.; Avis, et al., (eds.) (1993)
Pharmaceutical Dosage Forms: Parenteral Medications Dekker, New
York; Lieberman, at al., (eds.) (1990) Pharmaceutical Dosage Forms:
Tablets Dekker, New York; and Lieberman, et al., (eds.) (1990),
Pharmaceutical Dosage Forms: Disperse Systems Dekker, New York.
[0089] A pharmaceutical composition containing an IGF1R inhibitor
can be prepared using conventional pharmaceutically acceptable
excipients and additives and conventional techniques. Such
pharmaceutically acceptable excipients and additives include
non-toxic compatible fillers, binders, disintegrants, buffers,
preservatives, anti-oxidants, lubricants, flavorings, thickeners,
coloring agents, emulsifiers and the like. All routes of
administration are contemplated including, but not limited to,
parenteral (e.g., subcutaneous, intratumoral, intravenous,
intraperitoneal, intramuscular) and non-parenteral (e.g., oral,
transdermal, intranasal, intraocular, sublingual, inhalation,
rectal and topical).
[0090] A pharmaceutical composition containing an IGF1R inhibitor
can be prepared using conventional pharmaceutically acceptable
excipients and additives and conventional techniques. Such
pharmaceutically acceptable excipients and additives include
non-toxic compatible fillers, binders, disintegrants, buffers,
preservatives, anti-oxidants, lubricants, flavorings, thickeners,
coloring agents, emulsifiers and the like. All routes of
administration are contemplated including, but not limited to,
parenteral (e.g., subcutaneous, intratumoral, intravenous,
intraperitoneal, intramuscular) and non-parenteral (e.g., oral,
transdermal, intranasal, intraocular, sublingual, inhalation,
rectal and topical).
[0091] Injectables can be prepared in conventional forms, either as
liquid solutions or suspensions, solid forms suitable for solution
or suspension in liquid prior to injection, or as emulsions. The
injectables, solutions and emulsions can also contain one or more
excipients. Excipients are, for example, water, saline, dextrose,
glycerol or ethanol. In addition, if desired, the pharmaceutical
compositions to be administered may also contain minor amounts of
non-toxic auxiliary substances such as wetting or emulsifying
agents, pH buffering agents, stabilizers, solubility enhancers, and
other such agents, such as for example, sodium acetate, sorbitan
monolaurate, triethanolamine oleate and cyclodextrins.
[0092] In an embodiment, pharmaceutically acceptable carriers used
in parenteral preparations include aqueous vehicles, nonaqueous
vehicles, antimicrobial agents, isotonic agents, buffers,
antioxidants, local anesthetics, suspending and dispersing agents,
emulsifying agents, sequestering or chelating agents and other
pharmaceutically acceptable substances.
[0093] Examples of aqueous vehicles include Sodium Chloride
Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile
Water Injection, Dextrose and Lactated Ringers Injection.
Nonaqueous parenteral vehicles include fixed oils of vegetable
origin, cottonseed oil, corn oil, sesame oil and peanut oil.
Antimicrobial agents in bacteriostatic or fungistatic
concentrations must be added to parenteral preparations packaged in
multiple-dose containers which include phenols or cresols,
mercurials, benzyl alcohol, chlorobutanol, methyl and propyl
p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and
benzethonium chloride. Isotonic agents include sodium chloride and
dextrose. Buffers include acetate, histidine (e.g., with NaCl or
KCl; and with polysorbate 80; and with citrate, succinate or
glycine; e.g., at pH 6.0 or 6.5), phosphate and citrate.
Antioxidants include sodium bisulfate. Local anesthetics include
procaine hydrochloride. Suspending and dispersing agents include
sodium carboxymethylcelluose, hydroxypropyl methylcellulose and
polyvinylpyrrolidone. Emulsifying agents include Polysorbate 80
(TWEEN-80). A sequestering or chelating agent of metal ions
includes EDTA. Pharmaceutical carriers also include ethyl alcohol,
polyethylene glycol and propylene glycol for water miscible
vehicles; and sodium hydroxide, hydrochloric acid, citric acid or
lactic acid for pH adjustment.
[0094] In an embodiment, preparations for parenteral administration
can include sterile solutions ready for injection, sterile dry
soluble products, such as lyophilized powders, ready to be combined
with a solvent just prior to use, including hypodermic tablets,
sterile suspensions ready for injection, sterile dry insoluble
products ready to be combined with a vehicle just prior to use and
sterile emulsions. The solutions may be either aqueous or
nonaqueous.
[0095] An IGF1R inhibitor (e.g., dalotuzumab) may be administered
to a subject in need of such administration at any therapeutically
effective dosage, for example, wherein the dosage is about 1, 5, 10
or 20 mg/kg at any frequency such as once a week (e.g., on days 1,
8 and 15). Any suitable route of administration may be used,
including, for example, parenteral or non-parenteral e.g.,
intravenous, intramuscular, subcutaneous, or intratumoral. For
example, infusion may be done intravenously over a course of about
60 or 120 minutes.
[0096] When possible, the administration and dosage of any
chemotheapeutic agent is done according to the schedule listed in
the product information sheet of the approved agents, in the
Physicians' Desk Reference, e.g., 2012 Physicians' Desk References,
66th Edition, as well as therapeutic protocols well known in the
art.
Further Chemotherapeutic Agents
[0097] The present invention provides methods comprising
administering or selecting or identifying an IGF1R inhibitor (e.g.,
dalotuzumab) to a subject with a tumor that expresses IGF1 at a
threshold level. In an embodiment of the invention, the IGF1R
inhibitor is administered or selected or identified in association
with a further chemotherapeutic agent or therapeutic procedure as
set forth herein.
[0098] In an embodiment of the invention, the IGF1R inhibitor is in
association with any androgen/estrogen ablation therapy.
[0099] In an embodiment of the invention, the IGF1R inhibitor is in
association with one or more antiandrogens. Antiandrogens include
steroidal varieties such as cyproterone acetate and goserelin
acetate and nonsteroidal varieties such as bicalutamide, flutamide,
and nilutamide.
[0100] In an embodiment of the invention, the IGF1R inhibitor is in
association with one or more luteinizing hormone-releasing hormone
(LHRH) agonists (e.g., goserelin acetate, leuprolide acetate or
triptorelin pamoate). LHRH agonists induce a form of castration
that many men opt for in lieu of orchiectomy.
[0101] In an embodiment of the invention, the IGF1R inhibitor is in
association with diethylstilbestrol.
[0102] In an embodiment of the invention, the IGF1R inhibitor is in
association with one or more chemotherapeutic agents that prevent
the adrenal glands from making androgens. These agents include
ketoconazole and aminoglutethimide.
[0103] In an embodiment of the invention, the IGF1R inhibitor is in
association with one or more estrogens (e.g., synthetic estrogen
such as diethylstilbestrol) that can prevent the testicles from
producing testosterone.
[0104] In an embodiment of the invention, the IGF1R inhibitor is in
association with androgen-depleting agents including GnRH agonists
such as leuprolide and goserelin; in association with
anti-androgens such as bicalutamide, flutamide, nilutimide,
MDV-3100 or cyproterone acetate; or in association with both LHRH
agonists and anti-androgens.
[0105] In an embodiment of the invention, the IGF1R inhibitor is in
association with anti-androgens such as bicalutamide, flutamide,
nilutimide, MDV-3100, cyproterone acetate; in association with both
LHRH agonists and anti-androgens; in association with the CYP17
lyase inhibitors such as abiraterone acetate, galeterone, and
orteronel; or in association with ketoconazole.
[0106] In an embodiment of the invention, the IGF1R inhibitor is in
association with one or more additional IGF1R inhibitors (e.g., any
set forth herein).
[0107] In an embodiment of the invention, the IGF1R inhibitor is in
association with docetaxel, mitoxantrone and/or prednisone.
[0108] In an embodiment of the invention, the IGF1R inhibitor is in
association with an AKT inhibitor and/or a PI3 kinase (including
alpha, beta, gamma and/or delta) inhibitor. AKT inhibitors include
perifosine, SR13668, A-443654, triciribine phosphate
monohydrate,
##STR00003##
GSK690693, deguelin. PI3 kinase inhibitors include SF1126, TGX-221,
PIK-75, PI-103, SN36093, IC87114, AS-252424, AS-605240, NVP-BEZ235,
GDC-0941, ZSTK474, PX-866,
##STR00004##
LY294002 and wortmannin.
[0109] In an embodiment of the invention, the IGF1R inhibitor is in
association with any antiestrogen and/or selective estrogen
receptor modulator (SERM), including estrogen receptor alpha
antagonists and estrogen receptor beta agonists such as
diarylpropionitrile, raloxifene, droloxifene (3-hydroxytamoxifen),
4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene,
fulvestrant, acolbifene, lasofoxifene (CP-336156), idoxifene,
tamoxifen or toremifene citrate.
[0110] In an embodiment of the invention, the IGF1R inhibitor is in
association with erlotinib, dasatanib, nilotinib, decatanib,
panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171,
batabulin, ofatumumab, zanolimumab, edotecarin, tetrandrine,
rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab,
gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490,
cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdR, KRX-0402,
lucanthone, LY 317615, neuradiab, vitespan, Rta 744, Sdx 102,
talampanel, atrasentan, Xr 311, everolimus, trabectedin, abraxane,
TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na,
AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152,
enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358,
R-763 or AT-9263.
[0111] In an embodiment of the invention, the IGF1R inhibitor is in
association with a Notch inhibitor such as
cis-3-[4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]prop-
anoic acid
##STR00005##
[0112] Abraxane is an injectable suspension of paclitaxel
protein-bound particles comprising an albumin-bound form of
paclitaxel with a mean particle size of approximately 130
nanometers. Abraxane is supplied as a white to yellow, sterile,
lyophilized powder for reconstitution with 20 mL of 0.9% Sodium
Chloride Injection, USP prior to intravenous infusion. Each
single-use vial contains 100 mg of paclitaxel and approximately 900
mg of human albumin. Each milliliter of reconstituted suspension
contains 5 mg paclitaxel. Abraxane is free of solvents and is free
of cremophor (polyoxyethylated castor oil).
[0113] In an embodiment of the invention, the IGF1 R inhibitor is
in association with romidepsin, ADS-100380,
##STR00006##
CG-781, CG-1521,
##STR00007##
[0114] scriptaid, chlamydocin, JNJ-16241199,
##STR00008##
or vorinostat.
[0115] In an embodiment of the invention, the IGF1R inhibitor is in
association with etoposide.
[0116] In an embodiment of the invention, the IGF1R inhibitor is in
association with gemcitabine or a combination of gemcitabine in
association with erlotinib. In an embodiment of the invention, the
tumor is a pancreatic cancer tumor and the IGF1R inhibitor (e.g.,
MK0646) is in association with gemcitabine, and optionally,
ridaforolimus.
[0117] In an embodiment of the invention, the IGF1R inhibitor is in
association with doxorubicin; including Caelyx or Doxil.RTM.
(doxorubicin HCl liposome injection; Ortho Biotech Products L.P;
Raritan, N.J.). Doxil.RTM. comprises doxorubicin in STEALTH.RTM.
liposome carriers which are composed of
N-(carbonyl-methoxypolyethylene glycol
2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt
(MPEG-DSPE); fully hydrogenated soy phosphatidylcholine (HSPC), and
cholesterol.
[0118] In an embodiment of the invention, the IGF1R inhibitor is in
association with 5'-deoxy-5-fluorouridine.
[0119] In an embodiment of the invention, the IGF1R inhibitor is in
association with vincristine.
[0120] In an embodiment of the invention, the IGF1R inhibitor is in
association with temozolomide, any CDK inhibitor such as ZK-304709,
Seliciclib (R-roscovitine); any MEK inhibitor such as PD0325901,
AZD-6244; capecitabine; or pemetrexed.
[0121] In an embodiment of the invention, the IGF1R inhibitor is in
association with camptothecin, irinotecan; a combination of
irinotecan, 5-fluorouracil and leucovorin; or PEG-labeled
irinotecan.
[0122] In an embodiment of the invention, the IGF1R inhibitor is in
association with the FOLFOX regimen (oxaliplatin, together with
infusional fluorouracil and folinic acid).
[0123] In an embodiment of the invention, the IGF1R inhibitor is in
association with an aromatase inhibitor such as anastrazole,
exemestane or letrozole.
[0124] In an embodiment of the invention, the IGF1R inhibitor is in
association with an estrogen such as DES(diethylstilbestrol),
estradiol or conjugated estrogens.
[0125] In an embodiment of the invention, the IGF1R inhibitor is in
association with an anti-angiogenesis agent such as bevacizumab,
the anti-VEGFR-2 antibody IMC-1C11, other VEGFR inhibitors such as:
dovitinib,
##STR00009##
3-[5-(methylsulfonylpiperadinemethyl)-indolyl]-quinolone;
vatalanib, AG-013736; and the VEGF trap (AVE-0005), a soluble decoy
receptor comprising portions of VEGF receptors 1 and 2.
[0126] In an embodiment of the invention, the IGF1R inhibitor is in
association with a LHRH (Lutenizing hormone-releasing hormone)
agonist such as goserelin acetate; leuprolide acetate; triptorelin
pamoate.
[0127] In an embodiment of the invention, the IGF1R inhibitor is in
association with sunitinib or sunitinib malate.
[0128] In an embodiment of the invention, the IGF1R inhibitor is in
association with a progestational agent such as medroxyprogesterone
acetate, hydroxyprogesterone caproate, megestrol acetate or
progestins.
[0129] In an embodiment of the invention, the IGF1R inhibitor is in
association with any antiestrogen and/or selective estrogen
receptor modulator (SERM), including estrogen receptor alpha
antagonists and estrogen receptor beta agonists such as
diaryipropionitrile, raloxifene, droloxifene (3-hydroxytamoxifen),
4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene,
fulvestrant, acolbifene, lasofoxifene (CP-336156), idoxifene,
tamoxifen or toremifene citrate.
[0130] In an embodiment of the invention, the IGF1R inhibitor is in
association with an anti-androgen including, but not limited to
bicalutamide; flutamide; nilutamide and megestrol acetate.
[0131] In an embodiment of the invention, the IGF1R inhibitor is in
association with one or more inhibitors which antagonize the action
of the EGF Receptor or HER2 such as CP-724714; HKI-272; erlotinib,
lapatanib, canertinib, panitumumab, erbitux, EKB-569, PKI-166,
GW-572016, any anti-EGFR antibody or any anti-HER2 antibody.
[0132] In an embodiment of the invention, the IGF1R inhibitor is in
association with lonafarnib or any other FPT inhibitor such as:
##STR00010##
[0133] Other FPT inhibitors include BMS-214662, tipifarnib.
[0134] In an embodiment of the invention, the IGF1R inhibitor is in
association with Amifostine; NVP-LAQ824, suberoyl analide
hydroxamic acid, valproic acid, trichostatin A, depsipeptide,
sunitinib; sorafenib, KRN951, aminoglutethimide; Amsacrine;
Anagrelide; Anastrozole; Asparaginase; Bacillus Calmette-Guerin
(BCG) vaccine; bleomycin; Buserelin; Busulfan; Carboplatin;
Carmustine; Chlorambucil; Cisplatin; cladribine; clodronate;
cyclophosphamide; cyproterone; cytarabine; dacarbazine;
dactinomycin; daunorubicin; diethylstilbestrol; epirubicin;
fludarabine; fludrocortisone; fluoxymesterone; flutamide;
hydroxyurea; idarubicin; ifosfamide; imatinib; leucovorin;
leuprolide; levamisole; lomustine; mechlorethamine; melphalan;
mercaptopurine; mesna; methotrexate; mitomycin; mitotane;
mitoxantrone; nilutamide; octreotide; edotreotide (yttrium-90
labeled or unlabeled); oxaliplatin; pamidronate; pentostatin;
plicamycin; porfimer; procarbazine; raltitrexed; rituximab;
streptozocin; teniposide; testosterone; thalidomide; thioguanine;
thiotepa; tretinoin; vindesine or 13-cis-retinoic acid.
[0135] In an embodiment of the invention, the IGF1R inhibitor is in
association with one or more of any of: phenylalanine mustard,
uracil mustard, estramustine, altretamine, floxuridine,
5-deooxyuridine, cytosine arabinoside, 6-mercaptopurine,
deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine,
vinorelbine, topotecan, razoxin, marimastat, COL-3, neovastat,
BMS-275291, squalamine, endostatin, semaxanib, SU6668, EMD121974,
interleukin-12, IM862, angiostatin, vitaxin, droloxifene,
idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab,
denileukin, diftitox, gefitinib, bortezimib, paclitaxel, docetaxel,
epithilone B, BMS-247550 (see e.g., Lee et al., Clin. Cancer Res.
7:1429-1437 (2001)), BMS-310705, TSE-424, HMR-3339, ZK186619,
topotecan, PTK787/ZK 222584 (Thomas et al., Semin Oncol. 30(3 Suppl
6):32-8 (2003)), the humanized anti-VEGF antibody Bevacizumab,
VX-745 (Haddad, Curr Opin. Investig. Drugs 2(8):1070-6 (2001)), PD
184352 (Sebolt-Leopold, et al. Nature Med. 5: 810-816 (1999)), any
mTOR inhibitor, ridaforolimus, sirolimus,
40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001,
ABT-578; BC-210, LY294002, LY292223, LY292696, LY293684, LY293646,
wortmannin, sorafenib, ZM336372, L-779,450, any Raf inhibitor;
flavopiridol or 7-hydroxy staurosporine.
[0136] In an embodiment of the invention, the IGF1R inhibitor is in
association with interferon (e.g., PEG-interferon).
[0137] In an embodiment of the invention, the IGF1R inhibitor is in
association with one or more antiemetics including, but not limited
to, casopitant (GlaxoSmithKline), Netupitant (MGI-Helsinn) and
other NK-1 receptor antagonists, palonosetron (sold as Aloxi by MGI
Pharma), aprepitant (sold as Emend by Merck and Co.; Rahway, N.J.),
diphenhydramine (sold as Benadryl.RTM. by Pfizer; New York, N.Y.),
hydroxyzine (sold as Atarax.RTM. by Pfizer; New York, N.Y.),
metoclopramide (sold as Reglan.RTM. by AH Robins Co; Richmond,
Va.), lorazepam (sold as Ativan.RTM. by Wyeth; Madison, N.J.),
alprazolam (sold as Xanax.RTM. by Pfizer; New York, N.Y.),
haloperidol (sold as Haldol.RTM. by Ortho-McNeil; Raritan, N.J.),
droperidol (Inapsine.RTM.), dronabinol (sold as Marinol.RTM. by
Solvay Pharmaceuticals, Inc.; Marietta, Ga.), dexamethasone (sold
as Decadron.RTM. by Merck and Co.; Rahway, N.J.),
methylprednisolone (sold as Medrol.RTM. by Pfizer; New York, N.Y.),
prochlorperazine (sold as Compazine.RTM. by Glaxosmithkline;
Research Triangle Park, N.C.), granisetron (sold as Kytril.RTM. by
Hoffmann-La Roche Inc.; Nutley, N.J.), ondansetron (sold as
Zofran.RTM. by by Glaxosmithkline; Research Triangle Park, N.C.),
dolasetron (sold as Anzemet.RTM. by Sanofi-Aventis; New York,
N.Y.), tropisetron (sold as Navoban.RTM. by Novartis; East Hanover,
N.J.).
[0138] Other side effects of cancer treatment include red and white
blood cell deficiency. Accordingly, in an embodiment of the
invention, the IGF1R inhibitor is in association with an agent
which treats or prevents such a deficiency, such as, e.g.,
filgrastim, PEG-filgrastim, erythropoietin, epoetin alfa or
darbepoetin alfa.
[0139] In an embodiment of the invention, the IGF1R inhibitor is
administered in association with anti-cancer radiation therapy. For
example, in an embodiment of the invention, the radiation therapy
is external beam therapy (EBT): a method for delivering a beam of
high-energy X-rays to the location of the tumor. The beam is
generated outside the patient (e.g., by a linear accelerator) and
is targeted at the tumor site. These X-rays can destroy the cancer
cells and careful treatment planning allows the surrounding normal
tissues to be spared. No radioactive sources are placed inside the
patient's body. In an embodiment of the invention, the radiation
therapy is proton beam therapy: a type of conformal therapy that
bombards the diseased tissue with protons instead of X-rays. In an
embodiment of the invention, the radiation therapy is conformal
external beam radiation therapy: a procedure that uses advanced
technology to tailor the radiation therapy to an individual's body
structures.
[0140] In an embodiment of the invention, the radiation therapy is
brachytherapy: the temporary placement of radioactive materials
within the body, usually employed to give an extra dose--or
boost--of radiation to an area.
[0141] In an embodiment of the invention, a surgical procedure
administered in association with an IGF1R inhibitor is surgical
tumorectomy.
[0142] The term "in association with" indicates that the components
administered in a method of the present invention (e.g., anti-IGF1R
antibody or antigen-binding fragment thereof along with
ridaforolimus) can be formulated into a single composition for
simultaneous delivery or formulated separately into two or more
compositions (e.g., a kit). Each component can be administered to a
subject at a different time than when the other component is
administered; for example, each administration may be given
non-simultaneously (e.g., separately or sequentially) at several
intervals over a given period of time. Moreover, the separate
components may be administered to a subject by the same or by a
different route (e.g., wherein an anti-IGF1R antibody is
administered parenterally and gosrelin acetate is administered
orally).
EXAMPLES
[0143] The present invention is intended to exemplify the present
invention and not to be a limitation thereof. The methods (e.g.,
methods for using the IGF1 biomarker) and compositions (e.g.,
polypeptides, polynucleotides, plasmids, yeast cells) disclosed
below fall within the scope of the present invention.
Example 1
Pre-Clinical: IGF1 is Associated with IGF1R Antibody, MK-0646,
Sensitivity
[0144] H2122 cancer cells were grown in vitro with and without IGF1
present in the growth media containing low levels of growth
factors. Under these conditions, IGF1 significantly stimulated the
growth of H2122 cancer cells as compared to the control (H2122
cells grown without IGF1 present in the growth media). Anti-IGF1R
antibody, dalotuzumab (MK-0646), significantly blocked the
IGF1-dependent proliferation of H2122 cancer cells. In contrast,
MK-0646 did not significantly alter the proliferation of H2122
cells grown in the absence of IGF1. MK-0646, was capable of
blocking IGF1 ability to bind directly to the IGF1 receptor. This
prevented IGF1 from activating IGF1 receptor required for
increasing cancer cell growth. These preclinical data provided in
vitro evidence that the anti-IGF1R antibody, MK-0646 growth
inhibitory effects are strongly dependent on presence of IGF1,
which is required for IGF1 receptor activation (see FIG. 1).
[0145] In Vitro Methodology:
[0146] H2122 cells were obtained from the American Type Culture
Collection (ATCC) and propagated according to the conditions
provided by ATCC in media at 37.degree. C. H2122 cells in low serum
(2% fetal calf serum (Hyclone), at 2000 cells/well, were plated in
a 96 well plate and incubated with 10 ug/ml MK-0646 or vehicle
control for 96 hours in the presence or absence of IGF1 (10 ng;
SIGMA). Cells were harvested at day 0 and day 4 and cell growth was
measured by Cell Titer-Glo.RTM. (Invitrogen) according to
manufacturer instructions. The relative cell proliferation was
calculated by normalizing to day 0 levels.
[0147] In Vivo Methodology:
[0148] Primary colorectal xenograft tumor models were established
from 10 independent colorectal tumors obtained directly from cancer
patients. The relative levels of IGF1RNA expression were determined
by gene expression profiling using genomic microarrays. Of the ten
primary colorectal xenograft models evaluated, 2 models showed
markedly increased IGF1RNA expression levels (see FIG. 2). These 2
colorectal xenograft models, that were identified to have increase
IGF1RNA expression levels, among the 10 xenograft models evaluated,
showed the greatest tumor growth inhibition following treatment
with the anti-IGF1R antibody, MK-0646. These two tumor models
demonstrated at least 50% or more tumor growth inhibition. For the
8 xenografts tumor models with low IGF1 expression, all showed
minimal or no tumor growth inhibition following treatment with the
anti-IGF1R antibody, MK-0646. These preclinical data provided in
vivo evidence that increase sensitivity to the anti-IGF1R antibody,
MK-0646, was strongly associated with increase IGF1RNA expression
in the primary tumors.
[0149] Clinical and Assay Information:
[0150] Here we provide a summary of the work used to perform the
IGF1 quantitative real-time PCR (rtPCR) gene expression analysis on
actual clinical colorectal formalin-fixed paraffin embedded (FFPE)
tissue material and provide clinical evidence supporting the idea
that increased IGF1RNA expression levels, as detected directly
within the tumor microenvironment, may be important for determining
clinical benefit to an anti-IGF1R antibody (MK-0646)-based therapy.
The document also contains a detail description of the methods used
to process the samples, generate IGF1 RNA expression data and
perform the IGF1 analysis.
[0151] Methods:
[0152] Below is a detail description of the forward and reverse
primer sequences designed specifically to evaluate IGF1 by rtPCR
using RNA isolated from FFPE tissue material.
TABLE-US-00016 TABLE 1 Forward and reverse primer sequences for
determining IGF1 by RT-PCR. Self Self 3' Sequence comple- comple-
(5'->3') Length Tm GC% mentarity mentarity Primer pair 1 Forward
primer TGTGGAGACAGG 24 55.05 45.83 3.00 0.00 GGCTTTTATTTC (SEQ ID
NO: 3) Reverse primer GCAGCACTCATC 20 56.38 60.00 5.00 4.00
CACGATGC (SEQ ID NO: 8) >NM 000618.3 Homo sapiens insulin-like
growth factor 1 (somatomedin C) (IGF1), transcript variant 4, mRNA
product length = 93 Forward primer 1 TGTGGAGACAGGGGCTTTTATTTC 24
(SEQ ID NO: 4) Template 415 ... 438 Reverse primer 1
GCAGCACTCATCCACGATGC 20 (SEQ ID NO: 9) Template 507 ... 488 >NM
001111285.1 Homo sapiens insulin-like growth factor 1 (somatomedin
C) (IGF1), transcript variant 3, mRNA product length = 93 Forward
primer 1 TGTGGAGACAGGGGCTTTTATTTC 24 (SEQ ID NO: 5) Template 415
... 438 Reverse primer 1 GCAGCACTCATCCACGATGC 20 (SEQ ID NO: 10)
Template 507 ... 488 >NM 001111284.1 Homo sapiens insulin-like
growth factor 1 (somatomedin C) (IGF1), transcript variant 2, mRNA
product length = 93 Forward primer 1 TGTGGAGACAGGGGCTTTTATTTC 24
(SEQ ID NO: 6) Template 298 ... 321 Reverse primer 1
GCAGCACTCATCCACGATGC 20 (SEQ ID NO: 11) Template 390 ... 371 >NM
001111283.1 Homo sapiens insulin-like growth factor 1 (somatomedin
C) (IGF1), transcript variant 1, mRNA product length = 93 Forward
primer 1 TGTGGAGACAGGGGCTTTTATTTC 24 (SEQ ID NO: 7) Template 415
... 438 Reverse primer 1 GCAGCACTCATCCACGATGC 20 (SEQ ID NO: 12)
Template 507 ... 488
[0153] FIG. 3 sets forth the results from an in silica BLAST
analysis with the IGF1 forward and reverse primer sequences
described in this document. The graph shows the location where the
IGF1 forward and reverse primers bind directly on the IGF1 gene
sequence and provides a graphical view of the expected IGF1
amplification product (predicted size to be between 92-93 base
pairs in length).
[0154] FFPE Tissue RNA Isolation:
[0155] Pieces of human tumor disease tissue were obtained from 12
individual patients diagnosed with colorectal cancer. The tissue
obtained was then submerged in 10% neutral-buffered formalin for a
maximum of 24 hours and embedded in IHC-grade paraffin (known as a
FFPE tissue sample). Sections of the FFPE tissue sample were then
cut from a block--ranging in thickness from 5 to 10 microns, and
placed on positively- or negatively-charged glass slides. For each
FFPE tissue section on a glass slide--marcodisection and
deparaffinization was performed using xylene. The tissue was
disrupted and homogenized during proteinase K incubation. A
chaotrophic salt was used to bind nucleic acids to a silica
membrane allowing for RNA isolation. Following washing and elution,
the RNA was treated with DNase I to remove any residual genomic
contamination. The RNA was eluted using a low salt elution
buffer.
[0156] RNA Quality Controls:
[0157] All total RNA samples were analyzed for concentration and
purity by assessing the A.sub.260/A.sub.280 on the Nanodrop.TM.
1000 (Thermo Scientific.RTM.). All samples were deemed to be of
sufficient quality to proceed for further processing.
[0158] Reverse Transcription:
[0159] 96 ng of total RNA isolated from 12 Colorectal FFPE samples
was reverse transcribed using the Transcriptor First Strand cDNA
synthesis kit (Roche Applied Science). A combination of anchored
oligo-dT and random hexamer priming was used for reverse
transcription to ensure optimal priming of fragmented and modified
nucleic acids found in FFPE material.
[0160] Pre-Amplification:
[0161] The following twelve reference genes: CYC1, HMBS, TOP1,
SDHA, GUSB, PUM1, HPRT1, ACTB, UBC, B2M, GAPDH, TUBB2A and the
target gene of interest IGF1, in the reverse transcribed cDNA from
the 12 colorectal FFPE samples, were pre-amplified for 10 cycles.
Following pre-amplification, each sample was diluted 1:5 using TE
buffer prior to use for rtPCR analysis.
[0162] The IGF1 rtPCR assay was designed to avoid any appreciable
amplification of pseudogenes or other targets. Amplified product
from different PCR products was assessed to ensure that the IGF1
single product of the appropriate size was specifically amplified.
The IGF1 rtPCR assay was validated empirically using the 2100
bioanalyzer, DNA 1000 chip and identified the actual single
amplified product using the IGF1 primers described in this document
to be 94 base pairs in length--confirms IGF1 (Agilent; see FIG.
4).
[0163] Amplification Efficiency of IGF1 Target Gene:
[0164] The amplification efficiencies of IGF1 were previously
estimated, experimentally, using the slope from standard curves
generated using Universal Human Reference RNA (Stratagene). FIG. 5
showed the efficiencies for IGF1 rtPCR assay.
[0165] rtPCR Processing:
[0166] The levels of twelve reference gene transcripts genes (CYC1,
HMBS, TOP1, SDHA, GUSB, PUM1, HPRT1, ACTB, UBC, B2M, GAPDH, TUBB2A)
in addition to the target transcript, IGF1, were determined by real
time PCR for each of the pre-amplified FFPE colorectal samples. In
addition to each sample, pre-amplified reverse transcription
negative samples (RTneg) were included with each reference and the
IGF1 target gene. A no template control (NTC) was run as a negative
control for each target and a Universal Human Reference RNA (UHR)
triplicate was run as a positive control for each target. All
samples were processed using an `All Samples` design where all
samples were amplified on a single plate to avoid the need for
inter-plate calibrators (IPCs). All the rtPCR master mixes were
assembled and dispensed using the CAS-4200 liquid handling system
in a `clean` room free from amplified product. Each real time PCR
reaction was performed in triplicate. The pre-amplified cDNA was
added by a CAS-1200 liquid handling system in a separate room to
minimize the risk of reagent contamination. The real time PCR
thermal cycling was performed using a Roche Lightcycler.RTM. 480 I
running software version 1.5. The data obtained were analyzed using
the absolute quantification second derivative maximum method to
obtain Cq values.
[0167] Normalized expression data was obtained on all 12 of the
colorectal FFPE samples tested. The values presented in Table 2
below represent the IGP1 expression level relative to the reference
genes and range from -0.575 (highest IGF1 expression) to 9.033
(lowest IGF1 expression).
TABLE-US-00017 TABLE 2 Normalized IGF1 levels (Cq) for each of 12
patients. Number of Colorectal Cancer Subject (patient) IGF1 Cq
Samples ID values 1 14279 -0.575 2 14184 -0.385 3 13090 0.237 4
14265 0.305 5 13013 0.968 6 13073 0.985 7 14183 5.948 8 14323 6.407
9 15320 6.906 10 15316 7.182 11 16400 8.4 12 14303 9.033
[0168] The 12 human colorectal subjects with IGF1 normalized real
time PCR data had participated in a clinical study evaluating how
well the anti-IGF1R antibody, MK-0646, in combination with standard
of care agents (cetuximab and irinotecan) worked in treating
patients with metastatic colorectal cancer. All 12 subjects
received and were treated with the anti-IGF1R antibody
MK-0646-based therapy and clinical outcome data were available. The
patients above were classified into two groups. One group of
patients (#1-6 in Table above) was classified to have "increase"
IGF1 expression levels (Cq value ranged from -0.575 to 0.985). The
second groups of patients (#7-12 in Table above) were classified as
having "low" IGF1 expression levels (Cq value range from 5.95 to
9.03). The IGF1 Cq values were reflective of the relative IGF1RNA
levels detected within the colorectal tumor sampled directly from
the patient (tumor microenvironment). The diseased tissue was
obtained from the primary colorectal tumor prior to receiving the
anti-IGF1R antibody, MK-0646-based therapy.
[0169] FIG. 6 shows the IGF1 Cq values from the 12 colorectal
cancer patient FFPE samples evaluated with clinical response
(objective response=tumor shrinkage; no objective response=no tumor
shrinkage) following treatment with anti-IGF1R antibody,
MK-0646-based therapy.
[0170] For the patients classified as having increase IGF1RNA
expression levels (Cq values range from -0.575 to 0.985 in the bar
graph), clinical benefit was observed by confirmed partial
responses & tumor size shrinkage (PR=Objective response)
lasting at least 6 weeks (criteria Response Evaluation Criteria In
Solid Tumors (RECIST) v1.0) during treatment with the anti-IGF1R
antibody, MK-0646-based therapy. For patients classified as having
low IGF1RNA expression levels (Cq values range from 5.95 to 9.03),
no tumor shrinkage or clinical activity was observed, all the
patients with low IGF1 expression experienced progressive disease
(criteria RECIST v1.0) during treatment with the anti-IGF1R
antibody, MK-0646-based therapy.
[0171] Progression-free survival (PFS) was evaluated with treatment
with the anti-IGF1R antibody, MK-0646-based therapy for the 12
colorectal cancer patients studied. This was done by comparing PFS
for patient groups defined to have either increase (high=+) IGF1
expression (n=6) or low IGF1 expression (n=6). An improved
progression-free survival time (median PFS was 213 days) was
observed for the patients with increase IGF1 expression compared to
the patients with low IGF1 expression (median PFS was only 63
days). The PFS hazard ratio (HR) was 0.29 with a P-value=0.012; 95%
Cl 0.07 to 1.1. See FIG. 7.
[0172] The association between increase IGF1 expression levels with
improved overall survival was also evaluated on the same 12
colorectal cancer patients. Observed for the group of patients
defined to have increase IGF1 expression (n=6) a trend toward
improved overall survival (median OS=383 days) vs. the group of
patients defined to have low IGF1 expression levels (median OS=218
days). The overall survival hazard ratio (HR) was 0.58, the P-value
did not reach significance (P=0.316; 95% Cl 0.017 to 1.87). See
FIG. 8.
[0173] In addition for the 6 patients with highest IGF1RNA
expression who experienced clinical benefit to the anti-IGF1R
antibody, MK-0646, 4 out 6 (67%) had been diagnosed with having
rectal (rectum) cancer compared to 0 out 6 (0%) for the patients
with low levels of IGF1 expression. These data may suggest that
increased IGF1 levels are higher and more frequent in tumors
located in the rectum compared to colon.
TABLE-US-00018 TABLE 3 Normalized IGF1 levels (Cq) for each of 12
patients with tumor locations indicated. IGF1 Cq Subject ID Tumor
Location values 14279 Colon -0.575 14184 Rectum -0.385 13090 Rectum
0.237 14265 Colon 0.305 13013 Rectum 0.968 13073 Rectum 0.985 14183
Colon 5.948 14323 Colon 6.407 15320 Colon 6.906 15316 Colon 7.182
16400 Colon 8.4 14303 Colon 9.033
[0174] Conclusion:
[0175] This document provides both pre-clinical and clinical
evidence supporting the idea that increased levels of IGF1 are
useful for predicting sensitivity to agents targeting the IGF1
receptor pathway, such as the anti-IGF1R antibody MK-0646. A
sensitive and highly specific IGF1 rtPCR assay method that is
capable of quantization the amount of IGF1 RNA transcript present
directly within the tumor microenvironment using clinical FFPE
tissue specimens was also provided. The rtPCR data suggested that
increased IGF1 expression occurred more frequently in tumors
located from the rectum. Our idea is that an accurate &
sensitive measurement to determine the levels of IGF1 can be
acquired by use of the methods outlined in this document and
provide a means by which one could detect whether or not IGF1 is
present within the tumor microenvironment. Accurately determining
the levels of IGF1 expression in a clinical tumor specimens will be
a critical requirement in helping to identify cancer patients who
are most likely to benefit from cancer agents targeting the IGF1
pathway, such as the anti-IGF1R antibody MK-0646.
Example 2
Tumor IGF-1 Expression as a Predictive Biomarker for IGF1R-Directed
Therapy in Advanced Pancreatic Cancer (APC)
[0176] Background:
[0177] IGF1 up-regulates PC proliferation and invasiveness through
activation of PI3K/Akt signaling pathway and down-regulates PTEN.
We investigated IGF1 expression in tissue and blood as potential
predictive markers in a phase II study of IGF1R-directed monoclonal
antibody, MK-0646 in APC. Prior phase I studies established the MTD
of MK0646 at 5 mg/kg with Gemcitabine (G) and Erlotinib (E) and 10
mg/kg with G alone.
[0178] Methods:
[0179] Patients (pts) with stage 1V, previously untreated APC, ECOG
PS 0-1, adequate hematologic and organ function were enrolled.
[0180] Arm A: G 1000 mg/m.sup.2 over 100 min, weekly.times.3,
MK-0646 weekly.times.4;
[0181] Arm B: G 1000 mg/m.sup.2 and MK-0646+E 100 mg daily;
[0182] Arm C (control) was G 1000 mg/m.sup.2+E 100 mg.
[0183] Cycles were repeated every 4 weeks. Patients were equally
randomized in the 3 arms. The primary study objective was
progression-free survival (PFS). Pre-treatment peripheral blood
samples measured for IGF1 level by ELISA in all cases; archival
core biopsies were analyzed for IGF1 mRNA expression. RNA
extraction from FFPE samples used the Roche Transcriptor First
Strand cDNA Synthesis Kit. TaqMan PreAmp technique was used to
amplify target cDNA prior to TaqMan RT-PCR analysis. Cox
proportional hazards model for PFS analyzed the interaction between
tissue IGF1 expression and treatment.
[0184] Results:
[0185] 50 patients were enrolled (A=17, B=17, C=16 pts). Median PFS
of arms A, B and C were 5.5 months (95% Cl: 3.9--NA), 3.0 months
(95% Cl 1.8-5.6) and 2.0 months (95% Cl: 1.8--NA), respectively
(log-rank test; p-value=0.17). Median OS of A was 11.3 months (95%
Cl: 8.9--NA), B 8.9 months (95% Cl: 5.3--NA) and C 5.7 months (95%
Cl: 2.0--NA) (log-rank test; p-value=0.44). 35 archival core
biopsies were analyzed, 21 had adequate tissue for analysis. Using
a Multivariable Cox proportional hazards model for PFS, where IGF1
was dichotomized at the median, there was a 76% reduction in the
risk of disease of progression or death in arm A as compared with
the control (arm C) with a p=0.16. When IGF1 was fitted as a
continuous variable, this reduction was 96% (p=0.08).
[0186] Conclusion:
[0187] Tissue expression of IGF1 level represents a promising
predictive biomarker for IGF1R inhibitor therapy in APC.
Example 3
Low RAS and High IGF as Biomarkers for Dalotuzumab (MK-0646) and
Ridaforolimus (MK-8669) Combination Therapy in Ovarian
Carcinoma
[0188] Translational work has suggested that low RAS activity, as
determined by a RAS gene expression signature score, and high IGF
levels may enrich for response to combination therapy with the mTOR
inhibitor ridaforolimus and the IGF1R monoclonal antibody
dalotuzumab (Loboda et al., Clin. Pharmacol. Ther. 2009; 86
(1):92-6; Ebbinghaus et al., Mol. Cancer Ther. 10 (11), Suppl 1,
1158). Consistent with these observations, clinical responses have
been noted for several ER.sup.+ breast and ovarian cancer patients,
indications that may be enriched for low RAS and high IGF, in a
Phase I trial for ridaforolimus and dalotuzumab combination therapy
(Ebbinghaus et al., Mol. Cancer Ther. 10 (11), Suppl 1, 1158).
TABLE-US-00019 TABLE 4 RAS Gene Expression Score, IGF Levels, and
Response to Ridaforolimus and Dalotuzumab Combination Therapy in
Patient-Derived Xenograft (PDX) Models of Ovarian Carcinoma.
Combination RAS Response PDX Ovarian RAS/RAF pathway (% tumor
growth Tumor Model mutation score IGF1 IGF2 inhibition, TGI) ST025
wt -0.39 1.1 3.4 90 ST015 wt -0.38 1.6 3.1 139 ST187 wt -0.34 2.6
1.6 74 ST038 wt -0.24 2.7 2.1 82 ST070 wt -0.20 1.2 1.1 83 ST024 wt
0.02 1.2 2.8 46 ST013 wt 0.05 1.1 2.0 59 ST004 KRAS mut 0.14 1.2
0.82 38 ST022 KRAS mut 0.26 1.3 0.74 45 ST040 ND ND ND ND 19 ST088
ND ND ND ND 88 ST103 wt ND ND ND 59 Models are listed in order of
descending RAS score values. wt = wildtype; mut = mutant; ND = not
done
[0189] To provide further support for low RAS and high IGF as
response biomarkers, the anti-tumor activity of ridaforolimus and
dalotuzumab was assessed in 12 molecularly annotated
patient-derived primary xenograft (PDX) ovarian cancer models
(Table 4). Responses to combination therapy were assessed by
percentage tumor growth inhibition (TGI) at the end of 18-28 days
of therapy. TGI values ranged from minimal (19% TGI) to significant
regression (139% TGI). Gene expression profiling data were
generated for nine of the models to correlate response with
genotype. More responsive tumor models tended to be associated with
a low RAS gene signature and higher expression levels of IGF1 or
IGF2. In contrast, tumors with KRAS mutations or a high RAS gene
score were generally resistant to combination therapy.
Example 4
Evaluation of IGF1 Cq Value in 44 Colorectal Cancer Samples
[0190] An independent set of 44 colorectal cancer FFPE tissue
specimens (including stromal and tumor cells) was evaluated with
the IGF1 real time PCR FFPE assay to determine the relative
distribution of IGF1 expression levels and to determine potential
cut-points for identifying patients using FFPE specimens as being
IGF1 (+) or not. Prior IGF1 evaluation has suggested that IGF1
increased expression is elevated in approximately 18% (+/-5% STDEV)
of colorectal cancer specimens above background noise. Based on
this, we determined from the set of independent 44 colorectal
specimens tested with our specific IGF1 real time PCR FFPE assay
that the approximate cut-point for determining (+) IGF1 expression
was less than or equal to approximately between 1.83-2.03 (Table
3+/-5% STDEV of 1.93=18% cut-point; n=44) Cq value. Therefore,
colorectal cancer samples determined to have IGF1 Cq value< or
=2.03 (upper boundary+5% STDEV of 1.93) are likely to be IGF1 (+)
and may derive a clinical benefit by treatment with an IGF1R
inhibitor.
TABLE-US-00020 TABLE 5 Cq values determined for 44 colorectal
cancer samples. Random Set of Colorectal Cancer Samples IGF1 RT-PCR
IGF1 Likely (n = 44) Cq values Positive (+) 1 -1.04 (+) 2 -0.12 (+)
3 0.25 (+) 4 1.11 (+) 5 1.61 (+) 6 1.63 (+) 7 1.69 (+) 8 1.93 (+) 9
2.14 10 2.19 11 2.39 12 2.4 13 2.49 14 2.53 15 2.75 16 2.76 17 2.93
18 2.94 19 2.98 20 3.01 21 3.09 22 3.13 23 3.29 24 3.48 25 3.61 26
3.65 27 3.66 28 3.73 29 3.75 30 3.86 31 3.92 32 4.04 33 4.3 34 4.39
35 4.49 36 4.75 37 5.01 38 5.19 39 5.21 40 5.46 41 5.81 42 6.26 43
6.97 44 7.01
Example 5
Evaluation of IGF1 Cq Value in 21 Pancreatic Cancer Samples
[0191] Twenty one pancreatic cancer FFPE tissue specimens were
evaluated with the IGF1 real time PCR FFPE assay to determine the
relative distribution of IGF1 expression levels and to determine
potential cut-points for identifying pancreatic patients using FFPE
specimens as being IGF1 (+) or not. We determined that pancreatic
tumors exhibiting IGF1 expression levels above the median observed
in this study were IGF1 (+) whereas expression below the median was
IGF1(-). Thus, tumors with an IGF1 Cq value .ltoreq.2.87 were
considered to be IGF1 high expressers, IGF1(+).
TABLE-US-00021 TABLE 6 IGF-1 RT-PCR Data Analysis (n = 21) Normal-
ized trt IGF1 Pt trt (cy- PFS OS # SampleName Cq ID arm cles) (wks)
(wks) IGF1(+) 1 S0748PA0015 0.24 26 A 2 8 45 2 S0748PA0005 0.56 8 A
12 61 83 3 S0748PA0032 2.34 52 A 2 8 15 4 S0748PA0001 2.71 1 A 8 62
82 5 S0748PA0007 1.23 11 B 2 8 38 6 S0748PA0030 2.51 48 B 2 5 23 7
S0748PA0020 2.56 36 B 2 8 22 8 S0748PA0033 2.85 54 B 2.00 8 24 9
S0748PA0021 0.42 38 C 2 8 48 10 S0748PA0031 2.47 51 C 3.50 9 17 11
S0748PA0027 2.87 58 C 1 6 9 Cut point IGF1(-) 12 S0748PA0029 3.69
45 A 2 8 30 13 S0748PA0006 4.26 9 A 8 31 48 14 S0748PA0026 5.88 57
A 2 10 17 15 S0748PA0008 6.1 16 A 2 5 39 16 S0748PA0004 3.55 6 B 2
8 alive 17 S0748PA0011 5.22 19 B 2.00 9 19 18 S0748PA0028 5.97 70 B
5 22 31 19 S0748PA0012 6.93 22 B 3 13 13 20 S0748PA0016 3.28 30 C 4
8 34 21 S0748PA0017 3.43 31 C 6 23 63 Note - A total of 21 pts had
IGF1 RT-PCR data; Cut-point was established at `median` IGF1 Cq
value (.ltoreq.2.87) - this determined which pts to be IGF1 (+) or
IGF1 (-) for analysis Treatment Arm A = MK-0646 + gemcitabine ->
treatment arm to take forward for BMx evaluation Treatment Arm B =
MK-0646 + Erlotinib + gemcitabine Treatment Arm C = Erlotinib +
gemcitabine (this was the control arm)
[0192] In Table 7(A-B), below, in Treatment Arm A, MK-0646 and
gemcitabine in an IGF1 (+) population showed a median progression
free survival (PFS) of 8 months (34 weeks). In Treatment Arm C,
erlotinib and gemcitabine in an IGF1(+) population, showed a median
PFS of 2 months (8 wks). [P-value (2 sided)=0.08; one-sided=0.04].
This trend was confirmed using affimetrix IGF1 RNA array expression
profiling data in part B of Table 7.
TABLE-US-00022 TABLE 7 Clinical Results For 21 pts With RT-PCR data
Vs. The 17 pts With Affy FFPE Profiling Data. (A) 21 pts With
qRT-PCR Data Trt Partial # PFS OS Biomarker Arm N = 21 Responders
cycles (wks) (wks) IGF1 (+) A 4 2 6.0 34.5 63.5 B 4 0 2.0 8.0 23.5
C 3 0 2.2 8.0 17.0 IGF1 (-) A 4 1 3.5 9.0 34.5 B 4 0 3.0 11.0 19.0
C 2 1 5.0 15.5 48.5 (B) 17 pts For which we have Affy Profiling
Data (4 patients lost during the profiling attempt). Trt Partial #
PFS OS Biomarker Arm N = 17 Responders cycles (wks) (wks) IGF1 (+)
A 4 2 6.0 34.5 63.5 B 3 0 2.0 8.0 23.0 C 2 0 1.5 7.0 28.5 IGF1 (-)
A 4 1 3.5 9.0 34.5 B 2 0 2.5 10.5 13.0 C 2 1 5.0 15.5 48.5 Note -
the IGF1 (+/-) status above was detemined by `qRT-PCR` in both
sets. Overall, we observed similar clinical results between the two
sample data sets.
[0193] The present invention is not to be limited in scope by the
specific embodiments described herein. Indeed, the scope of the
present invention includes embodiments specifically set forth
herein and other embodiments not specifically set forth herein; the
embodiments specifically set forth herein are not necessarily
intended to be exhaustive. Various modifications of the invention
in addition to those described herein will become apparent to those
skilled in the art from the foregoing description. Such
modifications are intended to fall within the scope of the
claims.
[0194] Patents, patent applications, publications, product
descriptions, and protocols are cited throughout this application,
the disclosures of which are incorporated herein by reference in
their entireties for all purposes.
Sequence CWU 1
1
251219PRTArtificial Sequencehumanized immunoglobulin 1Asp Ile Val
Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu
Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25
30 Asn Gly Asn Thr Tyr Leu Gln Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Leu Tyr Gly
Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val
Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Trp Thr Phe Gly
Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro
Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155
160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp
Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln
Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu
Cys 210 215 2447PRTArtificial Sequencehumanized immunoglobulin 2Gln
Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10
15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Gly Gly
20 25 30 Tyr Leu Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu
Glu Trp 35 40 45 Ile Gly Tyr Ile Ser Tyr Asp Gly Thr Asn Asn Tyr
Lys Pro Ser Leu 50 55 60 Lys Asp Arg Val Thr Ile Ser Arg Asp Thr
Ser Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala
Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Tyr Gly Arg Val
Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser
Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro
Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145
150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
Pro Ser Ser Ser 180 185 190 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
Asn His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu
Pro Lys Ser Cys Asp Lys Thr His 210 215 220 Thr Cys Pro Pro Cys Pro
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265
270 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Ala Leu Pro
Ala Pro Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro
Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Arg Glu Glu
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390
395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
Arg 405 410 415 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
Ser Pro Gly Lys 435 440 445 324DNAArtificial Sequenceforward primer
3tgtggagaca ggggctttta tttc 24424DNAArtificial Sequenceforward
primer 4tgtggagaca ggggctttta tttc 24524DNAArtificial
Sequenceforward primer 5tgtggagaca ggggctttta tttc
24624DNAArtificial Sequenceforward primer 6tgtggagaca ggggctttta
tttc 24724DNAArtificial Sequenceforward primer 7tgtggagaca
ggggctttta tttc 24820DNAArtificial Sequencereverse primer
8gcagcactca tccacgatgc 20920DNAArtificial Sequencereverse primer
9gcagcactca tccacgatgc 201020DNAArtificial Sequencereverse primer
10gcagcactca tccacgatgc 201120DNAArtificial Sequencereverse primer
11gcagcactca tccacgatgc 201220DNAArtificial Sequencereverse primer
12gcagcactca tccacgatgc 20137370DNAHomo sapiens 13ttttgtagat
aaatgtgagg attttctcta aatccctctt ctgtttgcta aatctcactg 60tcactgctaa
attcagagca gatagagcct gcgcaatgga ataaagtcct caaaattgaa
120atgtgacatt gctctcaaca tctcccatct ctctggattt ctttttgctt
cattattcct 180gctaaccaat tcattttcag actttgtact tcagaagcaa
tgggaaaaat cagcagtctt 240ccaacccaat tatttaagtg ctgcttttgt
gatttcttga aggtgaagat gcacaccatg 300tcctcctcgc atctcttcta
cctggcgctg tgcctgctca ccttcaccag ctctgccacg 360gctggaccgg
agacgctctg cggggctgag ctggtggatg ctcttcagtt cgtgtgtgga
420gacaggggct tttatttcaa caagcccaca gggtatggct ccagcagtcg
gagggcgcct 480cagacaggca tcgtggatga gtgctgcttc cggagctgtg
atctaaggag gctggagatg 540tattgcgcac ccctcaagcc tgccaagtca
gctcgctctg tccgtgccca gcgccacacc 600gacatgccca agacccagaa
gtatcagccc ccatctacca acaagaacac gaagtctcag 660agaaggaaag
gaagtacatt tgaagaacgc aagtagaggg agtgcaggaa acaagaacta
720caggatgtag gaagaccctc ctgaggagtg aagagtgaca tgccaccgca
ggatcctttg 780ctctgcacga gttacctgtt aaactttgga acacctacca
aaaaataagt ttgataacat 840ttaaaagatg ggcgtttccc ccaatgaaat
acacaagtaa acattccaac attgtcttta 900ggagtgattt gcaccttgca
aaaatggtcc tggagttggt agattgctgt tgatctttta 960tcaataatgt
tctatagaaa agaaaaaaaa aatatatata tatatatatc ttagtccctg
1020cctctcaaga gccacaaatg catgggtgtt gtatagatcc agttgcacta
aattcctctc 1080tgaatcttgg ctgctggagc cattcattca gcaaccttgt
ctaagtggtt tatgaattgt 1140ttccttattt gcacttcttt ctacacaact
cgggctgttt gttttacagt gtctgataat 1200cttgttagtc tatacccacc
acctcccttc ataaccttta tatttgccga atttggcctc 1260ctcaaaagca
gcagcaagtc gtcaagaagc acaccaattc taacccacaa gattccatct
1320gtggcatttg taccaaatat aagttggatg cattttattt tagacacaaa
gctttatttt 1380tccacatcat gcttacaaaa aagaataatg caaatagttg
caactttgag gccaatcatt 1440tttaggcata tgttttaaac atagaaagtt
tcttcaactc aaaagagttc cttcaaatga 1500tgagttaatg tgcaacctaa
ttagtaactt tcctcttttt attttttcca tatagagcac 1560tatgtaaatt
tagcatatca attatacagg atatatcaaa cagtatgtaa aactctgttt
1620tttagtataa tggtgctatt ttgtagtttg ttatatgaaa gagtctggcc
aaaacggtaa 1680tacgtgaaag caaaacaata ggggaagcct ggagccaaag
atgacacaag gggaagggta 1740ctgaaaacac catccatttg ggaaagaagg
caaagtcccc ccagttatgc cttccaagag 1800gaacttcaga cacaaaagtc
cactgatgca aattggactg gcgagtccag agaggaaact 1860gtggaatgga
aaaagcagaa ggctaggaat tttagcagtc ctggtttctt tttctcatgg
1920aagaaatgaa catctgccag ctgtgtcatg gactcaccac tgtgtgacct
tgggcaagtc 1980acttcacctc tctgtgcctc agtttcctca tctgcaaaat
gggggcaata tgtcatctac 2040ctacctcaaa ggggtggtat aaggtttaaa
aagataaaga ttcagatttt ttttaccctg 2100ggttgctgta agggtgcaac
atcagggcgc ttgagttgct gagatgcaag gaattctata 2160aataacccat
tcatagcata gctagagatt ggtgaattga atgctcctga catctcagtt
2220cttgtcagtg aagctatcca aataactggc caactagttg ttaaaagcta
acagctcaat 2280ctcttaaaac acttttcaaa atatgtggga agcatttgat
tttcaatttg attttgaatt 2340ctgcatttgg ttttatgaat acaaagataa
gtgaaaagag agaaaggaaa agaaaaagga 2400gaaaaacaaa gagatttcta
ccagtgaaag gggaattaat tactctttgt tagcactcac 2460tgactcttct
atgcagttac tacatatcta gtaaaacctc gtttaatact ataaataata
2520ttctattcat tttgaaaaac acaatgattc cttcttttct aggcaatata
aggaaagtga 2580tccaaaattt gaaatattaa aataatatct aataaaaagt
cacaaagtta tcttctttaa 2640caaactttac tcttattctt agctgtatat
acattttttt aaaagtttgt taaaatatgc 2700ttgactagag tttccagttg
aaaggcaaaa acttccatca caacaagaaa tttcccatgc 2760ctgctcagaa
gggtagcccc tagctctctg tgaatgtgtt ttatccattc aactgaaaat
2820tggtatcaag aaagtccact ggttagtgta ctagtccatc atagcctaga
aaatgatccc 2880tatctgcaga tcaagatttt ctcattagaa caatgaatta
tccagcattc agatctttct 2940agtcacctta gaactttttg gttaaaagta
cccaggcttg attatttcat gcaaattcta 3000tattttacat tcttggaaag
tctatatgaa aaacaaaaat aacatcttca gtttttctcc 3060cactgggtca
cctcaaggat cagaggccag gaaaaaaaaa aaaaagactc cctggatctc
3120tgaatatatg caaaaagaag gccccattta gtggagccag caatcctgtt
cagtcaacaa 3180gtattttaac tctcagtcca acattatttg aattgagcac
ctcaagcatg cttagcaatg 3240ttctaatcac tatggacaga tgtaaaagaa
actatacatc atttttgccc tctgcctgtt 3300ttccagacat acaggttctg
tggaataaga tactggactc ctcttcccaa gatggcactt 3360ctttttattt
cttgtcccca gtgtgtacct tttaaaatta ttccctctca acaaaacttt
3420ataggcagtc ttctgcagac ttaacgtgtt ttctgtcata gttagatgtg
ataattctaa 3480gagtgtctat gacttatttc cttcacttaa ttctatccac
agtcaaaaat cccccaagga 3540ggaaagctga aagatgcact gccatattat
ctttcttaac tttttccaac acataatcct 3600ctccaactgg attataaata
aattgaaaat aactcattat accaattcac tattttattt 3660tttaatgaat
taaaactaga aaacaaattg atgcaaaccc tggaagtcag ttgattacta
3720tatactacag cagaatgact cagatttcat agaaaggagc aaccaaaatg
tcacaaccca 3780aaactttaca agctttgctt cagaattaga ttgctttata
attcttgaat gaggcaattt 3840caagatattt gtaaaagaac agtaaacatt
ggtaagaatg agctttcaac tcataggctt 3900atttccaatt taattgacca
tactggatac ttaggtcaaa tttctgttct ctcttcccca 3960aataatatta
aagtattatt tgaacttttt aagatgaggc agttcccctg aaaaagttaa
4020tgcagctctc catcagaatc cactcttcta gggatatgaa aatctcttaa
cacccaccct 4080acatacacag acacacacac acacacacac acacacacac
acacacacat tcaccctaag 4140gatccaatgg aatactgaaa agaaatcact
tccttgaaaa ttttattaaa aaacaaacaa 4200acaaacaaaa agcctgtcca
cccttgagaa tccttcctct ccttggaacg tcaatgtttg 4260tgtagatgaa
accatctcat gctctgtggc tccagggttt ctgttactat tttatgcact
4320tgggagaagg cttagaataa aagatgtagc acattttgct ttcccattta
ttgtttggcc 4380agctatgcca atgtggtgct attgtttctt taagaaagta
cttgactaaa aaaaaaagaa 4440aaaaagaaaa aaaagaaagc atagacatat
ttttttaaag tataaaaaca acaattctat 4500agatagatgg cttaataaaa
tagcattagg tctatctagc caccaccacc tttcaacttt 4560ttatcactca
caagtagtgt actgttcacc aaattgtgaa tttgggggtg caggggcagg
4620agttggaaat tttttaaagt tagaaggctc cattgttttg ttggctctca
aacttagcaa 4680aattagcaat atattatcca atcttctgaa cttgatcaag
agcatggaga ataaacgcgg 4740gaaaaaagat cttataggca aatagaagaa
tttaaaagat aagtaagttc cttattgatt 4800tttgtgcact ctgctctaaa
acagatattc agcaagtgga gaaaataaga acaaagagaa 4860aaaatacata
gatttacctg caaaaaatag cttctgccaa atcccccttg ggtattcttt
4920ggcatttact ggtttataga agacattctc ccttcaccca gacatctcaa
agagcagtag 4980ctctcatgaa aagcaatcac tgatctcatt tgggaaatgt
tggaaagtat ttccttatga 5040gatgggggtt atctactgat aaagaaagaa
tttatgagaa attgttgaaa gagatggcta 5100acaatctgtg aagatttttt
gtttcttgtt tttgtttttt tttttttttt actttataca 5160gtctttatga
atttcttaat gttcaaaatg acttggttct tttcttcttt ttttatatca
5220gaatgaggaa taataagtta aacccacata gactctttaa aactataggc
tagatagaaa 5280tgtatgtttg acttgttgaa gctataatca gactatttaa
aatgttttgc tatttttaat 5340cttaaaagat tgtgctaatt tattagagca
gaacctgttt ggctctcctc agaagaaaga 5400atctttccat tcaaatcaca
tggctttcca ccaatatttt caaaagataa atctgattta 5460tgcaatggca
tcatttattt taaaacagaa gaattgtgaa agtttatgcc cctcccttgc
5520aaagaccata aagtccagat ctggtagggg ggcaacaaca aaaggaaaat
gttgttgatt 5580cttggttttg gattttgttt tgttttcaat gctagtgttt
aatcctgtag tacatatttg 5640cttattgcta ttttaatatt ttataagacc
ttcctgttag gtattagaaa gtgatacata 5700gatatctttt ttgtgtaatt
tctatttaaa aaagagagaa gactgtcaga agctttaagt 5760gcatatggta
caggataaag atatcaattt aaataaccaa ttcctatctg gaacaatgct
5820tttgtttttt aaagaaacct ctcacagata agacagaggc ccaggggatt
tttgaagctg 5880tctttattct gcccccatcc caacccagcc cttattattt
tagtatctgc ctcagaattt 5940tatagagggc tgaccaagct gaaactctag
aattaaagga acctcactga aaacatatat 6000ttcacgtgtt ccctcttttt
ttttttcctt tttgtgagat ggggtctcgc actgtccccc 6060aggctggagt
gcagtggcat gatctcggct cactgcaacc tccacctcct gggtttaagc
6120gattctcctg cctcagcctc ctgagtagct gggattacag gcacccacca
ctatgcccgg 6180ctaatttttt ggatttttaa tagagacggg gttttaccat
gttggccagg ttggtctcaa 6240actcctgacc ttgtgatttg cccgcctcag
cctcccaaat tgctgggatt acaggcatga 6300gccaccacac cctgcccatg
tgttccctct taatgtatga ttacatggat cttaaacatg 6360atccttctct
cctcattctt caactatctt tgatggggtc tttcaagggg aaaaaaatcc
6420aagctttttt aaagtaaaaa aaaaaaaaga gaggacacaa aaccaaatgt
tactgctcaa 6480ctgaaatatg agttaagatg gagacagagt ttctcctaat
aaccggagct gaattacctt 6540tcactttcaa aaacatgacc ttccacaatc
cttagaatct gccttttttt atattactga 6600ggcctaaaag taaacattac
tcattttatt ttgcccaaaa tgcactgatg taaagtagga 6660aaaataaaaa
cagagctcta aaatcccttt caagccaccc attgacccca ctcaccaact
6720catagcaaag tcacttctgt taatccctta atctgatttt gtttggatat
ttatcttgta 6780cccgctgcta aacacactgc aggagggact ctgaaacctc
aagctgtcta cttacatctt 6840ttatctgtgt ctgtgtatca tgaaaatgtc
tattcaaaat atcaaaacct ttcaaatatc 6900acgcagctta tattcagttt
acataaaggc cccaaatacc atgtcagatc tttttggtaa 6960aagagttaat
gaactatgag aattgggatt acatcatgta ttttgcctca tgtattttta
7020tcacacttat aggccaagtg tgataaataa acttacagac actgaattaa
tttcccctgc 7080tactttgaaa ccagaaaata atgactggcc attcgttaca
tctgtcttag ttgaaaagca 7140tattttttat taaattaatt ctgattgtat
ttgaaattat tattcaattc acttatggca 7200gaggaatatc aatcctaatg
acttctaaaa atgtaactaa ttgaatcatt atcttacatt 7260tactgtttaa
taagcatatt ttgaaaatgt atggctagag tgtcataata aaatggtata
7320tctttcttta gtaattacat taaaattagt catgtttgat taattagttc
7370141621DNAHomo sapiens 14gcggcaggtc tctgcgcagc ccagcccgcc
ggtccacgcc gcgcaccgct ccgagggcca 60gcgccacccg ctccgcagcc ggcaccatgc
gcgagatcgt gcacatccag gcgggccagt 120gcggcaacca gatcggcgcc
aagttttggg aggtcatcag cgatgagcat gggatcgacc 180ccacaggcag
ttaccatgga gacagtgact tgcagctgga gagaatcaac gtgtactaca
240atgaggctgc tggtaacaaa tatgtacctc gggccatcct ggtggatctg
gagcctggca 300ccatggactc tgtcaggtct ggacccttcg gccagatctt
cagaccagac aacttcgtgt 360tcggccagag tggagccggg aataactggg
ccaagggcca ctacacagag ggagccgagc 420tggtcgactc ggtcctggat
gtggtgagga aggagtcaga gagctgtgac tgtctccagg 480gcttccagct
gacccactct ctggggggcg gcacggggtc cgggatgggc accctgctca
540tcagcaagat ccgggaagag tacccagacc gcatcatgaa caccttcagc
gtcatgccct 600cacccaaggt gtcagacacg gtggtggagc cctacaacgc
caccctctct gtccaccagc 660tggtggaaaa cacagatgaa acctactcca
ttgataacga ggccctgtat gacatctgct 720tccgcaccct gaagctgacc
acccccacct acggggacct caaccacctg gtgtcggcca 780ccatgagcgg
ggtcaccacc tgcctgcgct tcccgggcca gctgaacgca gacctgcgca
840agctggcggt gaacatggtg cccttccctc gcctgcactt cttcatgccc
ggcttcgcgc 900ccctgaccag ccggggcagc cagcagtacc gggcgctcac
ggtgcccgag ctcacccagc 960agatgttcga ctccaagaac atgatggccg
cctgcgaccc gcgccacggc cgctacctga 1020cggtggctgc catcttccgg
ggccgcatgt ccatgaagga ggtggacgag cagatgctca 1080acgtgcagaa
caagaacagc agctacttcg tggagtggat ccccaacaac gtgaagacgg
1140ccgtgtgcga catcccgccc cgcggcctga agatgtcggc caccttcatc
ggcaacagca 1200cggccatcca ggagctgttc aagcgcatct ccgagcagtt
cacggccatg ttccggcgca 1260aggccttcct gcactggtac acgggcgagg
gcatggacga gatggagttc accgaggccg 1320agagcaacat gaacgacctg
gtgtccgagt accagcagta ccaggacgcc acggccgacg 1380aacaagggga
gttcgaggag gaggagggcg aggacgaggc ttaaaaactt ctcagatcaa
1440tcgtgcatcc ttagtgaact tctgttgtcc tcaagcatgg tctttctact
tgtaaactat 1500ggtgctcagt tttgcctctg ttagaaattc acactgttga
tgtaatgatg tggaactcct 1560ctaaaaatta cagtattgtc tgtgaaggta
tctatactaa taaaaaagca tgtgtagaaa 1620a 1621155410DNAHomo sapiens
15agtgggccgc catgttgtcg gagtgaaagg taagggggag cgagagcgcc agagagagaa
60gatcgggggg ctgaaatcca tcttcatcct accgctccgc ccgtgttggt ggaatgagcg
120ttgcatgtgt cttgaagaga aaagcagtgc tttggcagga ctctttcagc
ccccacctga 180aacatcaccc tcaagaacca gctaatccca acatgcctgt
tgttttgaca tctggaacag 240ggtcgcaagc gcagccacaa ccagctgcaa
atcaggctct tgcagctggg actcactcca 300gccctgtccc aggatctata
ggagttgcag gccgttccca ggacgacgct atggtggact 360acttctttca
gaggcagcat ggtgagcagc ttgggggagg aggaagtgga ggaggcggct
420ataataatag caaacatcga tggcctactg gggataacat tcatgcagaa
catcaggtgc 480gttccatgga tgaactgaat catgattttc aagcacttgc
tctggaggga agagcgatgg
540gagagcagct cttgccaggt aaaaagtttt gggaaacaga tgaatccagc
aaagatggac 600caaaaggaat attcctgggt gatcaatggc gagacagtgc
ctggggaaca tcagatcatt 660cagtttccca gccaatcatg gtgcagagaa
gacctggtca gagtttccat gtgaacagtg 720aggtcaattc tgtactgtcc
ccacgatcgg agagtggggg actaggcgtt agcatggtgg 780agtatgtgtt
gagctcatcc ccgggcgatt cctgtctaag aaaaggagga tttggcccaa
840gggatgcaga cagtgatgaa aacgacaaag gtgaaaagaa gaacaagggt
acgtttgatg 900gagataagct aggagatttg aaggaggagg gtgatgtgat
ggacaagacc aatggtttac 960cagtgcagaa tgggattgat gcagacgtca
aagattttag ccgtacccct ggtaattgcc 1020agaactctgc taatgaagtg
gatcttctgg gtccaaacca gaatggttct gagggcttag 1080cccagctgac
cagcaccaat ggtgccaagc ctgtggagga tttctccaac atggagtccc
1140agagtgtccc cttggacccc atggaacatg tgggcatgga gcctcttcag
tttgattatt 1200caggcacgca ggtacctgtg gactcagcag cagcaactgt
gggacttttt gactacaatt 1260ctcaacaaca gctgttccaa agacctaatg
cgcttgctgt ccagcagttg acagctgctc 1320agcagcagca gtatgcactg
gcagctgctc atcagccgca catcggttta gctcccgctg 1380cgtttgtccc
caatccatac atcatcagcg ctgctccccc agggacggac ccctacacag
1440ctggattggc tgcagcagcg acactaggcc cagctgtggt ccctcaccag
tattatggag 1500ttactccctg gggagtctac cctgccagtc ttttccagca
gcaagctgcc gctgccgctg 1560cagcaactaa ttcagctaat caacagacca
ccccacaggc tcagcaagga cagcagcagg 1620ttctccgtgg aggagccagc
caacgtcctt tgaccccaaa ccagaaccag cagggacagc 1680aaacggatcc
ccttgtggca gctgcagcag tgaattctgc ccttgcattt ggacaaggtc
1740tggcagcagg catgccaggt tatccggtgt tggctcctgc tgcttactat
gaccaaactg 1800gtgcccttgt agtgaatgca ggcgcgagaa atggtcttgg
agctcctgtt cgacttgtag 1860ctcctgcccc agtcatcatt agttcctcag
ctgcacaagc agctgttgca gcagccgcag 1920cttcagcaaa tggagcagct
ggtggtcttg ctggaacaac aaatggacca tttcgccctt 1980taggaacaca
gcagcctcag ccccagcccc agcagcagcc caataacaac ctggcatcca
2040gttctttcta cggcaacaac tctctgaaca gcaattcaca gagcagctcc
ctcttctccc 2100agggctctgc ccagcctgcc aacacatcct tgggattcgg
aagtagcagt tctctcggcg 2160ccaccctggg atccgccctt ggagggtttg
gaacagcagt tgcaaactcc aacactggca 2220gtggctcccg ccgtgactcc
ctgactggca gcagtgacct ttataagagg acatcgagca 2280gcttgacccc
cattggacac agtttttata acggccttag cttttcctcc tctcctggac
2340ccgtgggcat gcctctccct agtcagggac caggacattc acagacacca
cctccttccc 2400tctcttcaca tggatcctct tcaagcttaa acctgggagg
actcacgaat ggcagtggaa 2460gatacatctc tgctgctcca ggcgctgaag
ccaagtaccg cagtgcaagc agcgcctcca 2520gcctcttcag cccgagcagc
actcttttct cttcctctcg tttgcgatat ggaatgtctg 2580atgtcatgcc
ttctggcagg agcaggcttt tggaagattt tcgaaacaac cggtacccca
2640atttacaact gcgggagatt gctggacata taatggaatt ttcccaagac
cagcatgggt 2700ccagattcat tcagctgaaa ctggagcgtg ccacaccagc
tgagcgccag cttgtcttca 2760atgaaatcct ccaggctgcc taccaactca
tggtggatgt gtttggtaat tacgtcattc 2820agaagttctt tgaatttggc
agtcttgaac agaagctggc tttggcagaa cggattcgag 2880gccacgtcct
gtcattggca ctacagatgt atggctgccg tgttatccag aaagctcttg
2940agtttattcc ttcagaccag cagaatgaga tggttcggga actagatggc
catgtcttga 3000agtgtgtgaa agatcagaat ggcaatcacg tggttcagaa
atgcattgaa tgtgtacagc 3060cccagtcttt gcaatttatc atcgatgcgt
ttaagggaca ggtatttgcc ttatccacac 3120atccttatgg ctgccgagtg
attcagagaa tcctggagca ctgtctccct gaccagacac 3180tccctatttt
agaggagctt caccagcaca cagagcagct tgtacaggat caatatggaa
3240attatgtaat ccaacatgta ctggagcacg gtcgtcctga ggataaaagc
aaaattgtag 3300cagaaatccg aggcaatgta cttgtattga gtcagcacaa
atttgcaagc aatgttgtgg 3360agaagtgtgt tactcacgcc tcacgtacgg
agcgcgctgt gctcatcgat gaggtgtgca 3420ccatgaacga cggtccccac
agtgccttat acaccatgat gaaggaccag tatgccaact 3480acgtggtcca
gaagatgatt gacgtggcgg agccaggcca gcggaagatc gtcatgcata
3540agatccggcc ccacatcgca actcttcgta agtacaccta tggcaagcac
attctggcca 3600agctggagaa gtactacatg aagaacggtg ttgacttagg
gcccatctgt ggccccccta 3660atggtatcat ctgaggcagt gtcacccgct
gttccctcat tcccgctgac ctcactggcc 3720cactggcaaa tccaaccagc
aaccagaaat gttctagtgt agagtctgag acgggcaagt 3780ggttgctcca
ggattactcc ctcctccaaa aaaggaatca aatccacgag tggaaaagcc
3840tttgtaaatt taattttatt acacataaca tgtactattt tttttaattg
actaattgcc 3900ctgctgtttt actggtgtat aggatacttg tacataggta
accaatgtac atgggaggcc 3960acatattttg ttcactgttg tatctatatt
tcacatgtgg aaactttcag ggtggttggt 4020ttaacaaaaa aaaaaagctt
taaaaaaaaa agaaaaaaag gaaaaggttt ttagctcatt 4080tgcctggccg
gcaagttttg caaatagctc ttccccacct cctcatttta gtaaaaaaca
4140aacaaaaaca aaaaaacctg agaagtttga attgtagtta aatgacccca
aactggcatt 4200taacactgtt tataaaaaat atatatatat atatatatat
atataatgaa aaaggtttca 4260gagttgctaa agcttcagtt tgtgacatta
agtttatgaa attctaaaaa atgccttttt 4320tggagactat attatgctga
agaaggctgt tcgtgaggag gagatgcgag cacccagaac 4380gtcttttgag
gctgggcggg tgtgattgtt tactgcctac tggatttttt tctattaaca
4440ttgaaaggta aaatctgatt atttagcatg agaaaaaaaa atccaactct
gcttttggtc 4500ttgcttctat aaatatatag tgtatacttg gtgtagactt
tgcatatata caaatttgta 4560gtattttctt gttttgatgt ctaatctgta
tctataatgt accctagtag tcgaacatac 4620ttttgattgt acaattgtac
atttgtatac ctgtaatgta aatgtggaga agtttgaatc 4680aacataaaca
cgttttttgg taagaaaaga gaattagcca gccctgtgca ttcagtgtat
4740attctcacct tttatggtcg tagcatatag tgttgtatat tgtaaattgt
aatttcaacc 4800agaagtaaat ttttttcttt tgaaggaata aatgttcttt
atacagccta gttaatgttt 4860aaaaagaaaa aaatagcttg gttttatttg
tcatctagtc tcaagtatag cgagattctt 4920tctaaatgtt attcaagatt
gagttctcac tagtgttttt ttaatcctaa aaaagtaatg 4980ttttgatttt
gtgacagtca aaaggacgtg caaaagtcta gccttgcccg agctttcctt
5040acaatcagag cccctctcac cttgtaaagt gtgaatcgcc cttccctttt
gtacagaaga 5100tgaactgtat tttgcatttt gtctacttgt aagtgaatgt
aacatactgt caattttcct 5160tgtttgaata tagaattgta acactacacg
gtgtacattt ccagagcctt gtgtatattt 5220ccaatgaact tttttgcaag
cacacttgta accatatgtg tataattaac aaacctgtgt 5280atgcttatgc
ctgggcaact attttttgta actcttgtgt agattgtctc taaacaatgt
5340gtgatcttta ttttgaaaaa tacagaactt tggaatctga aaaaaaaaaa
aaaaaaaaaa 5400aaaaaaaaaa 5410162594DNAHomo sapiens 16aggggccgcg
gagccgcggc taaggaacgc gggccgccca cccgctcccg gtgcagcggc 60ctccgcgccg
ggttttggcg cctcccgcgg gcgcccccct cctcacggcg agcgctgcca
120cgtcagacga agggcgcagc gagcgtcctg atccttccgc ccggacgctc
aggacagcgg 180cccgctgctc ataagactcg gccttagaac cccagtatca
gcagaaggac attttaggac 240gggacttggg tgactctagg gcactggttt
tctttccaga gagcggaaca ggcgaggaaa 300agtagtccct tctcggcgat
tctgcggagg gatctccgtg gggcggtgaa cgccgatgat 360tatataagga
cgcgccgggt gtggcacagc tagttccgtc gcagccggga tttgggtcgc
420agttcttgtt tgtggatcgc tgtgatcgtc acttgacaat gcagatcttc
gtgaagactc 480tgactggtaa gaccatcacc ctcgaggttg agcccagtga
caccatcgag aatgtcaagg 540caaagatcca agataaggaa ggcatccctc
ctgaccagca gaggctgatc tttgctggaa 600aacagctgga agatgggcgc
accctgtctg actacaacat ccagaaagag tccaccctgc 660acctggtgct
ccgtctcaga ggtgggatgc aaatcttcgt gaagacactc actggcaaga
720ccatcaccct tgaggtcgag cccagtgaca ccatcgagaa cgtcaaagca
aagatccagg 780acaaggaagg cattcctcct gaccagcaga ggttgatctt
tgccggaaag cagctggaag 840atgggcgcac cctgtctgac tacaacatcc
agaaagagtc taccctgcac ctggtgctcc 900gtctcagagg tgggatgcag
atcttcgtga agaccctgac tggtaagacc atcaccctcg 960aggtggagcc
cagtgacacc atcgagaatg tcaaggcaaa gatccaagat aaggaaggca
1020ttccttctga tcagcagagg ttgatctttg ccggaaaaca gctggaagat
ggtcgtaccc 1080tgtctgacta caacatccag aaagagtcca ccttgcacct
ggtactccgt ctcagaggtg 1140ggatgcaaat cttcgtgaag acactcactg
gcaagaccat cacccttgag gtcgagccca 1200gtgacactat cgagaacgtc
aaagcaaaga tccaagacaa ggaaggcatt cctcctgacc 1260agcagaggtt
gatctttgcc ggaaagcagc tggaagatgg gcgcaccctg tctgactaca
1320acatccagaa agagtctacc ctgcacctgg tgctccgtct cagaggtggg
atgcagatct 1380tcgtgaagac cctgactggt aagaccatca ctctcgaagt
ggagccgagt gacaccattg 1440agaatgtcaa ggcaaagatc caagacaagg
aaggcatccc tcctgaccag cagaggttga 1500tctttgccgg aaaacagctg
gaagatggtc gtaccctgtc tgactacaac atccagaaag 1560agtccacctt
gcacctggtg ctccgtctca gaggtgggat gcagatcttc gtgaagaccc
1620tgactggtaa gaccatcact ctcgaggtgg agccgagtga caccattgag
aatgtcaagg 1680caaagatcca agacaaggaa ggcatccctc ctgaccagca
gaggttgatc tttgctggga 1740aacagctgga agatggacgc accctgtctg
actacaacat ccagaaagag tccaccctgc 1800acctggtgct ccgtcttaga
ggtgggatgc agatcttcgt gaagaccctg actggtaaga 1860ccatcactct
cgaagtggag ccgagtgaca ccattgagaa tgtcaaggca aagatccaag
1920acaaggaagg catccctcct gaccagcaga ggttgatctt tgctgggaaa
cagctggaag 1980atggacgcac cctgtctgac tacaacatcc agaaagagtc
caccctgcac ctggtgctcc 2040gtcttagagg tgggatgcag atcttcgtga
agaccctgac tggtaagacc atcactctcg 2100aagtggagcc gagtgacacc
attgagaatg tcaaggcaaa gatccaagac aaggaaggca 2160tccctcctga
ccagcagagg ttgatctttg ctgggaaaca gctggaagat ggacgcaccc
2220tgtctgacta caacatccag aaagagtcca ccctgcacct ggtgctccgt
ctcagaggtg 2280ggatgcaaat cttcgtgaag accctgactg gtaagaccat
caccctcgag gtggagccca 2340gtgacaccat cgagaatgtc aaggcaaaga
tccaagataa ggaaggcatc cctcctgatc 2400agcagaggtt gatctttgct
gggaaacagc tggaagatgg acgcaccctg tctgactaca 2460acatccagaa
agagtccact ctgcacttgg tcctgcgctt gagggggggt gtctaagttt
2520ccccttttaa ggtttcaaca aatttcattg cactttcctt tcaataaagt
tgttgcattc 2580ccaaaaaaaa aaaa 2594171435DNAHomo sapiens
17ggcggggcct gcttctcctc agcttcaggc ggctgcgacg agccctcagg cgaacctctc
60ggctttcccg cgcggcgccg cctcttgctg cgcctccgcc tcctcctctg ctccgccacc
120ggcttcctcc tcctgagcag tcagcccgcg cgccggccgg ctccgttatg
gcgacccgca 180gccctggcgt cgtgattagt gatgatgaac caggttatga
ccttgattta ttttgcatac 240ctaatcatta tgctgaggat ttggaaaggg
tgtttattcc tcatggacta attatggaca 300ggactgaacg tcttgctcga
gatgtgatga aggagatggg aggccatcac attgtagccc 360tctgtgtgct
caaggggggc tataaattct ttgctgacct gctggattac atcaaagcac
420tgaatagaaa tagtgataga tccattccta tgactgtaga ttttatcaga
ctgaagagct 480attgtaatga ccagtcaaca ggggacataa aagtaattgg
tggagatgat ctctcaactt 540taactggaaa gaatgtcttg attgtggaag
atataattga cactggcaaa acaatgcaga 600ctttgctttc cttggtcagg
cagtataatc caaagatggt caaggtcgca agcttgctgg 660tgaaaaggac
cccacgaagt gttggatata agccagactt tgttggattt gaaattccag
720acaagtttgt tgtaggatat gcccttgact ataatgaata cttcagggat
ttgaatcatg 780tttgtgtcat tagtgaaact ggaaaagcaa aatacaaagc
ctaagatgag agttcaagtt 840gagtttggaa acatctggag tcctattgac
atcgccagta aaattatcaa tgttctagtt 900ctgtggccat ctgcttagta
gagctttttg catgtatctt ctaagaattt tatctgtttt 960gtactttaga
aatgtcagtt gctgcattcc taaactgttt atttgcacta tgagcctata
1020gactatcagt tccctttggg cggattgttg tttaacttgt aaatgaaaaa
attctcttaa 1080accacagcac tattgagtga aacattgaac tcatatctgt
aagaaataaa gagaagatat 1140attagttttt taattggtat tttaattttt
atatatgcag gaaagaatag aagtgattga 1200atattgttaa ttataccacc
gtgtgttaga aaagtaagaa gcagtcaatt ttcacatcaa 1260agacagcatc
taagaagttt tgttctgtcc tggaattatt ttagtagtgt ttcagtaatg
1320ttgactgtat tttccaactt gttcaaatta ttaccagtga atctttgtca
gcagttccct 1380tttaaatgca aatcaataaa ttcccaaaaa tttaaaaaaa
aaaaaaaaaa aaaaa 1435181235DNAHomo sapiens 18cccaggggcc gacgggagtg
gcggccgcgc ggaggaggcc aagatggcgg cagctgcggc 60ttcgcttcgc ggggtagtgt
tgggcccgcg gggcgcgggg ctcccgggcg cgcgtgcccg 120gggtctgctg
tgcagcgcgc gtcccgggca gctcccgcta cggacacctc aggcagtggc
180cttgtcgtcg aagtctggcc tttcccgagg ccggaaagtg atgctgtcag
cgctgggcat 240gctggcggca gggggtgcgg ggctggccgt ggctctgcat
tcggctgtga gtgccagtga 300cctggagctg caccccccca gctatccgtg
gtctcaccgt ggcctcctct cttccttgga 360ccacaccagc atccggaggg
gtttccaggt atataagcag gtgtgcgcct cctgccacag 420catggacttc
gtggcctacc gccacctggt gggcgtgtgc tacacggagg atgaagctaa
480ggagctggct gcggaggtgg aggttcaaga cggccccaat gaagatgggg
agatgttcat 540gcggccaggg aagctgttcg actatttccc aaaaccatac
cccaacagtg aggctgctcg 600agctgccaac aacggagcat tgccccctga
cctcagctac atcgtgcgag ctaggcatgg 660tggtgaggac tacgtcttct
ccctgctcac gggctactgc gagccaccca ccggggtgtc 720actgcgggaa
ggtctctact tcaaccccta ctttcctggc caggccattg ccatggcccc
780tcccatctac acagatgtct tagagtttga cgatggcacc ccagctacca
tgtcccagat 840agccaaggat gtgtgcacct tcctgcgctg ggcatctgag
ccagagcacg accatcgaaa 900acgcatgggg ctcaagatgt tgatgatgat
ggctctgctg gtgcccctgg tctacaccat 960aaagcggcac aagtggtcag
tcctgaagag tcggaagctg gcatatcggc cgcccaagtg 1020accctgtcca
gtgtctgctt gccatcctgc cagaacaggc cctcaagccc aagagccatc
1080ccaggcctgt tcaggcctca gctaagcctc tcttcatctg gaagaagagg
caagggggca 1140ggagaccagg ctctagctct gggccctcct tcagccccca
tcatgggaat aaattaattt 1200tctcaatgta aaaaaaaaaa aaaaaaaaaa aaaaa
1235191526DNAHomo sapiens 19ccggaagtga cgcgaggctc tgcggagacc
aggagtcaga ctgtaggacg acctcgggtc 60ccacgtgtcc ccggtactcg ccggccggag
cccccggctt cccggggccg ggggacctta 120gcggcaccca cacacagcct
actttccaag cggagccatg tctggtaacg gcaatgcggc 180tgcaacggcg
gaagaaaaca gcccaaagat gagagtgatt cgcgtgggta cccgcaagag
240ccagcttgct cgcatacaga cggacagtgt ggtggcaaca ttgaaagcct
cgtaccctgg 300cctgcagttt gaaatcattg ctatgtccac cacaggggac
aagattcttg atactgcact 360ctctaagatt ggagagaaaa gcctgtttac
caaggagctt gaacatgccc tggagaagaa 420tgaagtggac ctggttgttc
actccttgaa ggacctgccc actgtgcttc ctcctggctt 480caccatcgga
gccatctgca agcgggaaaa ccctcatgat gctgttgtct ttcacccaaa
540atttgttggg aagaccctag aaaccctgcc agagaagagt gtggtgggaa
ccagctccct 600gcgaagagca gcccagctgc agagaaagtt cccgcatctg
gagttcagga gtattcgggg 660aaacctcaac acccggcttc ggaagctgga
cgagcagcag gagttcagtg ccatcatcct 720ggcaacagct ggcctgcagc
gcatgggctg gcacaaccgg gtggggcaga tcctgcaccc 780tgaggaatgc
atgtatgctg tgggccaggg ggccttgggc gtggaagtgc gagccaagga
840ccaggacatc ttggatctgg tgggtgtgct gcacgatccc gagactctgc
ttcgctgcat 900cgctgaaagg gccttcctga ggcacctgga aggaggctgc
agtgtgccag tagccgtgca 960tacagctatg aaggatgggc aactgtacct
gactggagga gtctggagtc tagacggctc 1020agatagcata caagagacca
tgcaggctac catccatgtc cctgcccagc atgaagatgg 1080ccctgaggat
gacccacagt tggtaggcat cactgctcgt aacattccac gagggcccca
1140gttggctgcc cagaacttgg gcatcagcct ggccaacttg ttgctgagca
aaggagccaa 1200aaacatcctg gatgttgcac ggcagcttaa cgatgcccat
taactggttt gtggggcaca 1260gatgcctggg ttgctgctgt ccagtgccta
catcccgggc ctcagtgccc cattctcact 1320gctatctggg gagtgattac
cccgggagac tgaactgcag ggttcaagcc ttccagggat 1380ttgcctcacc
ttggggcctt gatgactgcc ttgcctcctc agtatgtggg ggcttcatct
1440ctttagagaa gtccaagcaa cagcctttga atgtaaccaa tcctactaat
aaaccagttc 1500tgaaggtgta aaaaaaaaaa aaaaaa 1526202405DNAHomo
sapiens 20tccggcgtgg tgcgcaggcg cggtatcccc cctcccccgc cagctcgacc
ccggtgtggt 60gcgcaggcgc agtctgcgca gggactggcg ggactgcgcg gcggcaacag
cagacatgtc 120gggggtccgg ggcctgtcgc ggctgctgag cgctcggcgc
ctggcgctgg ccaaggcgtg 180gccaacagtg ttgcaaacag gaacccgagg
ttttcacttc actgttgatg ggaacaagag 240ggcatctgct aaagtttcag
attccatttc tgctcagtat ccagtagtgg atcatgaatt 300tgatgcagtg
gtggtaggcg ctggaggggc aggcttgcga gctgcatttg gcctttctga
360ggcagggttt aatacagcat gtgttaccaa gctgtttcct accaggtcac
acactgttgc 420agcacaggga ggaatcaatg ctgctctggg gaacatggag
gaggacaact ggaggtggca 480tttctacgac accgtgaagg gctccgactg
gctgggggac caggatgcca tccactacat 540gacggagcag gcccccgccg
ccgtggtcga gctagaaaat tatggcatgc cgtttagcag 600aactgaagat
gggaagattt atcagcgtgc atttggtgga cagagcctca agtttggaaa
660gggcgggcag gcccatcggt gctgctgtgt ggctgatcgg actggccact
cgctattgca 720caccttatat ggaaggtctc tgcgatatga taccagctat
tttgtggagt attttgcctt 780ggatctcctg atggagaatg gggagtgccg
tggtgtcatc gcactgtgca tagaggacgg 840gtccatccat cgcataagag
caaagaacac tgttgttgcc acaggaggct acgggcgcac 900ctacttcagc
tgcacgtctg cccacaccag cactggcgac ggcacggcca tgatcaccag
960ggcaggcctt ccttgccagg acctagagtt tgttcagttc caccctacag
gcatatatgg 1020tgctggttgt ctcattacgg aaggatgtcg tggagaggga
ggcattctca ttaacagtca 1080aggcgaaagg tttatggagc gatacgcccc
tgtcgcgaag gacctggcgt ctagagatgt 1140ggtgtctcgg tccatgactc
tggagatccg agaaggaaga ggctgtggcc ctgagaaaga 1200tcacgtctac
ctgcagctgc accacctacc tccagagcag ctggccacgc gcctgcctgg
1260catttcagag acagccatga tcttcgctgg cgtggacgtc acgaaggagc
cgatccctgt 1320cctccccacc gtgcattata acatgggcgg cattcccacc
aactacaagg ggcaggtcct 1380gaggcacgtg aatggccagg atcagattgt
gcccggcctg tacgcctgtg gggaggccgc 1440ctgtgcctcg gtacatggtg
ccaaccgcct cggggcaaac tcgctcttgg acctggttgt 1500ctttggtcgg
gcatgtgccc tgagcatcga agagtcatgc aggcctggag ataaagtccc
1560tccaattaaa ccaaacgctg gggaagaatc tgtcatgaat cttgacaaat
tgagatttgc 1620tgatggaagc ataagaacat cggaactgcg actcagcatg
cagaagtcaa tgcaaaatca 1680tgctgccgtg ttccgtgtgg gaagcgtgtt
gcaagaaggt tgtgggaaaa tcagcaagct 1740ctatggagac ctaaagcacc
tgaagacgtt cgaccgggga atggtctgga acacggacct 1800ggtggagacc
ctggagctgc agaacctgat gctgtgtgcg ctgcagacca tctacggagc
1860agaggcacgg aaggagtcac ggggcgcgca tgccagggaa gactacaagg
tgcggattga 1920tgagtacgat tactccaagc ccatccaggg gcaacagaag
aagccctttg aggagcactg 1980gaggaagcac accctgtcct atgtggacgt
tggcactggg aaggtcactc tggaatatag 2040acccgtgatc gacaaaactt
tgaacgaggc tgactgtgcc accgtcccgc cagccattcg 2100ctcctactga
tgagacaaga tgtggtgatg acagaatcag cttttgtaat tatgtataat
2160agctcatgca tgtgtccatg tcataactgt cttcatacgc ttctgcactc
tggggaagaa 2220ggagtacatt gaagggagat tggcacctag tggctgggag
cttgccagga acccagtggc 2280cagggagcgt ggcacttacc tttgtccctt
gcttcattct tgtgagatga taaaactggg 2340cacagctctt aaataaaata
taaatgaaca aactttcttt tatttccaaa aaaaaaaaaa 2400aaaaa
2405211852DNAHomo sapiens 21accgccgaga ccgcgtccgc cccgcgagca
cagagcctcg cctttgccga tccgccgccc 60gtccacaccc gccgccagct caccatggat
gatgatatcg ccgcgctcgt cgtcgacaac 120ggctccggca tgtgcaaggc
cggcttcgcg ggcgacgatg ccccccgggc cgtcttcccc 180tccatcgtgg
ggcgccccag gcaccagggc gtgatggtgg gcatgggtca gaaggattcc
240tatgtgggcg acgaggccca gagcaagaga ggcatcctca ccctgaagta
ccccatcgag 300cacggcatcg tcaccaactg ggacgacatg gagaaaatct
ggcaccacac cttctacaat 360gagctgcgtg tggctcccga ggagcacccc
gtgctgctga ccgaggcccc cctgaacccc 420aaggccaacc gcgagaagat
gacccagatc atgtttgaga ccttcaacac cccagccatg 480tacgttgcta
tccaggctgt gctatccctg tacgcctctg gccgtaccac tggcatcgtg
540atggactccg gtgacggggt cacccacact gtgcccatct acgaggggta
tgccctcccc 600catgccatcc tgcgtctgga cctggctggc cgggacctga
ctgactacct catgaagatc
660ctcaccgagc gcggctacag cttcaccacc acggccgagc gggaaatcgt
gcgtgacatt 720aaggagaagc tgtgctacgt cgccctggac ttcgagcaag
agatggccac ggctgcttcc 780agctcctccc tggagaagag ctacgagctg
cctgacggcc aggtcatcac cattggcaat 840gagcggttcc gctgccctga
ggcactcttc cagccttcct tcctgggcat ggagtcctgt 900ggcatccacg
aaactacctt caactccatc atgaagtgtg acgtggacat ccgcaaagac
960ctgtacgcca acacagtgct gtctggcggc accaccatgt accctggcat
tgccgacagg 1020atgcagaagg agatcactgc cctggcaccc agcacaatga
agatcaagat cattgctcct 1080cctgagcgca agtactccgt gtggatcggc
ggctccatcc tggcctcgct gtccaccttc 1140cagcagatgt ggatcagcaa
gcaggagtat gacgagtccg gcccctccat cgtccaccgc 1200aaatgcttct
aggcggacta tgacttagtt gcgttacacc ctttcttgac aaaacctaac
1260ttgcgcagaa aacaagatga gattggcatg gctttatttg ttttttttgt
tttgttttgg 1320tttttttttt ttttttggct tgactcagga tttaaaaact
ggaacggtga aggtgacagc 1380agtcggttgg agcgagcatc ccccaaagtt
cacaatgtgg ccgaggactt tgattgcaca 1440ttgttgtttt tttaatagtc
attccaaata tgagatgcgt tgttacagga agtcccttgc 1500catcctaaaa
gccaccccac ttctctctaa ggagaatggc ccagtcctct cccaagtcca
1560cacaggggag gtgatagcat tgctttcgtg taaattatgt aatgcaaaat
ttttttaatc 1620ttcgccttaa tactttttta ttttgtttta ttttgaatga
tgagccttcg tgccccccct 1680tccccctttt ttgtccccca acttgagatg
tatgaaggct tttggtctcc ctgggagtgg 1740gtggaggcag ccagggctta
cctgtacact gacttgagac cagttgaata aaagtgcaca 1800ccttaaaaat
gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1852222321DNAHomo
sapiens 22gtcctcaacc aagatggcgc ggatggcttc aggcgcatca cgacaccggc
gcgtcacgcg 60acccgcccta cgggcacctc ccgcgctttt cttagcgccg cagacggtgg
ccgagcgggg 120gaccgggaag catggcccgg gggtcggcgg ttgcctgggc
ggcgctcggg ccgttgttgt 180ggggctgcgc gctggggctg cagggcggga
tgctgtaccc ccaggagagc ccgtcgcggg 240agtgcaagga gctggacggc
ctctggagct tccgcgccga cttctctgac aaccgacgcc 300ggggcttcga
ggagcagtgg taccggcggc cgctgtggga gtcaggcccc accgtggaca
360tgccagttcc ctccagcttc aatgacatca gccaggactg gcgtctgcgg
cattttgtcg 420gctgggtgtg gtacgaacgg gaggtgatcc tgccggagcg
atggacccag gacctgcgca 480caagagtggt gctgaggatt ggcagtgccc
attcctatgc catcgtgtgg gtgaatgggg 540tcgacacgct agagcatgag
gggggctacc tccccttcga ggccgacatc agcaacctgg 600tccaggtggg
gcccctgccc tcccggctcc gaatcactat cgccatcaac aacacactca
660cccccaccac cctgccacca gggaccatcc aatacctgac tgacacctcc
aagtatccca 720agggttactt tgtccagaac acatattttg actttttcaa
ctacgctgga ctgcagcggt 780ctgtacttct gtacacgaca cccaccacct
acatcgatga catcaccgtc accaccagcg 840tggagcaaga cagtgggctg
gtgaattacc agatctctgt caagggcagt aacctgttca 900agttggaagt
gcgtcttttg gatgcagaaa acaaagtcgt ggcgaatggg actgggaccc
960agggccaact taaggtgcca ggtgtcagcc tctggtggcc gtacctgatg
cacgaacgcc 1020ctgcctatct gtattcattg gaggtgcagc tgactgcaca
gacgtcactg gggcctgtgt 1080ctgacttcta cacactccct gtggggatcc
gcactgtggc tgtcaccaag agccagttcc 1140tcatcaatgg gaaacctttc
tatttccacg gtgtcaacaa gcatgaggat gcggacatcc 1200gagggaaggg
cttcgactgg ccgctgctgg tgaaggactt caacctgctt cgctggcttg
1260gtgccaacgc tttccgtacc agccactacc cctatgcaga ggaagtgatg
cagatgtgtg 1320accgctatgg gattgtggtc atcgatgagt gtcccggcgt
gggcctggcg ctgccgcagt 1380tcttcaacaa cgtttctctg catcaccaca
tgcaggtgat ggaagaagtg gtgcgtaggg 1440acaagaacca ccccgcggtc
gtgatgtggt ctgtggccaa cgagcctgcg tcccacctag 1500aatctgctgg
ctactacttg aagatggtga tcgctcacac caaatccttg gacccctccc
1560ggcctgtgac ctttgtgagc aactctaact atgcagcaga caagggggct
ccgtatgtgg 1620atgtgatctg tttgaacagc tactactctt ggtatcacga
ctacgggcac ctggagttga 1680ttcagctgca gctggccacc cagtttgaga
actggtataa gaagtatcag aagcccatta 1740ttcagagcga gtatggagca
gaaacgattg cagggtttca ccaggatcca cctctgatgt 1800tcactgaaga
gtaccagaaa agtctgctag agcagtacca tctgggtctg gatcaaaaac
1860gcagaaaata cgtggttgga gagctcattt ggaattttgc cgatttcatg
actgaacagt 1920caccgacgag agtgctgggg aataaaaagg ggatcttcac
tcggcagaga caaccaaaaa 1980gtgcagcgtt ccttttgcga gagagatact
ggaagattgc caatgaaacc aggtatcccc 2040actcagtagc caagtcacaa
tgtttggaaa acagcctgtt tacttgagca agactgatac 2100cacctgcgtg
tcccttcctc cccgagtcag ggcgacttcc acagcagcag aacaagtgcc
2160tcctggactg ttcacggcag accagaacgt ttctggcctg ggttttgtgg
tcatctattc 2220tagcagggaa cactaaaggt ggaaataaaa gattttctat
tatggaaata aagagttggc 2280atgaaagtgg ctactgaaaa aaaaaaaaaa
aaaaaaaaaa a 2321233734DNAHomo sapiens 23caaatgcgaa cttaggctgt
tacacaactg ctggggtctg ttctcgccgc ccgcccggca 60gtcaggcagc gtcgccgccg
tggtagcagc ctcagccgtt tctggagtct cgggcccaca 120gtcaccgccg
cttacctgcg cctcctcgag cctccggagt ccccgtccgc ccgcacaggc
180cggttcgccg tctgcgtctc ccccacgccg cctcgcctgc cgccgcgctc
gtccctccgg 240gccgacatga gtggggacca cctccacaac gattcccaga
tcgaagcgga tttccgattg 300aatgattctc ataaacacaa agataaacac
aaagatcgag aacaccggca caaagaacac 360aagaaggaga aggaccggga
aaagtccaag catagcaaca gtgaacataa agattctgaa 420aagaaacaca
aagagaagga gaagaccaaa cacaaagatg gaagctcaga aaagcataaa
480gacaaacata aagacagaga caaggaaaaa cgaaaagagg aaaaggttcg
agcctctggg 540gatgcaaaaa taaagaagga gaaggaaaat ggcttctcta
gtccaccaca aattaaagat 600gaacctgaag atgatggcta ttttgttcct
cctaaagagg atataaagcc attaaagaga 660cctcgagatg aggatgatgc
tgattataaa cctaagaaaa ttaaaacaga agataccaag 720aaggagaaga
aaagaaaact agaagaagaa gaggatggta aattgaaaaa acccaagaat
780aaagataaag ataaaaaagt tcctgagcca gataacaaga aaaagaagcc
gaagaaagaa 840gaggaacaga agtggaaatg gtgggaagaa gagcgctatc
ctgaaggcat caagtggaaa 900ttcctagaac ataaaggtcc agtatttgcc
ccaccatatg agcctcttcc agagaatgtc 960aagttttatt atgatggtaa
agtcatgaag ctgagcccca aagcagagga agtagctacg 1020ttctttgcaa
aaatgctcga ccatgaatat actaccaagg aaatatttag gaaaaatttc
1080tttaaagact ggagaaagga aatgactaat gaagagaaga atattatcac
caacctaagc 1140aaatgtgatt ttacccagat gagccagtat ttcaaagccc
agacggaagc tcggaaacag 1200atgagcaagg aagagaaact gaaaatcaaa
gaggagaatg aaaaattact gaaagaatat 1260ggattctgta ttatggataa
ccacaaagag aggattgcta acttcaagat agagcctcct 1320ggacttttcc
gtggccgcgg caaccacccc aagatgggca tgctgaagag acgaatcatg
1380cccgaggata taatcatcaa ctgtagcaaa gatgccaagg ttccttctcc
tcctccagga 1440cataagtgga aagaagtccg gcatgataac aaggttactt
ggctggtttc ctggacagag 1500aacatccaag gttccattaa atacatcatg
cttaacccta gttcacgaat caagggtgag 1560aaggactggc agaaatacga
gactgctcgg cggctgaaaa aatgtgtgga caagatccgg 1620aaccagtatc
gagaagactg gaagtccaaa gagatgaaag tccggcagag agctgtagcc
1680ctgtacttca tcgacaagct tgctctgaga gcaggcaatg aaaaggagga
aggagaaaca 1740gcggacactg tgggctgctg ctcacttcgt gtggagcaca
tcaatctaca cccagagttg 1800gatggtcagg aatatgtggt agagtttgac
ttcctcggga aggactccat cagatactat 1860aacaaggtcc ctgttgagaa
acgagttttt aagaacctac aactatttat ggagaacaag 1920cagcccgagg
atgatctttt tgatagactc aatactggta ttctgaataa gcatcttcag
1980gatctcatgg agggcttgac agccaaggta ttccgtacat acaatgcctc
catcacgcta 2040cagcagcagc taaaagaact gacagccccg gatgagaaca
tcccagcgaa gatcctttct 2100tataaccgtg ccaatcgagc tgttgcaatt
ctttgtaacc atcagagggc accaccaaaa 2160acttttgaga agtctatgat
gaacttgcaa actaagattg atgccaagaa ggaacagcta 2220gcagatgccc
ggagagacct gaaaagtgct aaggctgatg ccaaggtcat gaaggatgca
2280aagacgaaga aggtagtaga gtcaaagaag aaggctgttc agagactgga
ggaacagttg 2340atgaagctgg aagttcaagc cacagaccga gaggaaaata
aacagattgc cctgggaacc 2400tccaaactca attatctgga ccctaggatc
acagtggctt ggtgcaagaa gtggggtgtc 2460ccaattgaga agatttacaa
caaaacccag cgggagaagt ttgcctgggc cattgacatg 2520gctgatgaag
actatgagtt ttagccagtc tcaagaggca gagttctgtg aagaggaaca
2580gtgtggtttg ggaaagatgg ataaactgag cctcacttgc cctcgtgcct
gggggagaga 2640ggcagcaagt cttaacaaac caacatcttt gcgaaaagat
aaacctggag atattataag 2700ggagagctga gccagttgtc ctatggacaa
cttatttaaa aatatttcag atatcaaaat 2760tctagctgta tgatttgttt
tgaattttgt ttttattttc aagagggcaa gtggatggga 2820atttgtcagc
gttctaccag gcaaattcac tgtttcactg aaatgtttgg attctcttag
2880ctactgtatg caaagtccga ttatattggt gcgtttttac agttagggtt
ttgcaataac 2940ttctatattt taatagaaat aaattcctaa actcccttcc
ctctctccca tttcaggaat 3000ttaaaattaa gtagaacaaa aaacccagcg
cacctgttag agtcgtcact ctctattgtc 3060atggggatca attttcatta
aacttgaagc agtcgtggct ttggcagtgt tttggttcag 3120acacctgttc
acagaaaaag catgatggga aaatatttcc tgacttgagt gttccttttt
3180aaatgtgaat ttttatttct ttttaattat tttaaaatat ttaaaccttt
ttcttgatct 3240taaagatcgt gtagattggg gttggggagg gatgaagggc
gagtgaatct aaggataatg 3300aaataatcag tgactgaaac cattttccca
tcatcctttg ttctgagcat tcgctgtacc 3360ctttaagata tccatctttt
tctttttaac cctaatcttt cacttgaaag attttattgt 3420ataaaaagtt
tcacaggtca ataaacttag aggaaaatga gtatttggtc caaaaaaagg
3480aaaaataatc aagattttag ggcttttatt ttttcttttg taattgtgta
aaaaatggaa 3540aaaaacataa aaagcagaat tttaatgtga agacattttt
tgctataatc attagtttta 3600gaggcattgt tagtttagtg tgtgtgcaga
gtccatttcc cacatctttc ctcaagtatc 3660ttctattttt atcatgaatt
cccttttaat caactgtagg ttatttaaaa taaattccta 3720caacttaatg gaaa
373424987DNAHomo sapiens 24aatataagtg gaggcgtcgc gctggcgggc
attcctgaag ctgacagcat tcgggccgag 60atgtctcgct ccgtggcctt agctgtgctc
gcgctactct ctctttctgg cctggaggct 120atccagcgta ctccaaagat
tcaggtttac tcacgtcatc cagcagagaa tggaaagtca 180aatttcctga
attgctatgt gtctgggttt catccatccg acattgaagt tgacttactg
240aagaatggag agagaattga aaaagtggag cattcagact tgtctttcag
caaggactgg 300tctttctatc tcttgtacta cactgaattc acccccactg
aaaaagatga gtatgcctgc 360cgtgtgaacc atgtgacttt gtcacagccc
aagatagtta agtgggatcg agacatgtaa 420gcagcatcat ggaggtttga
agatgccgca tttggattgg atgaattcca aattctgctt 480gcttgctttt
taatattgat atgcttatac acttacactt tatgcacaaa atgtagggtt
540ataataatgt taacatggac atgatcttct ttataattct actttgagtg
ctgtctccat 600gtttgatgta tctgagcagg ttgctccaca ggtagctcta
ggagggctgg caacttagag 660gtggggagca gagaattctc ttatccaaca
tcaacatctt ggtcagattt gaactcttca 720atctcttgca ctcaaagctt
gttaagatag ttaagcgtgc ataagttaac ttccaattta 780catactctgc
ttagaatttg ggggaaaatt tagaaatata attgacagga ttattggaaa
840tttgttataa tgaatgaaac attttgtcat ataagattca tatttacttc
ttatacattt 900gataaagtaa ggcatggttg tggttaatct ggtttatttt
tgttccacaa gttaaataaa 960tcataaaact tgatgtgtta tctctta
987251310DNAHomo sapiens 25aaattgagcc cgcagcctcc cgcttcgctc
tctgctcctc ctgttcgaca gtcagccgca 60tcttcttttg cgtcgccagc cgagccacat
cgctcagaca ccatggggaa ggtgaaggtc 120ggagtcaacg gatttggtcg
tattgggcgc ctggtcacca gggctgcttt taactctggt 180aaagtggata
ttgttgccat caatgacccc ttcattgacc tcaactacat ggtttacatg
240ttccaatatg attccaccca tggcaaattc catggcaccg tcaaggctga
gaacgggaag 300cttgtcatca atggaaatcc catcaccatc ttccaggagc
gagatccctc caaaatcaag 360tggggcgatg ctggcgctga gtacgtcgtg
gagtccactg gcgtcttcac caccatggag 420aaggctgggg ctcatttgca
ggggggagcc aaaagggtca tcatctctgc cccctctgct 480gatgccccca
tgttcgtcat gggtgtgaac catgagaagt atgacaacag cctcaagatc
540atcagcaatg cctcctgcac caccaactgc ttagcacccc tggccaaggt
catccatgac 600aactttggta tcgtggaagg actcatgacc acagtccatg
ccatcactgc cacccagaag 660actgtggatg gcccctccgg gaaactgtgg
cgtgatggcc gcggggctct ccagaacatc 720atccctgcct ctactggcgc
tgccaaggct gtgggcaagg tcatccctga gctgaacggg 780aagctcactg
gcatggcctt ccgtgtcccc actgccaacg tgtcagtggt ggacctgacc
840tgccgtctag aaaaacctgc caaatatgat gacatcaaga aggtggtgaa
gcaggcgtcg 900gagggccccc tcaagggcat cctgggctac actgagcacc
aggtggtctc ctctgacttc 960aacagcgaca cccactcctc cacctttgac
gctggggctg gcattgccct caacgaccac 1020tttgtcaagc tcatttcctg
gtatgacaac gaatttggct acagcaacag ggtggtggac 1080ctcatggccc
acatggcctc caaggagtaa gacccctgga ccaccagccc cagcaagagc
1140acaagaggaa gagagagacc ctcactgctg gggagtccct gccacactca
gtcccccacc 1200acactgaatc tcccctcctc acagttgcca tgtagacccc
ttgaagaggg gaggggccta 1260gggagccgca ccttgtcatg taccatcaat
aaagtaccct gtgctcaacc 1310
* * * * *